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Abstract 
Cancer is a major cause of morbidity and mortality affecting populations in 
all countries and all regions. Breast cancer (BC) is the second leading cause 
of cancer death among women in the UK. Although the overall survival of 
BC has been significantly improved due to systemic therapy in early BC, 
the treatment of advanced/metastatic BC remains a major challenge. The 
main limitation of therapeutic failure is the de novo and acquired resistance 
of BC cells to conventional anticancer drugs.  
Cancer stem cells (CSCs) have been thought to be responsible for the 
chemoresistance. My study demonstrated that mammospheres manifested 
CSC characteristics and are highly resistant to several first line anti-BC 
drugs. This may be due to the hypoxia in the centre of the spheres. 
Transfection of BC cells with NFκB p65 induces CSC characters and 
chemoresistance. Therefore hypoxia-induced activation of NFκB could 
lead to escape of CSCs from apoptosis and regenerate the tumour after 
conventional chemotherapy. In clinic, the relapsed cancer is commonly 
pan-resistant to various drugs. Development of CSCs-targeting drug will be 
significantly important in clinic for cancer patients.  
Disulfiram (DS) is a commercially available anti-alcoholism drug with 
strong cytotoxicity in a wide range of cancer types and has a reversing 
 II 
 
effect on chemoresistance. In this study, the anticancer efficacy of DS on 
cancer cell lines and CSCs was investigated. DS was highly cytotoxic to 
BC cell lines in vitro in a copper (Cu)-dependent manner. CI-isobologram 
analysis demonstrated a synergistic effect between DS/Cu and paclitaxel 
(PAC) in BC cell lines. DS/Cu induces reactive oxygen species (ROS), 
activates JNK and p38 pathways and simultaneously inhibits NFκB activity 
in BC cell lines. DS/Cu may trigger intrinsic apoptotic pathway via 
modulation of the Bcl2 family. The in vitro clonogenicity and sphere-
forming ability of BC cell lines were inhibited by DS/Cu. The common 
stem cell markers such as aldehyde dehydrogenase (ALDH) and CD24-
/CD44+ as well as Nanog, Sox2, and Oct4 were also suppressed. In PAC 
resistant cell line, DS abolished CSC characters and completely reversed 
PAC resistance. Lipo-DS blocked NFκB activation and specifically 
targeted CSCs in vitro. Lipo-DS also targeted CSC population in vivo and 
showed very strong anticancer efficacy.  
This study elucidated the role of NFB in bridging hypoxia with CSC-
related chemoresistance. It also investigated the fundamental anticancer 
mechanisms of DS. The results derived from this study indicate that further 
study may be able to translate DS into cancer therapeutics in the future. 
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1. Introduction 
1. 1 Cancer overview 
Cancer is a serious worldwide public health problem characterized by 
uncontrolled growth of cells which cause serious problems by migrating 
from the original site and spreading to distant sites through the lymphatic 
system or bloodstream. It is a major cause of morbidity and mortality with 
approximately 14 million new cases and 8 million cancer-related deaths in 
2012, affecting populations in all countries and all regions. It was 
responsible for 28% of all deaths in the UK in 2010, with around 77,400 
more deaths due to cancer than coronary heart disease, and around 109,000 
more deaths due to cancer than strokes (Sasieni et al., 2011; Boyle et al., 
2003). The most commonly diagnosed cancers are breast, lung, colorectal 
and prostate cancers which account for over half of the cancer burden, and 
almost half of all cancer deaths are due to lung, bowel, breast and prostate 
cancers in the UK.  
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1. 2 Breast cancer  
1.2.1 Incidence and mortality rates in the United Kingdom 
Breast cancer (BC) is the most common female cancer in the UK. In 2010, 
49,961 people were diagnosed with BC in the UK, an increase of 1.8% 
compared to 2009. These incidence rates have increased by 90% between 
1971 and 2010(Statistical Information Team, CRUK, 2010). 
BC is the second leading cause of cancer death after lung cancer since 1998 
among women in the UK. In 2010, there were 11,633 deaths from BC; 
11,566 (99%) of these were in women and 77 (1%) were in men (Statistical 
Information Team, CRUK, 2010). BC accounts for around 15% of female 
cancerous deaths in the UK (Office for National Statistics, 2011). A large 
proportion of BC cases in developed countries are related to reproductive 
and hormonal factors, obesity, alcohol and physical activity (Cancer 
Research UK, 2012). It is estimated that about 27% of cases of female BC 
in the UK are linked to largely modifiable lifestyle and environmental 
factors (Parkin et al., 2011). In the past 30 years, despite the major 
advances that have been made in understanding the biological and clinical 
nature of BC, the survival estimates of BC have risen steadily. However, it 
is still the most prevalent type of cancer among women in the developed 
world and its incidence has shown a continuous rise in recent decades.  
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Nowadays, BC has become a significant public health problem due to high 
mortality worldwide.  
1.2.2 Classification of breast cancer 
1.2.2.1 Histopathological and biological classiﬁcation 
Histopathological Classification: BC is a complex heterogeneous disease 
with each group having distinctive molecular variations, which can be 
characterized by different morphological, biological and behavioural 
features. These cases demonstrate a variety of unique characteristics, 
histological patterns and clinical outcomes (Weigelt et al., 2009). BC is a 
malignant tumour that originates from breast tissue, usually from either the 
inner lining of milk ducts (ductal carcinomas) or gland lobules (lobular 
carcinomas). Ductal carcinomas and lobular carcinomas account for the 
majority of these cases. However, the cancer can originate in other areas of 
the breast, and include comedo, tubular, and medullary carcinomas (Li et 
al., 2005). BC can be histopathologically subdivided into 4 categories, 
including invasive ductal BC, invasive lobular BC, inflammatory BC and 
less common types of BC (Cancer Research UK, 2012). 
Biological Classification: New approaches have been considered to 
discover the molecular basis for the heterogeneity of BC. Molecularly 
deﬁned classes of BC have been identified with distinctive biological and 
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clinical features using a special analysis of gene expression proﬁling. BC 
can be subdivided into three major biological subtypes using gene 
expression profiling by pathological features, including estrogen receptor 
positive (ER) and progesterone receptor positive (PR) and human 
epidermal growth factor-2 status (HER2) (Moulder et al., 2008). Further 
sub-classification of tumour types into luminal A (ER+ and/or PR+, HER2-, 
low Ki67), luminal B (ER+ and/or PR+, HER2+), human epidermal growth 
factor receptor-2 (HER2)(ER-, PR2-, HER2+), and basal-like (ER-, PR-, and 
HER2-) BCs (Perou et al., 2000; Sorlie et al., 2001)(Table 1.1).  
Table 1.1 Molecular subtypes of breast cancer 
 
(Perou et al., 2000; Sorlie et al., 2001) 
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1.2.2.2 Stages of breast cancer 
The treatment decisions of BC patients depend on variables such as the site 
of the primary tumour, the size and number of tumours, cell type and 
tumour characteristics and grade. Classical number stages of BC system are 
commonly used in the UK. Details of this system are in Table 1.2. There is 
an American Joint Committee on Cancer (AJCC) staging system termed 
TNM (tumours/nodes/metastases) system. "T" denotes the degree of 
invasion of the intestinal wall, "N" denotes the degree of lymphatic node 
involvement, and "M" denotes the degree of metastasis. I will not discuss it 
in detail here. 
Table 1.2 Number stages of breast cancer 
 
(Cancer Research UK, 2012) 
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1.2.3 Therapeutic of breast cancer 
In clinical, four main treatment options such as surgery, radiotherapy, 
chemotherapy and molecular-based therapy will be available for the BC 
depends on different requiring of patients.  
1.2.3.1 Surgery 
Surgery is commonly the first treatment for BC which has not spread to the 
axillary lymph nodes. Surgical excision has been reduced to preserve most 
breast tissue in women suffering from stage I and II BC during the last 30 
years (Lakhani et al., 2006). With the development of lymph node mapping 
and biopsy techniques, many new cases will be diagnosed in the early 
stages of BC (Lakhani et al., 2006), therefore, patients may be offered a 
test to detect one or two critical sentinel lymph nodes at the beginning, but 
if cancer cells have already been detected in most lymph nodes by biopsy, 
an axillary dissection will be applied to surgically remove all the lymph 
nodes.  
1.2.3.2 Radiotherapy 
Radiotherapy is an important treatment to destroy cancer cells using high 
energy x-rays. Regular treatment will be given to achieve the greatest effect 
on the cancer cells while limiting the damage to normal cells. Radiotherapy 
is used to treat BC in different ways by eliminating any remaining cancer 
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cells in the breast where the cancer has been removed after surgery, 
including breast conserving surgery (a wide local excision or lumpectomy) 
or mastectomy. Moreover, radiotherapy can efficiently reduce the risk of 
cancer recurrences through treating the lymph nodes in the armpit which 
may still contain cancer cells and above the collarbone depending on the 
surgery (Clarke et al., 2005). Radiotherapy is most commonly used before, 
after or during courses of chemotherapy.  
1.2.3.3 Endocrine therapy and biological treatments 
BC cells are assessed for biological markers (ER, PR, and HER2). Around 
70% of BC cases overexpress ER and 15-20% of invasive BCs overexpress 
HER2. ER and HER2, when bonded by their natural ligand, would promote 
cell proliferation and differentiation therefore promoting cancer 
development (Lewis et al, 2002; Ward et al, 2009; Hind et al, 2007). 
Endocrine therapy is the treatment of BCs with additional hormone drugs, 
after surgery, in order to prevent cancer relapse. This treatment can block 
the signalling pathway between oestrogen and ERα by either interfering 
with ER-ligand interaction using tamoxifen which is one of the selective 
ER modulators (SERMs) or decreasing production of the ligand through 
ovarian ablation or suppression (OA/OS) or aromatase inhibition (Bao et 
al., 2007). Studies show that the use of endocrine therapy would effectively 
reduce BC recurrence rates by 40% and death rates by 30% (Statistical 
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Information Team, CRUK, 2009). Endocrine therapy represents the first 
targeted therapy to treat BC patients with the ER+ type of BC. Moreover, 
cancer cells that express ER and HER2 are more aggressive and are 
associated with increased risk of recurrence and death.  Anti-HER2 
antibody (trastuzumab) is used to treat the BC cells with the HER2+. The 
anti-HER2 antibody would bind to HER2, blocking the ligand binding site 
and inhibiting signal transduction. Studies showed that treating a HER2+ 
BC patient with trastuzumab would reduce the risk of relapse by 50% and 
death by 30% (Lewis et al, 2002; Ward et al, 2009).   
1.2.3.4 Chemotherapy 
Chemotherapy is  a  treatment  using  a  drug  or  combination  of  drugs  
which  is  cytotoxic  to rapidly dividing cells, such as cancer cells but also 
normal cells. The adjuvant chemotherapy can be used as an additional 
therapy before or after surgery and/or radiotherapy for primary invasive BC.  
Chemotherapy can be widely offered based on different factors including 
age and the size or grade of BC in patients（Howell et al., 2005）. When 
the BC cells have spread from the breast to other places, chemotherapy can 
be used for controlling the growth of metastatic BC. It may also reduce 
some symptoms caused by the metastatic BC. Cancer cells always grow in 
a disordered and uncontrolled way. The drugs work by disrupting the 
growth of cancer cells but the mechanisms of different chemotherapy drugs 
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are not the same. The chemotherapy drug targets cancer cells via the 
circulation of the blood in the body. Normal cell growth is a tightly 
controlled process coupled with cell death (apoptosis) to prevent excessive 
growth.  The growth of cancer cells is out of control coupled with 
inhibition of apoptosis. Chemotherapy inhibits cancer cell proliferation and 
induces cancer cells into apoptosis.  
In stage I BC cases, chemotherapy is used only for patients who are 
assessed to have a high risk of recurrence because of the side effects 
associated with chemotherapy drugs. The standard chemotherapy drugs 
used are anthracycline-based regimens such as epirubicin or doxorubicin 
(Dox) in clinic (Lister-Sharp et al, 2000; Takeda et al, 2008; McArthur et 
al, 2007). In stage II/III cases, where cancer cells are found in axillary 
lymph nodes, the patients would usually be treated with standard 
chemotherapy treatment followed by paclitaxel (PAC) or docetaxel. In 
stage IV cases, patients are treated with a larger selection of chemotherapy 
drugs, including the standard epirubicin or dFdC, PAC or docetaxel, 
platinum agents, cyclophosphamide, vinorelbine, nucleotide analogue and 
ixabepilone (Takeda et al, 2008; Jones et al, 2004; Ross et al, 2004; 
McArthur et al, 2007).  
More than 50 different anti-cancer drugs are available in clinic. These 
chemotherapeutic agents can be categorized as antimetabolites, 
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anthracyclines, plant alkaloids (Taxanes), alkylating agents, antitumour 
antibiotics, monoclonal antibodies and platinums (Raina et al., 2007). 
Many of them have been used in advanced BC treatment. Table 1.3 lists the 
anticancer drugs most commonly used in BC chemotherapy. In this section, 
I will focus on three first line anti-BC drugs which I will examine in my 
study (dFdC, Dox and PAC). 
Table 1.3 Drugs commonly used in breast cancer chemotherapy 
 
(Takeda et al, 2008; Jones et al, 2004; Ross et al, 2004; McArthur et al, 2007) 
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1.2.3.4.1 Gemcitabine  
Gemcitabine (2', 2'-difluorodeoxycytidine, dFdC) (Fig. 1.1) is a 
deoxycytidine analogue with proven anticancer activity both in vitro and in 
vivo, which was first synthesized in the 1980s by Eli Lilly Inc., 
Indianapolis, as an antiviral agent (Bergman et al., 2005). It is able to elicit 
chemotoxic activity upon a broad range of cancers. In clinical practice, it is 
an agent used to treat patients with advanced metastatic pancreatic cancer 
and in combination therapy for non-small cell lung cancer, bladder, ovarian 
and BC (Mini et al., 2006). 
 
Fig. 1.1 Structure of Gemcitabine (Image from PubChem) 
dFdC is a prodrug requiring intracellular phosphorylation to become active. 
Due to the hydrophilic nature of the molecule, specialised human 
nucleoside transporters (hNT) are required to facilitate the movement of the 
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molecule. These transporters are divided into two groups: the equilibrative 
(hENT) and the concentrative (hCNT) types (Shah et al., 2007). The 
hENT1 appeares to be the major transporter among the main dFdC 
transporters including hENT1, hENT2, hCNT1 and hCNT3. Once dFdC 
enters into the cell, it undergoes phosphorylation by dCK to dFdC 
monophosphate (dFdCMP), this is followed by further phosphorylation by 
nucleoside monophosphate kinase and nucleoside diphosphate kinase 
producing active dFdC diphosphate (dFdCDP) and triphosphate (dFdCTP) 
respectively (Ueno et al., 2007; Galmarini et al., 2004). The cytotoxic 
action of dFdC is mediated by these phosphorylated derivatives. dFdC 
diphosphate is able to indirectly inhibit DNA synthesis via inactivation of 
ribonucleotide reductase (RR), which is an enzyme essential for the 
conversion of RNA nucleotides to DNA nucleotides. This process results in 
the “self-potentiation” of dFdC as the concentration of naturally occurring 
deoxynucleotide triphosphates is reduced (Heinemann et al., 1992). 
It is believed that incorporation of dFdC triphosphate into the DNA strand 
is the major mechanism by which dFdC induces apoptosis, specifically 
acting upon S and G1/S phases of the cell cycle (Heinemann et al., 1992). 
Once dFdC triphosphate is incorporated into the DNA strand, DNA 
polymerases are unable to proceed. This process ("masked termination") 
protects the drug, as proofreading enzymes are unable to remove dFdC 
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from this position. Overall, the unique actions that dFdC metabolites exert 
on cellular regulatory processes along with dFdC triphosphate 
incorporation in the DNA serve to inhibit cell growth and induce cell death 
(Heinemann et al., 1992).  
1.2.3.4.2 Doxorubicin 
 Dox is a member of the anthracycline drug family which is isolated from 
different strains of Streptomyces in the 1970s (Woodruff et al., 1960) (Fig. 
1.2) and is widely used in the chemotherapy of solid tumours, lymphomas 
and leukaemia (Minotti et al., 2004). It is considered as the most effective 
therapeutic agent for BC chemotherapy (Smith et al., 2006). 
 
Fig. 1.2 Structure of Doxorubicin (Smith et al., 2000) 
The anti-cancer mechanisms of Dox are multifactorial. There are two 
proposed mechanisms of Dox acting in the cancer cell. It is believed that 
 14 
 
Dox intercalates into DNA and disrupts topoisomerase-II-mediated DNA 
repair and the other mechanism is that Dox can generate free radicals 
resulting in damaging to cellular membranes, DNA and proteins. Once Dox 
enters the cancer cells, firstly, it binds to DNA by inserting between the 
stacked paired bases of the super-coiled double helix. This process leads to 
uncoiling of the helix resulting in impairment of topoisomerase II activity. 
Topoisomerase II is an essential enzyme in controlling the supercoiling of 
DNA playing an important role in maintaining DNA structure by creating 
and repairing nicks in two adjacent parent DNA strands (D’Arpa et al., 
1989). When it has been inhibited, DNA replication and transcription will 
not work properly and results in permanent DNA cleavage (D’Arpa et al., 
1989). Dox may also alter membrane fluidity and affect ion transport and 
hence biochemical equilibria by binding to cell membrane. Dox induces 
DNA damage by generating semi quinone species that leads to the 
production of free radicals and hydroxyl radicals (Adama et al., 2003). 
Proteasomes have been reported to modulate the activity of Dox by 
degrading proteins through non-lysosomal mechanisms. The 26S 
proteasome has been shown to control an increasing number of essential 
biochemical mechanisms of the cellular lifecycle including processing and 
degradation of regulatory proteins (Adama et al., 2003; Cusack et al., 
2003). Dox is transported to the nucleus of the cells by the proteasome 
through a series of steps. After getting into the cancer cells, Dox 
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automatically binds to the 20S proteasomal subunit in the cytoplasm. This 
complex was driven into the nucleus through nuclear pores by an ATP-
dependent process. Dox shows its higher affinity to DNA resulting in 
dissociation from the proteasome and binding to DNA (Kiyomiya et al., 
2001). The final apoptosis signal will appear after accumulation of the 
degraded proteins. 
1.2.3.4.3 Paclitaxel  
PAC is derived originally from Taxus Brevifolia (Bark of Pacific 
yew/Western yew conifers) and it was discovered to be as an anti-leukemic 
agent in 1971 (Wani et al., 1971). In the past few years, as the first line 
anti-cancer drug in the clinical treatment, PAC has been successfully used 
to treat a range of human cancers including ovarian, metastatic breast and 
non-small cell lung carcinomas (Rowinsky et al., 1992). Due to a shortage 
of enough Taxus bark, this drug cannot be widely used for the patients until 
scientists have successfully developed semisynthetic derivatives based on 
the molecule structure of paclitaxel (Fig. 1.3).  
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Fig. 1.3 Structure of Paclitaxel (Smith et al., 2000) 
It is well known that PAC can suppress and inhibit cell growth, 
differentiation and proliferation in many cancer cell lines and it is the most 
preferred anti-cancer drugs by clinical doctors. PAC works completely 
differently from dFdC and Dox. The main mechanism of action of PAC is 
stabilising the microtubules and inhibiting the anaphase of the cell cycle. 
The stabilisation of the microtubules in anaphase would prevent separation 
of the chromosome which is essential for division of the parent cell into 
two daughter cells. The dynamic polymerisation and de-polymerisation of 
microtubules is essential for the normal function of cellular processes 
including chromosome separation and cytokinesis. A microtubule is a 
cylindrical assembly of tubulin dimers which are composed of α and β-
tubulin subunits (Chretien et al. 1992). The β-tubulin subunit is known to 
have the binding site for PAC. When PAC is binding to the β-subunit of 
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tubulin, the formation of structurally abnormal microtubules is relatively 
resistant to de-polymerisation. The subunits of microtubules are abnormally 
stabilized by PAC (Bharadwaj et al., 2004; Brito et al., 2008; Ganguly et 
al., 2010).  
1.3 Chemoresistance  
Chemotherapy is one of the principal treatments for advanced and 
metastatic BC. Drug resistance is the main limitation to the success of 
chemotherapy. Inadequate drug exposure, insufficient dosage, poor tumour 
vascularisation and poor drug bioavailability and distribution are the main 
causes of drug resistance during chemotherapy. Intrinsic and acquired drug 
resistance are the two main categories of chemoresistance (Longley et al., 
2005). Some cancer cells seem to be inherently resistant to anticancer drugs 
(Longley et al., 2005). There are a range of molecular mechanisms 
implicated in drug resistance, including multidrug resistance (MDR), DNA 
damage repair, CSCs, and tumour microenvironment. 
Cancer cells displaying reduced sensitivity to drugs through continued 
exposure can also become cross-resistant to other unrelated classes of 
chemotherapeutic drugs, which is known as MDR. A few kinds of 
chemotherapy drugs such as PAC and Dox could have totally different 
structures and mechanisms of cytotoxicity, but they share a common 
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transport mechanism which is controlled by ATP-binding cassette (ABC) 
transporter family (Moscow et al., 1988). Drugs are actively pumped out of 
the cell as a consequence of expression of ABC transporter proteins. The 
ABC transporter proteins are a large superfamily of membrane proteins 
comprising 49 members divided into seven different families based on 
sequence similarities (Moscow et al., 1988; Gottesman et al., 1993). 
Overexpression of the MDR1 gene in multidrug resistant cancer cells leads 
to a large production of MDR1 protein (P-glycoprotein (Pgp).  The anti-
cancer drugs were pumped out from the cytosol to the extracellular medium 
by using the energy of ATP hydrolysis. Pgp consistently plays the role of 
drug removal and expression on some functional barriers including kidney 
tubules, liver cells and blood tissue barriers, and it also has key functions in 
immunology and apoptosis by selective expression in the adrenal gland, 
haematopoietic stem cells, and T and B lymphocytes (Moscow et al., 1988; 
Gottesman et al., 1993). Some other members of the ABC transporter 
proteins superfamily, including multidrug resistance associated protein 
(MRP-1), lung resistance-related protein (LRP) and breast cancer resistance 
protein (BCRP) also show their special importance in drug resistance.  
A few chemotherapeutic drugs can induce DNA damage either directly or 
indirectly. The cellular response to DNA damage is repair or cell death. 
Therefore, the ability of DNA damage repair in cancer cells has a major 
 19 
 
influence on the effectiveness of drugs. DNA damage slows down the cell 
cycle allowing cells to repair the damage. In some cancers, functional 
alteration of oncogenes and/or suppressor genes can disrupt the regulation 
of cell cycle arrest. For example, p53 plays an important role in regulating 
numerous cell cycle checkpoints. Mutation of p53 can disrupt DNA-
damage-induced cell cycle arrest, and is frequently associated with drug 
resistance (Tergaonkar et al., 2002; Webster et al., 1999). 
Beside the cellular response, cancer microenvironment is considered to be 
another key factor in the initiation and maintenance of drug resistance. 
More recently, a new research paradigm suggesting the role of CSCs in the 
intractability of cancers has been discussed world-wide. CSCs have been 
found to express ABC family members such as BCRP and other ABC 
efflux pumps (Victor et al, 1997). This allows them to survive hypoxia and 
the effects of multiple chemotherapeutic drugs, and it has been also found 
that CSCs can initiate another tumour and differentiate so that the new 
tumour contains populations of CSCs and non-stem cells. There are still 
some other mechanisms to explain the drug resistance, including 
expression of important apoptosis-associated proteins such as BCL-2 
family (Reed et al., 1995; Clynes et al., 1998), the tumour suppressor 
protein p53 (Mueller et al., 1996), and dysfunctional metabolism of 
ceramide. Another common mechanism of resistance in cancer cells is 
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Glutathione up-regulation. This endogenous antioxidant is believed to 
cause resistance by providing protection against free radical damage 
(Lutzky et al., 1989). It relies on the ability of resistant tumour cells to 
efficiently promote glutathione S-transferase (GST)-catalyzed oxidation of 
glutathione (GSH) conjugation of anti-tumour drugs (O’ Brien et al., 1996). 
Three anticancer drugs (dFdC, PAC and Dox) were used in my study. The 
resistant mechanisms of these drugs are listed in Table 1.4.  
Table 1.4 Resistance mechanisms of chemotherapeutic agents 
 
(Bharadwaj et al., 2004; Heinemann et al., 1992; Kiyomiya et al., 2001) 
1.4 Nuclear Factor Kappa B  
The first member of nuclear factor kappa B (NFκB) protein family was 
discovered by Ranjan Sen and David Baltimore in 1986 as a factor in the 
nucleus of B cells that bound selectively to the enhancer of the kappa light 
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chain of immunoglobulin (Sen et al., 1986). Over 25 years of intense 
research demonstrated that NFκB transcription factor is ubiquitously 
expressed in almost all cell types or tissues, and regulates the expression of 
a large variety of genes which have NFκB binding site in their 
promoters/enhancers. It is now elucidated that NFκB plays a critical role in 
mediating responses to a remarkable diversity of external stimuli and is 
involved in complex biological processes such as inflammatory and 
immune responses of the cell, cell growth and development, pathogens, 
injuries, and other stressful conditions. Therefore, it is a pivotal element in 
multiple physiological and pathological processes (Oeckinghaus et al., 
2009). NFκB proteins have the ability to influence expression of numerous 
genes, so the activity of NFκB is tightly regulated at multiple levels.  
1.4.1 The structure of NFκB family members 
The NFκB family in mammalian cells consists of five structurally related 
and functionally conserved proteins: RelA (p65), RelB, c-Rel, NFκB1 
(p50/p105), and NFκB2 (p52/p100) (Frances E et al., 1999) (Fig. 1.4). All 
components share a highly conserved 300 amino acid sequence called Rel 
homology domain (RHD) at their N-termini, which is primarily responsible 
for DNA binding specificity, the C-terminal domain of this region is 
responsible for dimerization and IκB binding. Based on the synthesis and 
transactivation properties of sequences from C-terminal to the RHD, NFκB 
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proteins are divided into two classes. The class I NFκB proteins include 
NFκB1 and NFκB2 which are synthesized as large precursors (p105 and 
p100, respectively) with an N-terminal RHD and a long C-terminal domain 
that contains multiple copies of inhibitory series of ankyrin repeats. The 
processing of p105 and p100 is mediated by the ubiquitin/proteasome 
pathway and removes the C-terminal domain, resulting in production of the 
mature DNA-binding proteins (p50 and p52) that lack a transactivating 
domain. The class II NFκB proteins consist of RelA (p65), RelB and c-Rel 
which are synthesized in their mature forms and contain C-terminal 
transcription activation domains but without the inhibitory ankyrin repeats 
(Karin et al., 2002).  In unstimulated cells, NFκB dimers are located in the 
cytoplasm in an inactive form as a consequence of their association with 
members of another family of proteins called IκB (inhibitors of κB) (Karin 
et al., 2002). The IκB inhibitory proteins also form a family containing 
seven members in mammals including IκBα, IκBβ, IκBε, IκBγ, Bcl-3, and 
the carboxyl-terminal regions of NFκB1 (p105) and NFκB2 (p100) (Fig. 
1.4). The IκB proteins are characterized by the presence of multiple ankyrin 
repeats at their C-terminal domains through which they associate with the 
RHD of NFκB proteins (Momoko et al., 2005). This interaction retains 
NFκB in the cytoplasm. Class I NFκB proteins generally keep inactive, 
when they form dimers with members of class II NFκB proteins, the 
homodimers or heterodimers transcription will start by binding to 9-10 base 
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pairs DNA sites which are called κB  sites (kappaB sites, 5'-
GGGRNNYYCC-3'; R, purine; Y, pyrimidine; N, any 
nucleotide)( Momoko et al., 2005). 
The NFκB family members form various homo/heterodimers that recognize 
and bind to similar DNA sequences and regulate the expression of distinct 
sets of genes. In most mammal cells, the major Rel/NFκB complex is the 
heterodimer of the p65/RelA and p50 subunits. p50 and p52 play critical 
roles in modulating the specificity of NFκB function. In contrast to RelA, 
RelB and c-Rel, no transactivation domains are located in the C terminal 
halves of p50 and p52 NFκB subunits. In general, homodimers of p50 and 
p52 inhibit κB site transcription, but both p50 and p52 participate in 
targeting gene transactivation by forming heterodimers with RelA, RelB or 
c-Rel (Li et al., 2002). The diversity of Rel/NFκB proteins shows distinct 
abilities to form different dimers, binding to different κB sites and IκB 
inhibitor proteins (Barkett, et al., 1999). In different cell types, Rel/NFκB 
complexes can be induced with other transcription factors and regulatory 
proteins to regulate the expression of distinct gene sets.  
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Fig. 1.4 Members of the Rel/NFκB and IκB families of proteins. The arrows indicate the 
endoproteolytic cleavage sites of p105 and p100 which give rise to p50 and p52, respectively. Black 
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boxes indicate the PEST domains (polypeptide sequences enriched in proline, glutamic acid, serine, 
and threonine), green boxes on Bcl-3 indicate transactivation domains, orange boxes on RelB 
indicate leucine zipper domains, and yellow boxes indicate nuclear localization sequence (NLS). 
Abbreviations: RHD, Rel homology domain; ANK, ankyrin repeat; SS, signal-induced 
phosphorylation sites. N, nuclear localization sequence. 
1.4.2 The activation of NFκB pathways 
In normal quiescent cells, NFκB remains in the cytoplasm in an inactive 
form by binding to IκB proteins (Ghosh et al., 2002). Degradation of IκB is 
a tightly regulated event that is initiated by specific phosphorylation of IκB 
proteins via activation of the IκB kinase (IKK). The IκB kinase enzyme 
complex is part of the upstream NFκB signal transduction cascade. As a 
700-900 kDa complex, the IKKs complex consists of two catalytic kinase 
subunits, IKKα (IKK1) and IKKβ (IKK2), and a regulatory subunit IKKγ, 
also termed NEMO (NFκB essential modulator)(Ghosh et al., 2002). IKKα 
and IKKβ are 52% identical and form homodimers or heterodimers. IKK 
complex, residing at a key convergence site, leads to NFκB activation in 
multiple signalling pathways. IKKα and IKKβ are expressed everywhere 
and consist of an amino-terminal kinase domain, a leucine zipper, and a 
carboxy-terminal helix-loop-helix domain (HLH) (Ghosh et al., 2002).  
There are two IKK-dependent signalling pathways leading to NFκB 
activation: classical and the alternative pathway (Fig. 1.5). In the classical 
NFκB signalling pathway, it is triggered when the cells have been 
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stimulated by TNFα, T-cell receptors (TCR), B-cell receptors (BCR), Toll-
like receptor (TLR) or interleukin-1 receptor (IL-1R) superfamily members 
(Karin et al., 2000). IKKβ is both necessary and sufficient for 
phosphorylation of IκBα on Ser32 and Ser36, and IκBβ on Ser19 and Ser23 
(Karin et al., 2000). The role of IKKα in the classical pathway is not 
confirmed, but recent studies suggest it may regulate gene expression in the 
nucleus by modifying the phosphorylation status of histones (Karin et al., 
2000). The phosphorylation and activation of IKKβ can be induced by the 
stimulating factors. IκB proteins are phosphorylated by activated IKK 
complex at Ser32 and Ser36 of IκBα. Phosphorlation triggers 
polyubiquitination at sites equivalent to Lys21 and Lys22 of IκBα and 
degradation by 26S proteasome, releasing free NFκB (RelA/p50) dimmers 
to the nucleus (Karin et al., 2000). The alternative pathway depends only 
on the IKKα subunit, which functions by phosphorylating p100 and 
causing its inducible processing to p52. It is involved in the specific 
activation of RelB/p52 heterodimers. The p52/p100 protein binds to amino-
terminal of RHD in RelB and keeps the dimer in the cytoplasm. The 
activated IKKα dimers induce the degradation of p100 and results in the 
nuclear entry of RelB/p52 heterodimers. The alternative pathway is 
activated in response to a subset of NFκB inducers including LTβ and 
lymphotoxin B and B cell activating factor (BAFF) and CD40L via NFκB 
inducing kinase (NIK) (Bonizzi et al., 2004).  
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Fig. 1.5 Classical and alternative pathways of NFκB activation. The classical pathway mediated 
by IKKβ and leading to phosphorylation of IκB. Inputs for the classical pathway include TNFR1/2, 
TCR and BCR, TLR/IL-1R, and many others. The alternative pathway involves NIK activation of 
IKKα and leads to the phosphorylation and processing of p100, generating p52: RelB heterodimers. 
Input signals for the alternative pathway follow ligation of LTβR, BAFFR, and CD40R. These 
alternative pathway stimuli also activate the classical pathway. 
1.4.3 NFκB and cancer 
NFκB is a key factor in controlling both innate and adaptive immunity. The 
constitutive activation of NFκB pathways is often associated with 
inflammatory diseases. In 1858, Virchow suggested that chronic 
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inflammation might give rise to malignancy. Afterwards, accumulating 
data demonstrated that many types of cancers have been involved with 
chronic inflammation (Coussens et al., 2002). The animal study data 
demonstrated the important role of NFκB activation in tumour development. 
Deleted IKKβ in intestinal epithelial cells leads to a significant reduction in 
tumour incidence in a mouse model of colitis-associated cancer, whereas 
knocking out IKKβ in myeloid cells in these mice results in decreased 
tumour size by diminished expression of pro inflammatory cytokines that 
act as tumour growth factors (Coussens et al., 2002). Moreover NFκB 
plays a critical role in cancer progression by controlling epithelial to 
mesenchymal transition (EMT) and metastasis which is often associated 
with an up-regulation of matrix metalloproteinases (MMPs), freeing the 
extracellular matrix for  evasion of cancer cells (Huber et al., 2004). NFκB 
can also up-regulate vascular endothelial growth factor (VEGF) and its 
receptors to control vascularization in tumour progression (Xie et al., 2010; 
Yoshida et al., 1999). NFκB is important for survival of cancer cells and 
mediates aggressive tumour phenotype. It is widely accepted that NFκB in 
particular has a double-edged role in cancer. On one hand, constitutive 
activation of NFκB can induce a variety of pro-tumorigenic functions in 
many types of cancer. On the other hand, as a part of the immune 
defending system, activation of NFκB could lead to the targeting and 
elimination of transformed cells and involve for acute inflammatory 
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processes with a high activity of cytotoxic immune cells against cancer 
cells (Disis et al., 2010). 
Understanding the activity and function of NFκB in the context of 
tumourigenesis may provide opportunities for the development of new 
treatments to inhibit prolonged activation of this pathway and this is an 
important challenge for modern cancer biology. 
NFκB and Breast Cancer: Over the past 20 years, there have been 
significant gains in the understanding of the molecular events associated 
with BC development and therapeutic resistance. NFκB has been 
recognized as an upstream regulator of many important cellular signalling 
pathways, including those related to BC promotion. Furthermore, NFκB is 
also an important modulator of the apoptotic response of cells to injury. 
Regulation of the apoptotic pathway by NFκB may affect both the 
pathogenesis of BC and its response to chemotherapy and radiation. NFκB 
protein usually up-regulates anti-apoptotic genes resulting in the provision 
of a cell survival mechanism to withstand drug treatment in BC.  
BC cells have been shown to express constitutively active NFκB through 
abnormal signalling via the epidermal growth factor receptor, interleukin-1, 
or heregulin pathways (Bhat-Nakshatri et al., 2002). There is a cross-talk 
between the NFκB and ER pathways that have been found to get involved 
in metastasis and give a worse prognosis for patients with ER negative BCs 
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(Nozaki et al., 2000). The level of osteoclastogenic factors have been 
induced by constitutive activation of NFκB through the receptor activator 
of NFκB pathway, resulting in the promotion of  extensive bone loss within 
BC bony metastases (Lee et al., 2003). The cellular microenvironment may 
affect the expression of NFκB. Some growth factors and hypoxic condition 
within the tumour microenvironment may contribute to constitutive NFκB 
activity in BC (Kim et al., 1999). Finally, a positive feedback loop will 
start when NFκB protein is expressed aberrantly, leading to the expression 
of more NFκB protein (Kim et al., 1999).  
There is much evidences showing that NFκB DNA-binding and 
transcriptional activity is at a very high level in both mammary carcinoma 
cell lines and primary human BC tissues (Biswas et al., 2001). Furthermore, 
High IKK kinase activity has been detected in transformed BC cell lines 
and in primary human BC specimens, thereby NFκB activity will be 
decreased by inhibition of IKK activity in tumour cell lines (Deng et al., 
2002). The transforming growth factor β1 (TGF-β1) inhibits mammary 
tumour cell growth by the inhibition of aberrantly activated NFκB activity 
(Sovak, et al., 1999). Although much evidences suggests that NFκB is 
implicated in BC, it is still not clear whether constitutively activated NFκB 
plays a causal role in tumour formation. The mechanisms of NFκB 
activation in mammary tumours are also not totally understood. It is easy 
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for the cyclin D1 gene, as a common marker for BC, to be activated by 
NFκB activation in mammary tumorigenesis because the NFκB binding site 
was found in the cyclin D1 promoter, and in vitro experiments 
demonstrated its activation by NFκB (Guttridge et al., 1999; Hinz et al., 
1999). Furthermore, cyclin D1 overexpressed in the mammary gland can 
increase the incidence of mammary carcinomas, and knock out of cyclin 
D1 gene protects mice against BCs induced by MMTV-neu or MMTV-v-
Ha-ras (Wang et al., 1994; Yu et al., 2001). It has been proved that ErbB2 
and Ha-Ras can trigger signalling cascades that lead to NFκB activation 
during their involvement in cellular transformation in vitro. Results of 
studying the mice cell lines which carry MMTV-driven neu (ErbB2), 
heregulin/NDF, TGFα , v-Ha-ras, and c-myc transgenes have shown that 
certain oncogenes require and activate specific signal transduction 
pathways, including ERK/MAP kinase, JNK/SAP kinase, PI3K/AKT 
kinase, protein kinase C or the Src-related kinase pathways (Finco et al., 
1997; Jo et al., 2000; Pianetti et al., 2001; Zhou et al., 2000). 
NFκB is a cellular marker of an exciting molecular target. It is clear that 
NFκB activation, associated with the promotion of cell growth in mammary 
tumours and the inhibition of NFκB, possibly increases apoptosis and 
thereby increases BC response to chemotherapy and radiation. Future 
strategies that inhibit NFκB activation may prove to be of therapeutic value. 
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There is a need for clinical studies analysing NFκB as a predictor of 
response to treatment in BC. 
1.4.4 NFκB and cancer therapy 
NFκB plays an important role in many physiological processes, including 
innate and adaptive immune responses, cell proliferation, cell death, and 
inflammation. It has been widely accepted that regulation of NFκB activity 
in cell signalling pathways is not only involved in cancer development and 
progression, but also in resistance to chemo- and radiotherapy. Here, I will 
focus on the relationship between NFκB activity and cancer 
chemoresistance.  
Although NFκB can either promote or oppose tumour development, first 
and foremost, NFκB plays a major anti-apoptotic role in established 
tumours and in tumour metastases (Baldwin et al., 2001). Substantial 
evidence indicates that aberrant sustained activation of NFκB has been 
reported in numerous tumours, and was implicated in various stages of 
tumourigenesis (Greten et al., 2004; Baldwin et al., 2001). As a negative 
regulator of NFκB, the tumour-suppressor gene CYLD binds to IKKγ, 
inhibiting the phosphorylation and degradation of IκB and thereby 
maintains NFκB in the cytoplasm (Brummelkamp et al., 2003). Inhibition 
of CYLD enhances activation of NFκB and its loss promotes cancer 
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development in families with familial cylindromatosis (Brummelkamp et 
al., 2003). Furthermore, NFκB regulates expression of cell-adhesion 
molecules that are associated with tumour metastasis (Bonizzi et al., 2004). 
It has been reported that expression of IκBα in tumour cells decreases the 
frequency of metastases, which indicates that the NFκB pathway can 
promote metastasis (Huang et al., 2000). 
Nowadays, many chemotherapeutic agents have been discovered and 
successfully applied in treating patients with different types of cancer, such 
as BC. However, chemoresistance becomes the major obstacle of the 
cytotoxic effects of anti-cancer drug to effective cancer treatment. NFκB is 
activated in response to treatment with cytotoxic drugs. The NFκB pathway 
impinges on many aspects of cell growth and apoptosis. It has been 
reported that in HeLa cells, the topoisomerase I inhibitor SN38 (7-ethyl-10-
hydroxycamptothecin) and the topoisomerase II inhibitor Dox both induce 
NFκB nuclear translocation. The activation of NFκB targets genes directly 
through mobilization and stimulation of the IKK complex which is leading 
to cell survival (Bottero et al., 2001). Another study of vinblastine showed 
that the enhancer activity of the NFκB-binding site is upregulated by 
vinblastine thereby leading to the activation and nuclear translocation of 
NFκB. These results demonstrated that microtubule disassembly induced 
by vinblastine can transactivate the nuclear proto-oncogene MYC through 
 34 
 
NFκB, which will induce cell proliferation (Bourgarel et al., 2001). 
Interestingly, the upregulation of TNFα by chemotherapeutic agents 
induces not only apoptosis through a FAS-associated death domain/caspase 
dependent pathway, but also a survival pathway through the activation of 
AKT, which can activate IKK, leading to NFκB nuclear translocation. All 
these results indicated that anticancer drugs simultaneously activate several 
pathways that positively and negatively regulate the cell death process, and 
the modulation of the balance between death and survival signals plays a 
critical role in the process of cell apoptosis or proliferation.  
It has been reported that constitutive NFκB activation is a reason for 
tumour cells escaping apoptosis, which is also related to the development 
of drug resistance in cancer cells (Patel et al., 2000; Arlt et al., 2001; 
Mabuchi et al., 2004; Kikuchi et al., 2003). Constitutive NFκB activation is 
involved in genetic alterations, which affect the genes encoding NFκB or 
IκB. It has been reported that a similar trend has been detected between 
overexpression of p65 at the mRNA and protein level and the expression of 
the anti-apoptotic FLICE-inhibitory protein (FLIP) in 5-fluorouracil (5-
FU)-resistant colorectal and BC cell lines. The 5-FU-resistant cells showed 
high NFκB DNA-binding activity and co-transfected p65 and p50 cDNA 
induced 5-FU resistance in MCF7 BC cell lines (Wang et al., 2004). It has 
been believed that the most important function of p53 tumour suppress 
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gene is its ability to induce apoptosis, and disruption of this process can 
promote tumour progression and chemoresistance (Tergaonkar et al., 2002). 
Activated NFκB inhibits chemotherapy-induced stabilization and activation 
of p53, which results in resistance to chemotherapy (Tergaonkar et al., 
2002; Webster et al., 1999). NFκB promotes cell survival through 
expression of genes encoding anti-apoptotic proteins or directly blocking 
caspase activation. The expression of BCL-XL and BFL1 play an important 
role in the survival effect of NFκB in response to chemotherapeutic drugs 
in human lung carcinoma cell line (Cheng et al., 2000). In addition, recent 
studies have demonstrated that NFκB has a consensus-binding site for the 
human MDR1 (Bentires-Alj et al., 2003). This finding is further supporting 
the important role for NFκB in chemoresistance. All these data indicate that 
NFκB is a crucial target for cancer therapy and future cancer prevention. 
NFκB is known to inhibit apoptosis through induction of anti-apoptotic 
proteins and/or suppression of pro-apoptotic genes, thus understanding the 
mechanism of apoptosis and the role of NFκB in apoptosis will contribute 
to the discovery of a new target for cancer therapy.  
1.4.5 NFκB and hypoxia 
Aerobic organisms of human body need adequate oxygen for maintaining 
life. Decrease in O2 availability will trigger a wide range of processes to 
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adapt to these changed conditions. Hypoxia is characterized by a decreased 
O2 tension within cells and can occur under several physiologic and 
pathophysiological situations such as cancer and inflammation. Hypoxia 
response can be divided into different time scales, including an acute, an 
intermediate and a chronic response, and in different levels of oxygen 
concentration, including a moderate (5-8% O2) and an anoxic level (<1% 
O2) (normoxia is 21% O2) (Brahimi et al., 2007; Toescu et al., 2004; Lee et 
al., 2007). Hypoxia activates a number of genes that are important in the 
cellular adaptation to low oxygen conditions. Hypoxia inducible factor 
(HIF) is considered as a key regulator of hypoxia-inducible genes 
implicated in many different cellular functions such as cell survival, cell 
proliferation, apoptosis, glucose metabolism, and angiogenesis. HIF, also 
known as ARNT (aryl hydrocarbon nuclear translocator), is a 
heterodimeric factor composed from a tightly regulated α-subunit by PHDs 
(prolyl-hydroxylases) and constitutively expressed β-subunit (Gordan et al., 
2008). HIF is primarily regulated at the protein expression level in hypoxia 
through hydroxylation-dependent targeting to ubiquitination and 
subsequent proteaosomal degradation.  
There are three members in HIF family, HIF1, HIF2 and HIF3. HIF1 is 
ubiquitously expressed, whereas HIF2 is only expressed in endothelial cells 
and in the kidney, heart, lungs and small intestine (Semenza et al., 2001; 
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Piret et al., 2002; Gordan et al., 2008). HIF1α and HIF2α are closely 
related, and both activate hypoxia-response elements (HRE)-dependent 
gene transcription whereas HIF3α is the more distantly related isoform 
(Wenger et al., 2002). However, it has been reported that HIF1α and HIF2α 
may have distinct transcriptional targets (Rankin et al., 2007). Distinct roles 
for HIF1α versus HIF2α in promoting tumour growth have been most 
clearly defined in von Hippel–Lindau (VHL) disease–associated clear cell 
renal carcinoma (CCRC) (Raval et al., 2005). Furthermore, other data show 
the support of distinct roles for HIF1α and HIF2α in regulating cell 
differentiation and in promoting the growth of certain tumours (Kaelin et 
al., 2002; Covello et al., 2005). The HIF1 is composed of HIF1α and 
HIF1β subunit, both of them belong to the basic helix-loop-helix and PAS 
domain proteins family (Bracken et al., 2003). Under normoxic conditions, 
oxygen-sensitive HIF1α is degraded rapidly by hydroxylation of specific 
prolyl residues (Pro 402 and Pro 564), which are catalyzed by PHDs 
domain-containing proteins (Schofield et al., 2004). Furthermore, the VHL 
tumour suppressor protein promotes further degradation of HIF1α through 
the ubiquitin-proteasome pathway in this process (Maxwell et al., 1999). 
Under hypoxic conditions, HIF1α is stabilized, hypoxia triggers HIF1α to 
translocate into the nucleus binding with HIF1β, and transactivates 
downstream target genes containing HRE within their promoter or 
enhancer. 
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More than 50 years ago, it was first reported that human tumours grew 
under hypoxic condition. Hypoxia contributes to cancer cells resistance to 
apoptosis and mediates resistance to chemotherapy and radiotherapy 
(Thomlinson et al., 1955; Brown et al., 1998). Nowadays, hypoxia in 
human cancers, such as BC, the head and neck and cervical, is associated 
with increased metastasis and poor survival in patients (Hockel et al., 1999; 
Hockel et al., 2001). Nowadays, it is well accepted that HIFs play a pivotal 
role in tumour progression and metastasis. High expression of HIF1α, 
HIF2α and HIF3α proteins have been found in human cancers, which is 
associated with tumourigenesis and patient mortality (Kim et al., 2004; 
Semenza et al., 2003; Maynard et al., 2007). Furthermore, a few studies 
indicate that HIF1 may mediate resistance to chemotherapy and radiation 
(Unruh et al., 2003). Therefore, further investigation of the HIF1 pathway 
and understanding the regulation of its transcriptional activity may 
contribute to the discovery of a new therapeutic target for cancer treatment. 
Currently, several approved therapeutic agents such as Trastuzumab 
(Herceptin) and Camptothecin have been reported which inhibit HIF1 
activity either by inhibition of the ability of HIF1 to interact with proteins, 
or through inhibition of signal transduction pathways (Blau et al., 2001). 
However, none of these drugs specifically target HIF1 even if they inhibit 
HIF1 activity. The lack of specific targeting increases the difficulty in 
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making clinical responses in patients, but these drugs still have a potential 
as anticancer agents (Kim et al., 2004). 
HIF1α stabilization and induction was shown to be NFκB dependent under 
normoxic conditions (Bonello et al., 2007). HIF1α is continuously 
produced in the cells but quickly degraded under normoxic conditions by 
tanscriptional and post-transcriptional regulation. Increasing the expression 
and transcription rate of HIF1α is involved in activation of protein kinase C 
and NFκB.  Reactive oxygen species (ROS) induce activation of the PI3K 
and AKT pathway increases the translational rate of HIF1α protein 
(Semenza et al., 2003). The stabilization of HIF1α is also implicated by 
inflammatory cytokines, transforming growth factor B, lipopolysaccharide, 
and stem cell factor in various cell types (Pedersen et al. 2008). For a long 
time, HIF1α was the major factor investigated in tumour hypoxia, but 
recently it has been demonstrated that active HIF2α can contribute to the 
development of tumour aggressiveness. HIF2α becomes stabilized at higher 
oxygen tensions than HIF1α in both non-malignant and malignant cells. 
High HIF2α expression has been linked to poor prognosis in several 
tumour types (Bonello et al., 2007). Therefore, our data showed that only 
HIF2α (but not HIF1α) plays a critical role in BC cell lines and BC stem 
cell related study.  
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A number of studies have now shown that cross-talk exists between the 
NFκB and HIF signalling pathways (Fig. 1.6). NFκB stimulates the 
transcription of HIF1, and HIF1 was shown to regulate the activation of 
NFκB (Scortegagna et al., 2008). The human HIF1α promoter contains 
NFκB binding site at a site -197/-188 base pairs upstream of the 
transcriptional start site, the mutation of which leads to a loss of hypoxic 
HIF1α up-regulation. All NFκB subunits could activate the HIF1α 
promoter which is supported by evidence that NFκB family members bind 
to the HIF1α promoter. In vitro, inflammatory mediators increase HIF1α 
mRNA expression through NFκB dependent mechanisms. In vivo study 
demonstrated that NFκB up-regulates HIF1α through transcriptional up-
regulation and furthermore that basal NFκB is a prerequisite for 
constitutive HIF1α expression (Rius et al., 2008). Their study showed 
NFκB has a pivotal role in the high level of constitutive HIF1α mRNA. On 
the other hand, HIF1α can induce NFκB activation. Firstly, 
phosphorylation of IκB leads to its degradation releasing p65 for nuclear 
translocation. p65 was then phosphorylated on Ser276 by ERK1/2. In 
general, inhibition of NFκB might influence the activity of HIF1α and vice 
versa. Further investigation of the mechanisms of hypoxic activation of 
HIF and NFκB and how these signalling pathways interact will guide a new 
therapeutic strategy.  
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Fig. 1.6 Cross-talk between HIF and NFκB in hypoxia. Under normoxic conditions, activated 
HIF1α binds to pVHL and is followed by proteasomal degradation. Hypoxia leads to 
phosphorylation of IκB, releasing NFκB to the nucleus, where it binds to a distinct element at 
197/188 bp of the HIF1α promoter, thus increasing HIF1α mRNA and protein levels. (Adapted from 
Scortegagna et al., 2008) 
1.5 Cancer stem cell 
All tissues in the body have a small population of organ-specific stem cells 
that are defined by their capacity to perpetuate themselves through self-
renewal as well as to differentiate into the mature cells that comprise each 
organ. There has been a growing interest recent years in the role stem cells 
play in health and disease.  
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1.5.1 The concept of cancer stem cells 
It has been proposed that stem cell biology could provide new insights into 
cancer biology. The relationship between stem cells and tumour cells is 
developed from the following observation. First, normal stem cells and 
cancer cells share the similar mechanisms that regulate self-renewal; 
second, tumour cells might be derived from normal stem cells; and third, 
the notion of CSCs with unclear proliferative potential that drives the 
differentiation and growth of tumour cells. 
During the past century, many scientists tried to develop a theory to explain 
cancer pathogenesis and resistance to medications, but the controversial 
topic still exists and there is a largely unknown field in the cancer 
pathogenesis. In a series of landmark experiments, Jacob Furth and Morton 
Kahn demonstrated that after transplantion into a mouse, a single 
leukaemic cell was able to produce a new hematopoietic malignancy (Furth 
et al., 1937). This means certain cells from the cancer cell population might 
possess the ability to repopulate the cancer tissue and initiate new tumour 
growth. In 1960, McCulloch and other researchers found evidence to 
demonstrate that a small population of cells can renew themselves after 
injecting bone marrow cells into irradiated mice (McCulloch et al., 1960). 
All these experiments establish the princple of CSC and provide support for 
the CSC hypotheses. 
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The early definition of the CSC concept is described as “a concept of 
neoplasms”, based upon developmental and oncological principles. It states 
that carcinomas are caricatures of tissue renewal, in that they are composed 
of a mixture of malignant stem cells, which have a marked capacity for 
proliferation and a limited capacity for differentiation under normal 
homeostatic conditions, and of the differentiated, possibly benign, progeny 
of these malignant cells (Pierce et al., 1988). With a greater understanding 
of the role which mutations in oncogenes play in cancer, a clonal evolution 
concept of CSCs was proposed by Nowell, who described that “most 
neoplasms arise from a single cell of origin, and tumour progression results 
from acquired genetic variability within the original clone allowing 
sequential selection of more aggressive sublines. Tumour cell populations 
are apparently more genetically unstable than normal cells. The acquired 
genetic instability and associated selection process, most readily recognized 
cytogenetically, results in advanced human malignancies being highly 
individual karyotypically and biologically. Hence, each person’s cancer 
may require individual specific therapy, and even this may be thwarted by 
emergence of a genetically variant subline resistant to the treatment” 
(Nowell et al., 1976). More recently, with accumulating data from CSCs 
research, the new CSCs hypothesis has been proposed in line with the other 
concepts. This hypothesis has two separate but related components. First, 
tumours originate in either tissue stem cells or their immediate progeny 
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through dysregulation of the normally tightly regulated process of self-
renewal. Second, tumours contain a group of cells that have key stem cell 
properties, which include self-renewal and differentiation. 
Although some scientists have questioned whether CSCs are genuine or not, 
the existence of CSCs has been confirmed by a number of studies on 
experimental animal models. The first confirmation that CSCs existence 
was reported by the John Dick group in 1994. They successfully identified 
and purified human acute myeloid leukaemia initiating cells with distinct 
stem properties (Lapidot et al., 1994). After this, CSCs have been well 
identified and isolated in various hematological as well as solid 
malignancies. In recent years, detecting specific surface markers and 
signalling pathways in CSCs is the main research strategy that leads to 
development of new drugs targeting CSCs in the future. There are several 
limitations and inconsistencies regarding the explanation of CSC origin, 
CSC identification and isolation in CSC hypotheses. Therefore, many 
authors thought that the CSC model couldn’t on its own explain as the only 
reason of cancer pathogenesis. There are many connections between stem 
cells and cancer that are important to understand. More research on stem 
cell biology is producing insight into the origins of cancer and will 
ultimately yield new approaches to fight this disease. The promise of more 
effective new cancer therapies has proven a powerful driver of CSC 
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research, and several theories, supported by sound and sophisticated 
experimental evidence, now merge into a more consistent picture. 
1.5.2 Role of cancer stem cells in tumourigenesis 
The current understanding of human cancer is that cancers can be caused 
by the accumulation of specific genetic mutations. Tumourigenesis 
involves aberrant tissue organization and cell proliferation. CSC is the key 
point to link these two events together. First, CSC provides a cellular 
mechanism that can explain how the genetic and epigenetic changes give 
rise to the tissue changes, and these mechanisms may get involved in 
cancer initiation, progression, invasion, and metastasis. It has been reported 
that overpopulation of mutant colonic SCs is the key point between 
initiating genetic changes with the earliest tissue changes in colon 
tumourigenesis in hereditary cancer patients (Boman et al., 2001; Boman et 
al., 2004). This report indicates that cancer initiation involves the 
development of CSC overpopulation. A number of recent papers show that 
many cancers contain a small population (~1%) of CSCs (Al-Hajj et al., 
2003; Ginestier et al., 2007; Singh et al., 2004; O’Brien et al., 2007). 
However, these cells can regenerate up to 108 - 1013 in total number of fully 
developed cancer cells. Indeed, this must have occurred during all phases 
of tumourigenesis (Boman et al., 2007). It has been found that 
dysregulation of crypt mechanisms can lead to initiation and progression of 
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colon cancer. Moreover, SC overpopulation links abnormalities at the gene 
level and abnormalities at the tissue level from cancer initiation to 
metastasis (Boman et al., 2008). There is a growing amount of evidence, 
which suggests that metastases develop when distant organs are seeded 
with CSCs that arise from a primary tumour. These facts indicate that CSCs 
play a critical role in the seeding and growth of metastatic lesions (Balic et 
al., 2006).  
1.5.3 Cancer stem cells marker 
In the early nineties, some crucial technologies were developed for 
studying hematopoietic stem cells and bone marrow transplantation. A 
single CSC was identified in acute myeloid leukemia (AML) by FACS 
detecting the cell surface markers CD34+CD38- and mouse xenograft 
assays (Lapidot et al., 1994; Bonnet et al., 1997). Nowadays, an important 
step in characterizing CSCs is the detection of specific surface markers. 
This may impact future strategies in anti-cancer drugs design and 
development. Nevertheless, further research efforts are required to 
determine the clinical significance of these findings, and to show whether 
CSCs are a universal property of all cancers. CSCs have been successfully 
isolated from many types of cancers, including the breast, brain, blood 
(leukemia), skin (melanoma), head and neck, thyroid, cervix, lung, organs 
of the gastrointestinal and reproductive tract and retina (Mimeault et al.,  
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2007). Although many CSC-speciﬁc surface markers have been identified 
(Table.1.5), the targeted therapeutic destruction of CSCs remains a 
challenge. Here, I will mainly discuss some important CSCs markers, 
which I am going to use in my study. 
Table 1.5 CSC markers for distinct solid tumour types 
 
(Medema et al., 2013) 
As shown in the table above, although different types of cancer may have 
specific CSC markers, for example, CD271 in melanoma stem cells 
(Quintana et al., 2010), there are a few “pan” CSC markers that are 
expressed in a range of distinct malignancies. These markers are not only 
highly relevant for studies on the biology of CSC, but also could serve as 
useful markers to monitor the efficacy of differentiation therapy and may 
have a potential role as a targeted in cancer therapy. 
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Aldehyde dehydrogenase (ALDH) is a functional marker of CSCs 
(Ginestier et al., 2007). High ALDH activity in the cells may lead to cells 
resistant to chemotherapy drugs (Ginestier et al., 2007). There are 17 
isoforms of ALDH in the human body that also localize to the 
mitochondria in addition to cytosol (Sladek et al., 2003). The kidney and 
liver have been observed to express the highest levels of ALDH (Lissa et 
al., 2013). ALDH has been extensively considered to be a potential marker 
for CSCs due to ALDH activity, which has been linked to normal 
multipotent stem and progenitor cells (Lissa et al., 2013). ALDH positive 
cell population appeared to have better engraftment potential in NOD/SCID 
mice than their ALDH negative counterparts in acute myeloid leukemic 
cells (Cheung et al., 2007). ALDEFLUOR flow showed that on average 8% 
of normal mammary epithelial cells had ALDH activity (Ginestier et al., 
2007). Furthermore, ALDH positive BC cells were capable of forming 
xenograft tumours with as few as 500 cells. However, ALDH negative cells 
cannot form xenograft tumours with as many as 50,000 cells. When we 
isolate breast CSCs by ALDH combined with CD44+/CD24- markers, as 
few as 20 positive cells could form tumours. ALDH activity as a marker for 
CSCs can be used in a number of other solid tumours such as lung, 
pancreas, prostate, liver and head and neck squamous cancer (Ucar et al., 
2009; Jimeno et al., 2009; Hellsten et al., 2011; Ma et al., 2008; Clay et al., 
2010).  
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As early as 1984, the potential role of ALDH in chemoresistance had 
already been identified in a cyclophosphamide-resistant L1210 leukemic 
cell line by John Hilton (Hilton et al., 1984). An experiment result 
regarding early passage colon cancer xenograft tumours found that more 
ESA+, CD44+, ALDH positive cell populations were in the surviving 
tumour cells after cyclophosphamide treatment. When these ESA+CD44+ 
colon CSCs have treated with ALDH inhibitors or ALDH1A1-targeted 
siRNA, CSCs sensitivity to cyclophosphamide increased (Dylla et al., 
2008). That means the chemoresistance seen in their model was specifically 
attributed to elevated ALDH activity (Dylla et al., 2008). Continued studies 
with ALDH inhibitors or inhibitors related pathways that influence ALDH 
activity may provide useful tools in overcoming chemoresistance in CSCs 
or directly impairing CSC growth. 
The other prominent markers among these are CD34, CD133, CD44, and 
CD24 (Al-Hajj et al., 2003; Singh et al., 2003; Ginestier et al., 2007). 
CD34 is one of the first CSC markers to be well characterized in acute 
myeloid leukemia stem cells as a hematopoietic stem cell marker (Singh et 
al., 2004). As a famous CSC surface marker, CD133 has also been widely 
investigated since its identification as a marker of glioblastoma multiforme 
stem cells (You et al., 2010). CD133 is a glycosylated protein with five 
transmembrane domains and two large extracellular loops. At the 
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beginning, CD133 positive phenotype was used to identify and isolate brain 
tumour stem cells in malignant tumours, but more recently, it has been used 
to define the CSC populations in some different types of cancer, including 
breast, lung, pancreatic, liver, prostate, gastric, colorectal, and head and 
neck cancers. CD133 positive cell populations show the ability to maintain 
CSCs in multiple tissues. Furthermore, CD133 positive cells undergo 
multi-lineage differentiation to neurons, astrocytes, and oligodendrocytes in 
vitro. Nestin, BMI1, Olig2, and Nanog genes have been found up-regulated 
in CD133 positive populations of brain, lung, liver and prostate cancers 
(Ma et al., 2008; Miki et al., 2007; Bertolini et al., 2009). CSCs are 
considered to be one of the reasons for resistance to traditional 
chemotherapies. CD133 positive cells have an increased survival rate in 
vitro and have been enriched in vivo after treatment with cisplatin (CDDP), 
etoposide, Dox, and PAC (Chen et al., 2008; Zhang et al., 2010a). CD44 is 
an 85-90kDa transmembrane glycoprotein containing 10 standard exons 
and four major domains, including the hyaluronan binding and variably 
spliced regions, the transmembrane sequence and the intracellular 
cytoskeletal-signalling domain (Fang et al., 2012). CD44 is presenting the 
characteristics of CSCs across tissues, including breast, pancreas, gastric, 
head and neck, ovarian and colon, whereas CD24 is not (Verkaik et al., 
1999). Results showed that invasive CD44 positive prostate cells also 
induced the expression of Nanog, BMI1 and SHH, which is similar to 
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CD133 positive cells (Klarmann et al., 2009). CD44+and CD24- is a marker 
to define the breast CSCs population (Al-Hajj et al., 2003). Around 50% of 
tumour initiating cells with a wide spectrum of CSC markers could be 
found in this whole tumour cell population, such as CD133, CD271 and 
ALDH1. Despite the huge number of melanoma stem cells, some have 
argued that the CSC model may not apply to melanoma (Quintana et al., 
2010; Roesch et al., 2005). The rate of CSC population can vary widely 
from 1% to 50% based on the different cancer type with their tumorigenic 
potential (Hoek et al., 2010). Moreover, other studies have suggested that 
the ability of CSCs to transition between invasive and proliferative states is 
governed by prevailing tumour microenvironment (Hoek et al., 2010). 
Regardless of the debate over the existence of CSCs, tumour 
transdifferentiation still presents an attractive therapeutic opportunity 
because the cancer cells will transit to a postmitotic and terminally 
differentiated state, which could significantly attenuate tumour progression. 
1.5.4 Cancer stem cells and chemotherapy 
Nowadays, although significant advances have been made in molecular 
biology and clinical medicine, cancer still remains a major public health 
problem all over the world. Standard chemotherapy and radiotherapy have 
failured to eliminate all malignant cells in the body. Chemotherapy remains 
an important part of treatment for most types of cancer. Unfortunately, 90% 
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of drug failures in metastatic cancers are attributed to chemoresistance 
leading to cancer recurrence (Longley et al., 2005). Understanding the 
mechanisms of chemoresistance is very important for developing new 
therapeutic approaches to treating cancer. There is growing evidence that 
CSCs play a critical role in chemoresistance in a number of cancers. 
Identification and isolation of CSCs in various tumours is the first step to 
investigating the mechanisms by which CSCs can contribute to tumour 
initiation as well as continued tumour progression. Understanding the 
mechanisms of CSCs in chemotherapy and tumour relapse is important as it 
provides clues to better addressing cancer therapy. 
It is often suggested that CSCs are resistant to therapy in the same way that 
normal stem cells are protected against insult. These protection 
mechanisms include, quiescence (Guzman et al., 2002), expression of ABC 
drug pumps (Jones et al., 2004), high expression of anti-apoptotic proteins 
and resistance to DNA damage (Richardson et al., 2004). They may display 
increased resistance to chemotherapy agents compared with more 
differentiated cells that comprise the bulk of tumours. It has been reported 
that leukemic stem cells are more resistant to chemotherapy than are the 
more differentiated myeloblastic cells that constitute the vast majority of 
cells in leukemia. A similar finding has shown that myeloma stem cells are 
resistant to the chemotherapy used for myeloma therapeutics (Guzman et 
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al., 2002; Jones et al., 2004; Richardson et al., 2004). Long-term 
quiescence may be a crucial mechanism for the resistance of CSCs to anti-
proliferative chemotherapy. CSCs occur in a quiescence state under certain 
conditions. Cell cycle assay shows that many CSCs are not cycling and are 
in G0 and thus resistant to cell cycle-specific chemotherapy agents. 
Moreover, stem cells are often identified by their propensity to retain DNA 
labels much longer than their rapidly proliferating offspring. This would 
explain the appearance of local recurrence or distant metastasis after long 
lag periods. Apart from this, there are still several molecular mechanisms 
that may lead to the resistance of CSCs to apoptosis.  
1.5.5 Cancer stem cells and hypoxia 
Over the past decade, accumulating data indicated that hypoxia contributes 
to cancer progression by activating adaptive transcriptional programs that 
promote cell survival, motility and tumour angiogenesis. I have discussed 
the role of NFκB in the cancer cells under hypoxic condition and the 
interaction between NFκB and HIF pathways in the previous paragraphs. 
Hypoxia can activate the NFκB signalling pathway in cancer cells. NFκB 
stimulates the transcription of HIF-1, and HIF1 was shown to regulate the 
activation of NFκB (Scortegagna et al., 2008). In general, inhibition of 
NFκB might influence the activity of HIFs and vice versa. CSCs are rare in 
cancer cells but have been recognized as a new mechanism to explain 
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chemoresistance and tumour relapse. Here, I will discuss hypoxia and 
CSCs concepts, the molecular connections between hypoxia-induced 
transcription factors (HIFs) and NFκB in CSCs, and how these results add 
an important new facet to our traditional view of hypoxia and cancer. 
Stem cell “niche” is defined as a physiologically limited and specialized 
microenvironment that maintains the combined properties of stem cell self-
renewal and multipotency. The common features and functions of all stem 
cell niches have been described as follows. (a) The stem cell niche is 
composed of a special population of cells that functions to maintain stem 
cells. (b) Stem cells are anchored in the niche by adhesion molecules, 
which are involved in the interaction between stem cells and the niche and 
between stem cells and the extracellular matrix. (c) The niche generates 
extrinsic factors that control stem cell numbers through the balance 
between proliferation and differentiation. (d) Hypoxia is a major 
characteristic of cells in the niche. Both normal stem cell and CSC share 
the common features of self-renewal and slow cycling in the niches to 
protect them from chemotherapy. The CSCs in the hypoxic niche have 
been implicated in tumorigenesis (Simsek et al., 2010). 
CSCs are slow growing subpopulations of tumours with the ability to 
repopulate eradicated cancer cells resulting in cancer recurrence and patient 
mortality. Most solid tumours exhibit hypoxic conditions inside their mass. 
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Hypoxia is both a physiologic stimulus and a micro environmental feature 
in a range of cancers including BC and brain tumours. Hypoxia may lead to 
increased resistance to radiotherapy and chemotherapy through activation 
of HIF factors in cancer therapy. Moreover, hypoxia may directly change 
the function of tumour cells with stimulation of de-differentiate and release 
angiogenic factors to increase blood and oxygen supply (Holmquist et al., 
2006). It is believed that CSCs play critical roles in treatment resistance 
and recurrence after conventional therapy through multiple mechanisms 
and networks. A number of studies have confirmed that hypoxia and HIF 
signalling pathway play an important role in both intrinsic and acquired 
resistance to conventional therapeutics in most solid tumours. Clonogenic 
assay showed that high expression of HIF1 increased the resistance to 
radiation under both normoxic and hypoxic conditions. Meanwhile, when 
the activation of HIF1 signalling pathway has been blocked by HIF1α 
inhibitors, the sensitivity of tumour to radiation therapy has increased in 
vitro and in vivo (Liao et al., 2007; Strofer et al., 2011). Several 
mechanisms of how hypoxia and HIF pathway lead to therapeutic 
resistance have been proposed, some of which are similar to the CSCs 
resistant mechanisms, such as hypoxia-induced cell cycle arrest, impaired 
DNA repair system, altered cellular metabolisms through multiple 
signalling pathways, and decreased cytotoxicity due to the lack of oxidation 
of DNA free radicals by hypoxia. It has also been considered that hypoxia 
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induced development and maintenance of CSCs would contribute to 
increased therapeutic resistance.  
There is plenty of supportive evidence showed that hypoxia and HIF 
signalling pathway play pivotal roles in the regulation of the phenotype and 
function of CSCs. Hypoxia regulates the sub-population of normal stem 
cells and maintains the normal tissues or non-stem cell tissues in a stem cell 
state during embryonic and adult development (Fraker et al., 2009; 
Dunwoodie et al., 2009). In glioma CSCs, hypoxia enhances the self-
renewal capacity and maintenance of undifferentiated state of CSCs (Soeda 
et al., 2009; Panchision et al., 2009). Hypoxia maintains the stem-like 
phenotypes in neuroblastomas and activates signalling pathways that are 
associated with undifferentiated phenotypes of normal stem cells (McCord 
et al., 2009). Moreover, hypoxia triggers cancer stemness genes such like 
(sex determining region Y)-box 2 (Sox2), octamer-binding transcription 
factor 4 (Oct4) and Nanog may be one of the major reasons of tumour 
aggressiveness. Accumulating data show that there is a special areas which 
is hypoxic called niche in a tumour and it is also the areas of necrotic 
tumour tissues where CSCs reside (Simsek et al., 2010). It is possible that 
tumours may develop from mutation in normal stem cells or from non-stem 
cell population during hypoxic conditions. It is believed that HIF1α and 
HIF2α are the main factors to regulate the hypoxia-mediated phenotype and 
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function of CSCs (Zeng et al., 2011; Heddleston et al., 2010). The 
expression of both HIF1α and HIF2α are associated with tumour 
aggressiveness. Several studies have demonstrated that hypoxia-induced 
HIF-1α overexpression promotes the phenotype and function of CSCs, and 
up-regulation HIF targeting genes such as Oct4, Nanog, c-Myc, Notch-1, 
and CD133 (Li et al., 2010; Mathieu et al., 2011; Covello et al., 2006; 
Gordan et al., 2008). HIF2α also plays an important role in the regulation 
of CSCs. In my study, it has been shown that HIF2α is highly expressed in 
CSCs of BC. Hypoxia induces the expression of HIF2α thereby increasing 
the expression of stem cell markers including CD133, Oct4, Nanog, Sox2, 
and c-Myc in CSCs (Bar et al., 2011). All these findings strongly suggest 
that HIF1α and HIF2α are required for the phenotype and function of CSCs. 
HIFs activate the expression of at least 150 genes encoding proteins, 
including NFκB. The NFκB is a well-known critical transcription factor in 
a wide range of cancers that regulates the expression of NFκB target genes 
associated with a variety of cellular processes. Moreover, NFκB also plays 
an important role in CSCs, contributing to tumour aggressiveness (Wang et 
al., 2009; Sarkar et al., 2008; Widera et al., 2008). Many studies have 
indicated that hypoxia could activate NFκB signalling pathway in cancer 
cells. NFκB is primarily a regulator of anti-apoptotic gene expression. It is 
very possible to believe that under hypoxic condition, the activation of 
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NFκB is required to inhibit apoptosis to enable a hypoxic cell to survive. 
Both HIF and NFκB signalling pathways are play a critical role in 
maintenance of stem cell phenotype and function in tumour 
microenvironment. Overall, it is reasonable to speculate that hypoxia 
induced NFκB activation may be contributing to the maintenance of CSCs 
during the development and progression of tumours.  Understanding of the 
precise molecular mechanism of hypoxia regulation of NFκB in CSCs 
would allow designing of targeted approach for the development of new 
therapeutics to improve the overall survival of malignancies patients. 
1.6 Disulfiram 
Disulfiram (DS), tetraethylthiuram disulfide, was developed in 1881. A 
German chemist called M. Grodzki had synthesized a new compound from 
thiocarbamide with its stoichiometric formula C10H20N2S4 (Grodzki et al., 
1881). Twenty years later, DS was first introduced in the developing rubber 
industry to accelerate the vulcanization of rubber (Eneanya et al, 1981) and 
widely used in the vulcanization of both natural rubber and synthetic rubber 
products. From the early 1940s, DS was used in medicine by two British 
physicians as it was a promising drug against scabies (Gordon et al., 1942). 
Then, it was used in the treatment of chronic alcoholism based on the 
finding of Hald and Jacobsen that ingestion of alcohol after DS treatment 
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would lead to highly disagreeable reactions (Eneanyn et al, 1981). Its 
clinical use over a long period of time has shown it to be a very safe drug 
with minimal and manageable toxic effects, even at fairly high doses of 300 
to 500 milligrams a day. Its bioavailability is excellent (more than 80%), 
and after taking the drug 20% remains in the body for up to two weeks 
(Sauna et al., 2005).  
After cases of alcoholic BC patients being treated with DS whose cancer 
spontaneously regressed, some scientists began investigations into the 
possible uses of DS in cancer treatment (Wang et al., 2003). As cancer 
research further develops, a key issue in anticancer therapy is reversing 
drug resistance. Many investigations have been carried out into agents that 
may target more than one cellular pathway in order to decrease the 
development of drug resistant tumour cells or to sensitise cancer cells to 
chemotherapy drugs (Guo et al., 2009; Wang et al., 2003).  
1.6.1 Disulfiram metabolism  
DS could be viewed as two molecules of diethyldithiocarbamic acid 
molecules joined together by a disulphide bridge with its molecular weight 
296.54 (Fig. 1.7). 
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Fig. 1.7 Chemical structure of Disulfiram (Sauna et al., 2005) 
The metabolism of DS is described in Fig. 1.8. First, DS (I) is converted to 
diethyldithiocarbamic acid (DDC) (II) by a reduction of the disulfide 
linkage to its corresponding thiol. Some groups reported that the 
glutathione reductase can reduce DS in the erythrocytes. The data showed 
that up to 50g of DS can be decreased by the adult human erythrocyte 
within 24 hours (Stromme et al., 1963). In vitro studies showed that DS 
was promptly reduced to the thiol within 4 min (Cobby et al., 1977). There 
are four different pathways for DDC to be further metabolized, including 
glucuronidation, nonenzymatic degradation, methylation, and oxidation. 
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Fig. 1.8 The metabolic fate of disulfiram. I. Tetraethylthiuram disulfide (disulfiram), II. 
Diethyldithiocarbamic acid, III.  Glucuronide of diethyldithiocarbamate, IV. Diethylamine, V. 
carbonyl disulfide, VI. Sulfur, VII. Carbonyl sulfide, VIII. Carbon dioxide, IX. Sulfate, X. methyl 
ester of diethyldithiocarbamate, XI. Methyl mercaptan, XII. Formaldehyde, XIII. thiocarboxylic acid. 
(a) Glutathione reductase, (b) conjugation, (c) nonenzymatic degradation, (d) oxidative desulfuration 
(C-P450), (e) oxidation, (f) sulfoxidase, (g) esterases, (h) S-methylation: S-adenosyl methionine 
transmethylase. (Eneanyn et al, 1981) 
Glucuronidation The main detoxification mechanism of DS is DDC 
conjugation of glucuronic acid in mammals (Fig. 1.8). 50% of a given dose 
of glucuronide metabolite is excreted in urine by the metabolism studies of 
radioactive DS in a rat. (III) (Stromme et al., 1966) (Fig. 1.9). However, 
there is still another possibility, that a small number of the conjugated 
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glucuronide are hydrolyzed by the esterases in the intestine during 
enterohepatic circulation without relating to DDC. 
 
Fig. 1.9 Glucuronidation of diethyldithiocarbamic acid (Eneanyn et al, 1981). 
Nonenzymatic degradation DDC decomposition rate is pH dependent. 
DDC decomposes rapidly to diethylamine (IV) and carbon disulphide (V) 
in acid environment (Stromme et al., 1966). There is a possibility that 
diethylamine may be further degraded to ammonia and to acetaldehyde.  
Carbon disulfide is oxidatively desulfurated to carbonyl sulfide (VII) and 
sulfur with the help of NADPH and cytochrome P450 (Dematteis et al., 
1974). Carbonyl sulfide can be further oxidized to carbon dioxide and 
sulfur, meanwhile, it can be metabolized to sulfate by the sulfoxidases 
(Faiman et al., 1978). During either carbon disulfide poisoning or DS 
intoxication, a large number of sulfate ions is found in the urine of 
mammals from these observations 
Methylation Radiochemical experiments results showed that there is still 
0.05% of the given dose of DS present as methyl ester of DDC (MeDDC) 
intraperitoneally and 2 hours later (Cobby et al., 1977). Furthermore, when 
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DDC was administered to dogs intravenously, S-methylation accounted for 
approximately 27% of metabolism of the given dose (Gessner et al., 1972). 
S-methylation is normally implicated in the metabolism thiopurines, 
thiopyrimidines, and thiopentals (McBain et al., 1969). Esterases may 
target the methyl ester of the DDC derivative (X) to generate a methyl 
mercaptan which may in turn be oxidized to sulfate and formaldehyde. It is 
important to know that the production of sulfate from other thioester 
compounds is a rapid process. For example, 6-methylmercaptopurine 
generates sulfates quicker than 6-mercaptopudne when administered to rats 
(Canellakis et al., 1953). The possible reason may be S-methyl compound 
oxidation to produce inorganic sulfate by cleavage of methyl mercaptan 
(Maw et al., 1954). 
This methylation pathway is an important sulfate-forming pathway in the 
metabolism of DS as 62-74% of sulfate formed, which is involved in 
methylmercaptan oxidation (Gessner, et al., 1972). The methyl ester of 
DDC does not go through the covalent disulfide interchange reaction by 
which DS inhibits aldehyde dehydrogenase, so it is very stable in blood 
(Kitson et al., 1976). Thioalcohol (XIII) formed from this methylester can 
be glucuronidated and excreted in urine. 
Oxidation It is known that under atmospheric oxygen condition, DDC can 
be reoxidized to DS. Interesting data demonstrated that DDC can change 
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back to DS by reoxidation (Strume et al., 1965), but only about 4% of DDC 
involved. Such a reoxidation can be effected by the oxidases in the body. 
1.6.2 Disulfiram and diseases treatment 
1.6.2.1 Anti-alcoholism  
DS has been used for over 50 years as an anti-alcoholism drug (Petersen et 
al., 1992; Johnsen et al, 1992; Kampman et al., 2009). DS and many of its 
metabolites (S-Methyl-N,N-diethylthiocarbamate sulfoxide  (MeDTC-SO), 
S-Methyl-N,N-diethyldithiocarbamate sulfoxide  (MeDDC-SO)  and S-
Methyl-N,N-diethyldithiocarbamate sulfine (MeDDC-sulfine))  are 
irreversible inhibitors of the enzyme ALDH1 by oxidising  essential  
sulfhydryl groups  to form irreversible  internal  S-S  bonds  (Vallari et al,  
1982). Alcohol consumption after having taken DS would lead to the build-
up of acetaldehyde in the plasma as a result of alcohol oxidation. ALDH1 
plays a role in the removal of acetaldehyde. Acetaldehyde in the plasma 
would mediate histamine release leading to flushing of the skin, owing to 
cutaneous vasodilatation particularly on the trunk, hypotension because of 
decreased diastolic blood pressure, reflex tachycardia, tachypnoea, a 
sensation of warmth, palpitations, anxiety, headache, nausea, and vomiting.  
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1.6.2.2 Anti-cancer treatment  
DS has also been studied as a potential anti-cancer drug (Brar et al, 2004). 
In vitro, DS demonstrated the ability to inhibit the growth of several cancer 
cell lines. Importantly, in a single case study on a 64 year old woman with 
hepatic metastasis that originated from ocular melanoma, DS showed the 
ability to suppress hepatic metastasis and shrink the tumours by >50% in 
size. In addition, the woman remained clinically well and physically active 
after 53 continuous months of DS therapy (Brar et al, 2004). It has been 
reported that DS could sensitise chemotherapy resistant tumours to 
chemotherapy treatments by inhibiting ATP-driven efflux pumps in cancer 
cells (Sauna et al, 2005). On top of chemosensitizing effect of DS, studies 
also showed that DS is cytotoxic to cancer cells in a biphasic manner 
(Wickstrom et al, 2007; Cohen et al, 1990). A clinical trial has shown that 
the prognosis was improved for a group of BC patients who received 
anticancer treatment plus DS compared with another group who had the 
same treatment without DS (Dufour et al., 1993). To date, although the full 
effects of DS are still not fully understood, studies have shown that DS and 
its metabolites target a number of different cellular pathways within the 
human body and have several mechanisms of action, mainly due to their 
metal chelating properties and reactions with key cysteine residues in 
particular proteins (Sauna et al., 2005). These signalling pathways include, 
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inhibition of DNA topoisomerase preventing DNA transcription and 
replication, inhibition of MMPs leading to the inhibition of tumour cell 
metastasis, inhibition of the proteasome leading to inhibition of the NFκB 
signalling pathway and downstream expression of cancer survival genes, 
and inhibition of superoxide dismutase (SOD) and increasing intracellular 
copper (Cu) level leading to toxic build-up of ROS (Sauna et al., 2005).  
1.6.2.3 Reactive Oxygen Species and Copper 
ROS are essential for biological functions. The unpaired electrons of 
oxygen react to form partially reduced highly reactive species that are 
defined as ROS, including superoxide (O2
-), hydrogen peroxide (H2O2), 
hydroxyl radical, and peroxynitrite. Mitochondria are considered the major 
source of cellular ROS, electron leakage from the mitochondrial respiratory 
chain may react with molecular oxygen, resulting in the formation of 
superoxide, which can subsequently be converted to other ROS (Schafer et 
al., 2001). ROS can be also gained through a reaction catalysed by NADPH 
oxidase complexes or as a by-product of certain biochemical reactions, 
such as β-oxidation in peroxisomes, prostaglandin synthesis and 
detoxification reactions by cytochrome P450 (Perry et al., 2000). A mild 
increase in the level of ROS can promote cell proliferation and 
differentiation, whereas excessive amounts of ROS can cause irreversible 
oxidative damage to lipids, proteins and DNA, leading to cell death 
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(Boonstra et al., 2004; Schafer et al., 2001; Perry et al., 2000). Therefore, 
maintaining the ROS level is important for cell growth and survival. The 
ROS level is controlled in cells by balancing ROS generation with their 
elimination by ROS-scavenging systems such as superoxide dismutases 
(SOD1, SOD2, and SOD3), glutathione peroxidase, peroxiredoxins, 
glutaredoxin, thioredoxin and catalase (Boonstra et al., 2004). Cancer cells 
are known to be metabolically active and under increased oxidative stress. 
Increased cellular ROS regulates signalling pathways by directly reacting 
with and modifying the structure of proteins, transcription factors and 
genes to control cell growth and differentiation. The following mechanisms 
are considered to contribute to increase ROS in cancer cells. (a) Oncogenic 
signals inducing ROS generation. (b) Malfunction of the mitochondrial 
respiratory chain leading to increased amounts of ROS. (c) High level of 
ATP energy demand putting a further stress on the mitochondrial 
respiration chain to induce ROS generation. (d) Decreasing the expression 
or the activity of antioxidant enzymes, which causes ROS accumulation 
(Davies et al., 1999).  
High ROS stress can induce various biological responses, including 
adaptation, increased cell proliferation, DNA damage, apoptosis, and 
necrosis (Davies et al., 1999). In order to protect cells against increased 
ROS stress, one adaptation mechanism is the glutathione system 
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(GSSG/2GSH) and thioredoxin system, which maintain cellular redox 
balance (Schafer et al., 2001; Sasada et al., 1996). Another mechanism is to 
up-regulate the expression of antioxidant enzymes such as SOD, catalase, 
and peroxidases. It is known that an increase of certain ROS such as 
superoxide and hydrogen peroxide may promote the proliferation of cancer 
cells due to modulation by ROS of the redox states of signalling molecules. 
The transcription factors NFκB, HIF-1α and intermediate signalling 
molecules such as MAPK and JNK have also been shown to be involved in 
ROS-mediated modulation of cell growth and cell survival (Martindale et 
al., 2002). Moreover, ROS could induce DNA lesion due to its capacity to 
attack various components of DNA, leading to the generation of a variety 
of ROS-mediated modified products including oxidized bases, DNA strand 
breaks, and DNA intra-strand adducts (Randerath et al., 1996; Lloyd et al., 
1997). Excessive ROS may induce cellular injury and cell death by 
damaging the mitochondrial membrane, and this damage is likely to cause 
the release of cytochrome c and activate the apoptotic cascades (Hensley et 
al., 2000). ROS show low or mild level in many cancer cells, and further 
increased ROS will lead cells to apoptosis after exposure to anti-cancer 
drugs.  
Cu is an essential trace element for humans and high intracellular 
concentrations of Cu have been found to generate ROS in cells which can 
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damage DNA, protein and lipid membranes eventually resulting in 
apoptosis. The transport of Cu into cells is tightly controlled by a member 
of the Cu transporting family which termed Ctr1. As DS is a strong metal 
chelator (Morrison et al., 2010), it can increase the cellular uptake of Cu 
leading to activation of ROS and apoptosis. ROS also activates NFκB, 
triggering anti-apoptotic factors which decrease this effect but the DS/Cu 
complex both increases ROS and inhibits NFκB, so the overall effect seems 
to sensitise cells to chemotherapy drugs (Guo et al., 2009; Liu et al., 2012; 
Yip et al., 2011). It has been reported that DS can enhance the anti-tumour 
efficacy of external-beam γ-irradiation and 131I-metaiodobenzylguanidine 
(131I-MIBG) through induction of ROS and inhibition of proteasome 
activity (Rae et al., 2013). Moreover, DS used alone or in combination with 
Cu, causes loss of mitochondrial membrane potential, and activates the 
production of ROS and death caspases in malignant haematological cell 
lines (Conticello et al., 2012). The important role of ROS in this was 
shown as the effect could be reversed by addition of the antioxidant N-
acetylcysteine. There have also been reports of DS, in conjunction with 
zinc, triggering ROS production leading to apoptosis in pancreatic 
adenocarcinoma cell lines. The apoptotic effects of DS/zinc were stronger 
when used in combination with dFdC, and the effects were even more 
pronounced in dFdC-resistant cells (Dalla et al., 2011). 
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Due to the high oxygen demands of cancer cells and the inability of the 
microenvironment to deliver this demand, cancer cells develop hypoxia 
(Ruan et al, 2009). Under hypoxia conditions, cancer cells increase the 
production of ROS as a result of incomplete metabolism. ROS are 
signalling molecules that activate the expression of and stabling of 
hypoxia-inducible factors (HIFs). HIFs are transcription factors that 
activate hypoxia response genes, such as VEGF and SOD (Ruan et al, 2009; 
Tuller et al, 2009).VEGF promotes blood vessel growth (angiogenesis) to 
the tumour, thus providing the tumour with its own blood supply of 
unlimited source of nutrients and a route for tumour metastasis (Chen et al., 
2009). In addition, ROS also inhibit PTEN, a phosphatase which inhibits 
AKT signalling pathway by the dephosphorylation of phosphatidylinositol-
3, 4, 5-trisphosphate (PI-3, 4, 5-P3) to phosphatidyl-4, 5-bisphosphate (PI-4, 
5-P2) (Fruehauf et al, 2007). Activation of the AKT pathway would inhibit 
apoptosis and stimulate cell proliferation. However, too much ROS is 
cytotoxic and could damage nuclear and mitochondrial DNA. Therefore, 
ROS levels are tightly controlled in cancer cells by maintaining an 
adequate level of SOD and glutathione-peroxidase. SOD catalyses the 
conversion of ROS to H2O2 and H2O2 is converted to water by glutathione-
peroxidase (Fruehauf et al, 2007). Interestingly, high Cu levels would 
induce hepatocellular injury and cell death. Cu-induced cell death is 
associated with an increase in ROS generation (O2-) through reduction of 
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Cu2+ to Cu1+ in the GSH to GSSH. This would eventually deplete the 
glutathione pool leading to accumulation of high ROS levels and cell death. 
Cancer cells carefully maintain this balance of Cu and ROS levels to 
prevent death while accessing the ROS signalling pathway to stimulate 
hypoxia-induced cancer cell proliferation. DS has been shown to increase 
the intracellular Cu level (Cen et al, 2004).  
1.6.2.4 Cytotoxic mechanisms of disulfiram  
The exact mechanisms of DS to target cancer cells still remains to be 
elucidated. However, studies suggested that DS targets many signalling 
pathways which are essential for the survival of cancer cells. In vivo and in 
vitro studies showed DS to be an effective anti-cancer drug capable of 
reducing cancer cell proliferation and metastasis. More importantly, the 
cytotoxicity of DS is cancer specific (Daniel et al., 2005). The theory has 
been put forward that the mode of cancer specificity is due to elevated 
intracellular Cu level in cancer cells. DS chelated Cu to form a complex 
Cu(deDTC)2inside cancer cells (Margalioth et al., 1983). This would lead 
to the inhibition of the proteasome and NFκB pathway. The DS/Cu 
complex is the active inhibitor of the proteasome, therefore, the higher Cu 
level in cancer cells would result in higher DS/Cu complex formation, 
which is toxic to cancer cells. The level of DS/Cu complex formed in 
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normal cells does not reach the toxicity level observed in cancer cells, thus 
making DS-cytotoxicity cancer-specific. 
Inhibition of aldehyde dehydrogenase and NFκB 
It has been found that amplified ALDH activity can be used as a marker of 
CSCs (Ginestier et al., 2007) and can be a factor in causing resistance of 
BC cell lines MDA-MB-231 and MDA-MB-468 to chemotherapeutic drugs 
and radiotherapy (Croker et al., 2012). DS inhibits ALDHs (Eneanya et al., 
1981) and studies from our groups  found that that DS/Cu inhibited the 
ALDH-positive cells in a BC stem cell population, preventing them from 
creating mammospheres after 24 hours of exposure to the drug. 
NFκB is a transcription factor and the signalling pathways which activate it 
have a central role in the immune system’s response to infection. It is found 
in the cytoplasm of normal cells as an inactive protein complex consisting 
of five subunits, p50/p105, p52/p100, p65(RelA), RelB and C-Rel which 
can bind as homo- or hetero-dimers to the promoter region of target DNA 
sites (known as κB sites) to trigger gene expression downstream in the 
signalling pathway. When stimulated, its inhibitor IκB is phosphorylated, 
ubiquitinised and degraded, therefore allowing NFκB dimers to be freed 
from the complex, which then translocate to the nucleus to begin 
transcription. Therefore, NFκB plays an important role in cancer 
development and progression. Inhibition of the proteasome is an indirect 
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method of inhibiting NFκB. Because NFκB is constitutively active and 
over-expressed in cancer cells, it suggests that NFκB must be vital for 
cancer cell survival, development and metastasis. Therefore, inhibition of 
NFκB would result in the inhibition of cancer cell survival, development 
and metastasis. 
It has been shown that DS and its active metabolites such as 
diethydithiocarbamate (DDC) can inhibit NFκB activity, which has been 
activated by ROS, in colorectal cancer cell lines, p53 mutant DLD-1 and 
p53 wild-type RKOWT, by interacting with the sulfhydryl groups on the 
Rel homology (RH) domain, which enhances the cytotoxic effect of 5-FU 
anticancer drug and reverses the resistance of the cell line to 5-FU (Wang 
et al., 2003). Our groups showed that a DS and Cu complex increased the 
cytotoxicity of dFdC by inhibiting the increased NFκB activity caused by 
over-exposure to the drug and reversed the resistance to the drug in breast 
and colon cancer cell lines.  NFκB activity has been shown to be decreased 
by DS in hepatoma Hep G2 cells, and this study also showed that DS 
caused apoptosis and G1/S arrest mediated by p53 (Liu et al., 1998). Other 
research demonstrated that when treated with DS, the NFκB activity 
decreased in cerebral endothelial cells, in this case thought to be due to its 
ability to increase cellular levels of zinc (Kim et al., 2000). Data showed 
that induction of cleaved caspase-3 (a marker of apoptosis) expression 
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occurred via inhibition of the NFκB signalling pathway when human 
herpes virus-8 infected primary effusion lymphoma cells were treated with 
DDC (Matsuno et al., 2012). 
1.7 Project aims 
CSCs play a main role in cancer cell chemoresistance which is the major 
obstacle for the success of BC chemotherapy. Therefore, development of 
CSCs-targeting drug is of significant clinical importance. The ultimate goal 
of my study is to determine the anticancer efficacy of a newly developed 
liposome encapsulated disulfiram (Lipo-DS) in vitro and in vivo. This 
project was designed to achieve the following aims. 
To determine the relationship between hypoxia and CSCs and investigate 
the function of NFκB in bridging hypoxia and CSC-related 
chemoresistance in BC cell lines. 
To investigate the CSC traits and chemoresistant characteristics in acquired 
chemoresistant BC cell line. 
To examine the cytotoxic effect of a newly developed Lipo-DS on BC cell 
lines, especially BCSCs, in vitro and in vivo. 
To investigate the molecular anticancer mechanisms of Lipo-DS in vitro 
and in vivo. 
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2. Material and Methods 
2.1 Materials  
2.1.1 General reagents, enzymes and kits  
Enhanced Chemiluminescence Western Blot Signal Detection Kit 
(Amersham Biosciences, UK)  
BD FACSCalibur™ Flow Cytometer, CellQuest™ Pro (BD Biosciences, 
Oxford, UK) 
Stuart® 3 block heater (Bibby Scientific Ltd., Straffordshire, UK) 
EZ-ECL chemiluminescence detection kit for horse radish peroxidise 
Solution A and B (Biological Industries Beit Haemek Ltd., Isreal) 
Bio-Rad protein assay kit II (Bio-Rad Laboratories, Hertfordshire, UK) 
Dulbecco’s Modified Eagle Medium (DMEM) with 4.5 g/L glucose, Foetal 
Calf Serum (FCS), L-Glutamate (200 mM) (BioWhittaker® Lonza, 
Walkersville, USA) 
Penicillin-streptomycin mixture (10,000U/ml penicillin and 10,000U/ml 
Streptomycin) (BioWhittaker® Lonza, Walkersville, USA) 
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Sterile Phosphate Buffer Saline (PBS) (0.0067M PO4) (BioWhittaker® 
Lonza, Walkersville, USA) 
Trypsin-EDTA (10x) (BioWhittaker® Lonza, Walkersville, USA) 
Microscope slide (ERIE SCIENTICFIC Company Portmouth.N.H., US) 
Fuji Medical X-Ray Film Super RX (13x18) (Fujifilm UK Ltd., 
Bedfordshire, UK) 
Amersham Hybond ™ - P (PVDF membrane), Amersham Hybond TM - N+ 
(GE Healthcare, Buckinghamshire, UK) 
30% acrylamide:bis-acrylamide (37.5:1) (GeneFlow, UK) 
10× Transfer buffer (GeneFlow, UK) 
10× Electricpresis buffer (GeneFlow, UK) 
Semi-dry transfer unit (Hoefer, Inc., Holliston, USA) 
NuPAGE ® LDS Sample Buffer (4x), SeeBlue plus 2 pre-stained protein 
markers (Invitrogen Ltd., Paisley, UK) 
10×TAE buffer, G418, Trizol, Optimem, Hygromycin B, Lipofectamine 
transfection reagent (Invitrogen Ltd., Paisley, UK) 
Nalgene Cryoware™ Cryogenic vials (Labware, Roskilde, Denmark)  
Marvel dried milk (Marvel, Dublin, Ireland)   
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10, 25, 50 and 100 ml tubes (Merck Sharp & Dohme (MDS) Ltd., 
Hertfordshire, UK) 
AccuGel 40% (19:1 acrylamide:bis), Running buffer (10X, contains 
distilled H2O, Tris/Glycine/SDS) (National Diagnostics, Yorkshire, UK)  
BamH I and Hind III enzymes and associated buffers (New England 
Biolabs) 
Restriction enzymes and associated buffers, pfu polymerase, Luciferase 
assay kit, Gel shifting assay kit, 1Kb DNA ladder, 100Kb DNA ladder, 
Dual Luciferase Assay reagents, Access RT-PCR system (Promega UK 
Ltd., Southampton, UK)  
Qiaquik gel extraction kit, Qiafilter maxiprep kit, Qiafilter miniprep kit 
(Qiagen, West Sussex, UK) 
RNase A (100 mg/ml) (Qiagen Ltd., West Sussex, UK) 
Complete EDTA free protease inhibitor tablets, Rapid Ligation kit (Roche 
Diagnostics Ltd., East Sussex, UK)  
Complete easy packs-Protease inhibitor cocktail tablets (Roche Diagnostics 
Ltd., West Sussex, UK)   
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96-well flat-bottom tissue culture plates with lids, Tissue culture Cell+ 
flasks with PE ventilation caps, Filtropur V50.0.2 Vacuum Filter (500 ml), 
Cell scrapper (Sarstedt Ltd., Leicester, UK) 
disulfiram, Cu Chloride (CuCl2), minisapt plus (0.20 μm) filter, cisplatin 
(CDDP), paclitaxel (PAC) , doxorubicin (Dox) , gemcitabine (dFdC), 99.9% 
Dimethylsulfoxide (DMSO), Tris HCl, Tris Base, Tween 20, EDTA, 
Ammonium persulfate (APS), Sodium Dodecyl Sulfate (SDS, 98.5% GC 
grade), Methanol, Isopropanol, Glycine, HEPES, Sodium Chloride (NaCl), 
Thymidine, KH2PO4, Sodium hydroxide (NAOH), Nonident p40, Ethidium 
Bromide, LB broth, polydIdC (PdIdC), Triton X-100, Agarose, 3MM paper,  
Propidium iodide (powder), Tetramethylethylenediamine (TEMED), 
fixer/replenisher, developer/replenisher, DL-dithiothreitol (DTT) solution 
(1 M in H2O) (Sigma Aldrich Company Ltd., Dorset, UK) 
Multiskan Ascent and Multidrop 384 (Thermo Fisher Scientific Inc., 
Leicestershire, UK)  
2.1.2 Antibodies 
p-p65 (S276) antibody (Abcam, Cambridge, UK) 
Horse radish peroxidase conjugated secondary anti-mouse and anti-goat 
antibodies (Amersham Biosciences, UK) 
Ki-67 antibody (BD Biosciences, Oxford, UK) 
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AKT, p-AKT, Sox2, Oct4, Nanog, JNK, p-JNK, c-Jun, p-c-Jun, p-p38, 
ERK antibodies (Cell Signalling, Herts, UK) 
Enhanced ChemiLuminescence (ECL) ™ anti-mouse antibody (Ab), ECL 
™ anti-rabbit antibody (GE Healthcare, Buckinghamshire, UK) 
HIF2α antibody (Novus Biologicals, CO, USA) 
p65, dCK, RRM1, p21, BCL-2, BAX, Cleaved PARP, Nucleolin, 
ALDH1A1, ALDH2, ALDH1A3, IκBα, MDR1 antibodies (Santa Cruz 
Biotechnology Inc., Heidelberg, Germany) 
Anti-vinculin monoclonal antibody, Anti-tubulin monoclonal antibody, 
FITC-conjugated anti-mouse IgG antibody （Sigma Aldrich Company Ltd., 
Dorset, UK） 
2.1.3 Cell lines 
Human breast cancer cell lines: MCF7, T47D, ZR75, and MDA-MB-231   
Human normal breast epithelial cell line: MCF10A （American Tissue 
Culture Collection, Rockville, USA） 
The normal human vascular endothelial cells, HeCV （Prof Wenguo Jiang, 
University of Cardiff, UK） 
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Human endothelial cell line: EAhy926 （Dr Angel Armesilla, University 
of Wolverhampton, UK） 
NFκB p65 transfected (P1, C2) and mock transfected MCF7 human breast 
cancer cell line （Dr Weiguang Wang, University of Wolverhampton, UK） 
2.1.4 Buffers 
Complete protease inhibitor  
A (25x) complete protease inhibitor (Roche Diagnostics Limited, West 
Sussex, UK) was prepared by dissolving 1 tablet of complete protease 
inhibitor in 25 ml of distilled water, and stored at -20°C until use. 
Glycine Buffer 
Glycine buffer solution (500 ml) was prepared by dissolving 3.75 g glycine 
and 2.92 g NaCl in distilled water. The pH of the glycine buffer was 
adjusted to pH 10.5 using 5 M NaOH. The glycine buffer solution was 
stored in room temperature until use. 
RIPA Buffer for Whole Protein Extraction 
10x RIPA Buffer was prepared by the list below, and RIPA Buffer was 
stored in -20°C until use. 
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Tris HCL                                       25 g/l 
Sodium dodecyl sulphate              0.1% per ml  
Triton-X 100                                 1%  
NaCl                                              0.15 M  
EDTA                                            1 mM  
Protease inhibitor                          0.001% per ml 
Buffer A for Nuclear Protein Extraction 
Buffer A was prepared by mixing 200 μl 500 mM HEPES, 50 μl 2 M KCl, 
2 μl 500 mM EGTA (pH 8.0), 2 μl 500 mM EDTA (pH 8.0), 20 μl 0.5 M 
DTT, and 500 μl (25X) protease inhibitor in 9.2 ml water. Buffer A was 
stored in -20°C until use. 
Buffer C for Nuclear Protein Extraction 
Buffer C was prepared by mixing 60 μl 500 mM HEPES, 120 μl 5M NaCl, 
3 μl 500 mM EGTA, 3 μl 500 mM EDTA, 3 μl 0.5 M DTT, 75 μl (25X) 
protease inhibitor, and 75 μl 100% glycerol in 1161 μl water, and stored at 
-20°C. 
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Separating buffer 
Separating buffer was prepared by mixing 90.8 g Tris base and 2g SDS in 
500 ml of distilled water. The pH of the solution was then adjusted to pH 
8.8 using HCl. The separating buffer was stored in room temperature until 
use. 
Stacking buffer 
Stacking buffer was prepared by mixing 30 g Tris base and 2 g SDS in 500 
ml of distilled water. The pH of the solution was then adjusted to pH 6.8 
using HCl. The stacking buffer was stored in room temperature until use. 
Tris-buffered saline Tween-20 (TBS-T) 
A stock (10x) TBS-T solution was prepared by dissolving 12.11 g Tris base 
and 81.8 g NaCl in 1 litre of distilled water. The (1x) TBS-T buffer was 
then prepared by mixing100 ml (10x) TBS-T, 900 ml distilled water and 
500 μl of Tween-20. 
Blocking buffer 
Blocking buffer was prepared by dissolving 5 g Marvel milk powder in 100 
ml of (1x) TBS-T. 
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Transfer buffer 
Transfer buffer was prepared by mixing 100 ml of 10 x stock solution, 200 
ml of methanol and 700 ml distilled water. This solution was stored at 
room temperature until use. 
Running buffer 
Running buffer was prepared by mixing 100 ml of 10X stock solution with 
900 ml distilled water. 
2.2 Methods 
2.2.1 Cell culture 
Serum-containing medium 
Serum-containing medium consists of DMEM medium containing 1% (v/v) 
L-glutamate, 1% (v/v) penicillin-streptomycin and 10% Foetal Calf Serum 
(BioWhittaker® Lonza, Walkersville, USA) 
Serum-free medium 
Serum-free medium consists of DMEM medium containing 1% (v/v) L-
glutamate, 1% (v/v) penicillin-streptomycin (BioWhittaker® Lonza, 
Walkersville, USA).  
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Trypsin 
Working solution of trypsin (1x) was prepared by diluting stock solution of 
trypsin (10x) in sterile PBS (BioWhittaker® Lonza, Walkersville, USA) 
Freezing Medium for cryogenic storage of cell samples 
Freezing medium was prepared by mixing 90% foetal calf serum with 10% 
DMSO (Sigma Aldrich Company Ltd., Dorset, UK), and stored at 4°C until 
use. 
Recovering Cell Lines from Liquid Nitrogen Storage 
A 75 cm2 tissue culture flask (Sarstedt Ltd., Leicester, UK) was prepared 
by adding 19 ml of serum-containing medium. Cells were recovered from 
liquid nitrogen storage, rapidly defrosted in 37°C water bath, and then 
transferring the 1 ml content of the cryovial into the prepared 75 cm2 tissue 
culture flask. The recovered sample was then stored in an incubator, at 
37°C with 5% CO2. 
Trypsinization of Adherent Cell Lines 
Cell culture medium was removed from the tissue culture flask, rinsed with 
5 ml of sterile PBS, and 2 ml of trypsin added to the adherent cells and 
spread evenly. The flask was then placed in the incubator and checked 
regularly, under the microscope and by gentle tapping of the flask, to 
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determine that the cells were no longer adhered to the tissue culture flask. 
When the cells were no longer adhered to the tissue culture flask, 2 ml of 
serum-containing medium was added and the cells were re-suspended 
thoroughly by pipetting the 4 ml volume up and down. 
General Cell Line Maintenance 
Cell cultures were regularly checked under the microscope (2-3 times a 
week) for cell density, and changes in the colour of the medium. When 
there is a change in the colour of the medium but the cell density is low, 
(defined as adhered cells are spread out and very few cells are touching 
each other), the medium is removed and replaced with fresh serum-
containing medium. When there is a change in the colour of the medium 
and the cell density is high, (defined as cells are overgrown leading to some 
cells no longer being adhered to the tissue culture flask and are in 
suspension), cells are sub-cultured. Sub-culturing was done by trypsinizing 
the cells. The 4 ml of cells were then collected into a 15 ml falcon tube. In 
the case when cells were not needed, half of the cells (2 ml) were disposed 
of. In the case when cells were needed, the cells where then centrifuged at 
800 g for 3 minutes. The medium was then removed and cell pellet was re-
suspended in 2 ml of fresh serum-containing medium. Two 75 cm2 tissue 
culture flasks were then prepared by adding 19 ml of serum-containing 
medium, and to this 1 ml of the cell suspension was then added. The cells 
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were then stored in an incubator, at 37°C with 5% CO2, with the tissue 
culture flask lying down. 
Preparing Cell Lines for Liquid Nitrogen Storage 
Cells were trypsinised, spun for 3minutes at 800 g and the cell pellet 
collected. The cell pellet was then re-suspended in freezing medium and 
aliquot into 1 ml/labelled-cryovial. Each cryovial was then wrapped in 
tissue paper, put into a disposable labelled-glove and placed in -80°C 
overnight. The following day, the cryovials were removed from the gloves 
and tissue papers, and transferred into liquid nitrogen (-180°C) for long-
term storage. The locations of the samples stored in liquid nitrogen are 
recorded in the liquid nitrogen storage log. 
2.2.2 Cytotoxicity assay 
Stock MTT solution  5 mg/ml MTT solution (500 ml) (Sigma Aldrich 
Company Ltd., Dorset, UK) was prepared by adding 2.5 g of 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in 500 ml of sterile 
PBS, mixed to dissolve using a magnetic stirrer, with the bottle wrapped in 
foil to protect the MTT from direct light. This MTT mixture was then 
filtered using a vacuum filter connected to a pump. This filtered MTT 
solution, wrapped in foil, was stored at 4°C until use. 
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MTT assay is one of the widely used methods to evaluate the effect of anti-
cancer drugs on cell viability. Cells were cultured in 96-well plates (1 × 
104/well) and left overnight to allow the cells attached to the bottom in the 
incubator at 37°C. Cells were exposed to different concentrations of anti-
cancer drug prepared by a two-fold serial dilution using medium i.e. 10 µM, 
5 µM, 2.5 µM, 1.25 µM, 0.625 µM, 0.3125 µM. Meanwhile, there was also 
a negative control of cells which was untreated. After removing the spent 
media from the wells, the medium (200 μl) with different concentrations of 
drug was distributed in each well.  Normally there are 3 wells with the 
same drug concentration and cell type in each plate at the same time to 
calculate the standard deviation. After incubation at 37°C for 72 hours, 50 
μl of MTT (5 mg/ml) was added to the wells and the plates were wrapped 
in the aluminium foil to prevent the deterioration of MTT by light. The 
solution was removed after incubation for 4 hours at 37°C, and 60 μl of 
99.9% DMSO and 10 μl glycine buffer were added. The readings were 
tabulated and IC50 of the cell lines was calculated from the graph after 
reading the plates by a spectrophotometer at a wavelength of 540 nm. 
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2.2.3 Western Blot 
10% Ammonium Persulphate (APS) 
10% Ammonium Persulfate (APS) (Sigma Aldrich Company Ltd., Dorset, 
UK) was prepared by dissolving 0.1 g APS in 1 ml of distilled water. This 
was prepared fresh before use. 
Preparation of Separating Gel 
Separating gel was prepared by adding 5.5 ml of separating buffer to 6.5 ml 
of distilled water. To this mixture, 4.4 ml of 40% (19:1) acrylamide:bis 
(AccuGel) (Sigma Aldrich Company Ltd., Dorset, UK) was added, 
followed by 120 μl of 10% APS and 15 μl TEMED  (Sigma Aldrich 
Company Ltd., Dorset, UK). 4 ml of this separating gel solution was added 
to the glass gel rack. A small amount of isopropanol, just enough to cover 
the top of the separating gel solution, was added on top of the separating 
gel. The gel was left to set. 
Preparation of Stacking Gel 
Stacking gel was prepared by adding 4.2 ml of stacking buffer to 6.6 ml of 
distilled water. To this mixture, 1.2 ml of AccuGel was added. The 
isopropanol (Sigma Aldrich Company Ltd., Dorset, UK) from the 
separating gel was removed and rinsed with distilled water when the gel 
was set. Then to the stacking gel mix, 250 μl of 10% APS and 20 μl 
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TEMED was added. The final stacking gel mix was added on top of the 
separating gel. A comb was immediately placed on the top layer of the 
stacking gel, to form the protein loading wells, while avoiding bubbles. The 
gel was left to set before removing the comb. 
Cytoplasmic and Nuclear Protein Extraction 
Nuclear protein extracts were prepared by washing the cells in PBS, 
suspended in buffer A and left on ice for 15 minutes, to which, 5 μl 10% 
NP-40 (Sigma Aldrich Company Ltd., Dorset, UK) was added and then 
centrifuged for 5 minutes at 800 g. The supernatant was collected 
(cytoplasmic protein) and the pellet was re-suspended in 500 μl buffer A, 
centrifuged for 5 minutes at 800 g, and the supernatant removed. The pellet 
was then re-suspended in 100 μl of buffer C, left to spin on a rotator at 4°C 
for 1 hour, then centrifuged for 5 minutes at 12,000 g and the supernatant 
collected (nuclear protein). 
Protein Concentration Measurement 
A BSA protein serial standard was prepared by serially diluting the 3.0 
mg/ml BSA solution in RIPA buffer to the following concentrations:  3.0 
mg/ml, 1.5 mg/ml, 1.0 mg/ml, 0.75 mg/ml, 0.50 mg/ml, 0.25 mg/ml and 0 
mg/ml (30 μl RIPA buffer). The BioRad reagent A/S was prepared by 
adding 20 μl of reagent S to every ml of reagent A and mixed by vortex. 
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Protein samples were diluted to a 1:10 or 1:5 ratio in distilled water 
depending on the size of the cell pellet when preparing the protein sample. 
5 μl of the BSA standards (duplicates) and the diluted protein samples were 
pipetted into a 96-well flat-bottomed plate, in triplicates, to which 25 μl of 
reagent A/S was added. 200 μl of reagent B was then added, incubated at 
room temperature for 10 minutes and then the absorbance read at 650 nm. 
The protein concentration of the samples was calculated from plotting the 
absorbance versus protein concentration of the BSA serial standard. 
SDS-PAGE Electrophoresis 
The prepared SDS-PAGE gels were assembled into the electrophoresis tank 
loaded with 1 x running buffer. The protein samples were prepared by 
mixing, in a 0.5 ml eppendorf, 16 μl of loading buffer (4x), 1 μl of 1 M 
DTT, 50 μg of protein sample and distilled water to make up a final volume 
of 64 μl. This mixture was then heated using a PCR block heater at 90°C 
for 10 minutes, then centrifuged at 10,000 g for 30 seconds and stored on 
ice until use. 10 μl of pre-stained protein markers and 30 µl of each protein 
mixture were then loaded into the loading wells using a pipette. The gel 
was then run at 200 V for 1 hour. 
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Blotting 
3MM paper (Sigma Aldrich Company Ltd., Dorset, UK) was cut into 12 x 
12 cm size and wet with transfer buffer. PVDF membrane was cut into 7 x 
9 cm size and wet with methanol. A semi-dry transferring unit was setup by 
placing the SDS-PAGE gel (Sigma Aldrich Company Ltd., Dorset, UK) on 
top of the PVDF membrane, which is then sandwiched by 2 layers of 3 x 3 
MM paper. Protein was transferred from the SDS-PAGE gel to the PVDF 
membrane by apply 2 W current for 1 hour and 20 minutes. 
Blocking of the membrane 
The TBS-T(1x) working solution supplemented with 5% fat-free milk was 
used to block the protein-containing PVDF membrane (Sigma Aldrich 
Company Ltd., Dorset, UK) for 1 hour along with agitation in order to 
prevent non-specific binding of primary and secondary antibodies. 
Antibody Staining 
5 ml of primary antibody (Table 2.1) was prepared as described in the 
blocking buffer. After shaking the PVDF membrane in the blocking buffer 
for at least 1 hour, the membrane was placed in a plastic bag with the 
primary antibody, sealed, and left overnight at 4°C on a shaker. On the 
following day, the PVDF membrane was washed twice with TBS-T (1x) 
for 10 minutes. The PVDF membrane was then soaked in the secondary 
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antibody at room temperature for at least 1 hour on a shaker. The PVDF 
membrane was then washed twice with TBS-T (1x) for 10 minutes. 
Table 2.1 Primary Antibodies 
Target Molecule Dilution Ratio Antibody Company 
p-p65 (S276) 1:1000 Abcam, Cambridge, UK 
Ki67 1:1000 BD Biosciences, Oxford, UK 
AKT 1:1000 Cell Signalling, Herts, UK 
p-AKT 1:1000 Cell Signalling, Herts, UK 
Sox2 1:1000 Cell Signalling, Herts, UK 
Oct4 1:1000 Cell Signalling, Herts, UK 
Nanog 1:1000 Cell Signalling, Herts, UK 
JNK 1:1000 Cell Signalling, Herts, UK 
p-JNK 1:1000 Cell Signalling, Herts, UK 
c-Jun 1:1000 Cell Signalling, Herts, UK 
p-c-Jun 1:1000 Cell Signalling, Herts, UK 
p-p38 1:1000 Cell Signalling, Herts, UK 
ERK 1:1000 Cell Signalling, Herts, UK 
HIF2α 1:1000 Novus Biologicals, CO, USA 
HIF1α 1:1000 Novus Biologicals, CO, USA 
p65 1:1000 Santa Cruz, Heidelberg, Germany 
dCK 1:1000 Santa Cruz, Heidelberg, Germany 
RRM1 1:1000 Santa Cruz, Heidelberg, Germany 
p21 1:1000 Santa Cruz, Heidelberg, Germany 
BCL-2 1:1000 Santa Cruz, Heidelberg, Germany 
BAX 1:1000 Santa Cruz, Heidelberg, Germany 
Cleaved PARP 1:1000 Santa Cruz, Heidelberg, Germany 
Nucleolin 1:1000 Santa Cruz, Heidelberg, Germany 
ALDH1A1 1:1000 Santa Cruz, Heidelberg, Germany 
ALDH2 1:1000 Santa Cruz, Heidelberg, Germany 
ALDH1A3 1:1000 Santa Cruz, Heidelberg, Germany 
IκBα 1:1000 Santa Cruz, Heidelberg, Germany 
MDR1 1:1000 Santa Cruz, Heidelberg, Germany 
p53 1:1000 Santa Cruz, Heidelberg, Germany 
Tubulin 1:8000 Sigma Aldrich, Dorset, UK 
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Signal detection 
In the dark room, 2 ml prepared EZ-ECL solution (Thermo Fisher 
Scientific Inc., Leicestershire, UK) which was mixing solution A with 
solution B at a 1:1 ratio was added to PVDF membrane. Leave the PVDF 
membrane in the A/B mixture solution for 3-5 minute and then remove 
excess solution by pouring onto a tissue paper. The PVDF membrane was 
then wrapped in cling film and then exposed to a Fuji film. The length of 
exposure depends on the strength of the signal. 
2.2.4 Flow Cytometry 
Propidium Iodide   
Propidium iodide (Thermo Fisher Scientific Inc., Leicestershire, UK) was 
prepared by dissolving 50 mg of propidium iodide powder into 50 ml of 
distilled water. This solution was kept at 4°C wrapped in foil until use. 
Preparation of Ethanol 
70% ethanol (Thermo Fisher Scientific Inc., Leicestershire, UK) was 
prepared by diluting in PBS from ethanol stock solution. 
After 72 hours incubation of cell cultures with the appropriate test drugs, 
the supernatant containing cells in suspension was collected into a 25 ml 
tube. In addition, adhered cells were trypsinised and also collected into the 
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same 25 ml tube. The cells were pelleted by centrifugation at 800 g for 5 
minutes. The supernatant was removed and the cells washed twice with 5 
ml of sterile PBS. The final cell pellet was re-suspended in 0.5 ml of sterile 
PBS. Using a vortex mixing the 0.5 ml cell suspension, 2 ml of 70% 
ethanol was slowly added and left for 10 minutes. After 10 minutes have 
passed, the cell was pelleted by centrifugation at 800 g for 5 minutes, the 
ethanol was removed and the cell pellet re-suspended in 1 ml of sterile PBS. 
To this cell suspension, 1 μl of 100 mg/ml RNaseA was added followed by 
50 μl of 1 mg/ml propidium iodide and incubation for 30 minutes at room 
temperature wrapped in foil. Samples were stored at 4°C until they were 
analysed by flow cytometry. 
2.2.5 Electrophoretic mobility shift assay (EMSA) 
Gel preparation 
10 x TAE-10 ml of 50 x TAE + 40 ml of dH2O (Invitrogen Ltd., Paisley, 
UK) 
30% polyacrylamide Protogel, TEMED 10% Ammonium persulfate (APS)-
1 g of APS + 1 ml of dH2O (10% APS) (Thermo Fisher Scientific Inc., 
Leicestershire, UK) 
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Sample preparation 
10 x Binding Buffer, 1 μg/μl Poly (dI-dC), 50% Glycerol, Biotin End-
Labelled Target DNA, 5 x Loading Buffer (Thermo Fisher Scientific Inc., 
Leicestershire, UK) 
Probes Preparation  
Wild Type (WT) Unlabelled Target DNA (upper and downer probes) 40 
µm. Mutant (MUT) Unlabelled Target DNA (upper and downer probes) 40 
µm. 
Annealing the upper and downer probes: The probes were heated at 100ºC 
for 10 minutes and were cooled down to room temperature. Store the 
samples at -20ºC. Note: after the upper and downer probes have annealed, 
the final probe concentration is 20 µm since each annealed probe contains 
one upper and downer probe. 
Samples Preparation 
10 x Binding Buffer, 1 μg/μl Poly (dI-dC), 50% Glycerol, WT Unlabeled 
Target DNA, MUT Unlabeled Target DNA, and Biotin End-Labelled 
Target DNA were thawed on ice. Nuclear protein was added with final 
amount 25 nM of biotin-labeled oligonucleotide in binding buffer 
consisting of 10 mM Tris at pH 7.5, 50 mM KCl, 1 mM DTT, 2.5% 
glycerol, 5 mM MgCl2, and 50 ng of poly (dI-dC). WT and MUT samples 
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were prepared without adding Biotin End-Labelled Target DNA. The 
samples were incubated on ice for 15 minutes and then 10 minutes at RT. 
Meanwhile, the other samples were prepared without adding Biotin End-
Labelled Target DNA. All samples were added 1 μl of Biotin End-Labelled 
Target DNA and were incubated on ice for 15 minutes followed by 10 
minutes at RT. 5 μl of 5 x Loading Buffer were added into each sample.  
Electrophoresis 
All samples (23 µl/well) were loaded into their designated wells 
respectively, and then the gel was run for 45 minutes at 120 V on ice. 
Blotting 
The nylon membranes (Amersham Hybond TM-N+, GE Healthcare, UK) 
and 3MM papers were soaked in 1 xTAE for a minimum of 5-10 minutes. 
The probes were transfered from the gel to the nylon membrane using wet 
or semi-dry units following manufacture protocol at 200 mA for 1 hour. 
Cross-link 
The membranes were wrapped in cling film and were exposed for 10-15 
minutes on a trans-illuminator equipped with a 312 nm bulb (Ingenious 
Syngene Bio-Imaging). 
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Blocking 
The blocking buffer and the 4 x wash buffer (Thermo Fisher Scientific Inc., 
Leicestershire, UK) were pre-warmed to 37-50°C to dissolve any 
precipitation, then the membranes were soaked in blocking buffer for 15 
minutes at room temperature on a shaker. At the same time, 30 μl 
Stabilized Streptavidin-Horseradish Peroxidase Conjugate were added to 
10 ml Blocking Buffer. The membranes were soaked in the blocking buffer 
with conjugated HRP for 15 minutes at room temperature on a shaker. 
Washing 
1 x wash solution (40-60 ml) (Thermo Fisher Scientific Inc., Leicestershire, 
UK) were prepared for washing the membranes for 10 minutes twice in a 
clean tray, then the membranes were transferred to a new container adding 
10 ml Equilibration Buffer for 5 minutes at room temperature on a shaker. 
Signal detection 
(Luminol/Enhancer Solution): (Stable Peroxide Solution) (Thermo Fisher 
Scientific Inc., Leicestershire, UK) were mixed in 1:1 ratio and were 
evenly spread on the membranes, for 5 minutes. The membranes were 
exposed to film in the dark room. 
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2.2.6 Luciferase reporter gene assay  
Cell culture 
Different cell lines were harvested by trypsinisation. Plate 5 x 104/100 µl of 
medium/well on to 96 well plates and allowed them to grow overnight at 
37°C. 
Lipofectamine Transfections 
On the following day, the transfection solution I and II were prepared first, 
then the pGL3-Basic and other luciferase vectors (0.2 µg of each 
vector/well) in triplicate and internal control pRL-SV40 (0.002 µg/well) 
were co-transfected by using Lipofectamine 2000.  
Solution I: 0.2 µg of each Luciferase reporter plasmid DNA and 0.002 μg 
pRL-SV40 (Renilla) DNA was diluted in 25 μl of opti-MEM medium 
without serum. 
Solution II: 0.5 µl of lipofectamine 2000 was diluted in 250 µl of opti-
MEM for each DNA samples and incubated at room temperature for 5 
minutes. 
The equal amount of solution I and solution II were mixed for 20 minutes 
at room temperature and then were added to the cell culture. The cells were 
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incubated at 37°C, 5% CO2 for 24 hours and were fed with fresh medium 
for further 24 hours incubation prior to luciferase assay test. 
Luciferase assay test & analysis 
The growth medium was removed after 48 hours, and the wells were 
washed with 1 x PBS. 100 μl of 1 x lysate buffer was added to each well 
and incubated at room temperature for 10 minutes with agitation. 20 µl of 
each lysate sample was transferred into a polypropylene plate to test. 30 µl 
of Luciferase assay reagent II was added and read in a luminometer. The 
reading corresponds to firefly luciferase activity. 30 μl Stop & Glo reagent 
was added and the reading was taken which corresponds to renilla activity. 
The process was repeated for each sample in a fresh plate each time. The 
luciferase activity of each well was normalized by the pRL-SV40 Renilla 
value using the formula: Ln = L/R (Ln: normalised luciferase activity; L: 
luciferase activity reading and R: Renilla activity reading). Transcriptional 
activity of the control, pGL3-Basic, was used to further standardize Ln 
using the formula: RLU = Ln/pGL3-basic (RLU: relative luciferase unit) 
(Promega UK Ltd., Southampton, UK).  
2.2.7 Stable transfection 
About 0.5-1 million cells/well were cultured in 6 well-plates with 2 ml 
medium overnight to about 70-80% confluence. Transfection solution was 
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prepared with 10 μg of DNA and 10 μl lipofectamine 2000 by mixing 
together for 20 minutes, the cells were sub-cultured at 1:10 ratio in fresh 
medium with adding packing DNA for 48 hours transfection. DMEM 
medium with 1000 μg/ml G418 or/and 150 μg/ml hygromycin was used as 
a selection agent. The cells were allowed 7-10 days culture for the growth 
of cell colonies and were routinely checked every two days. When the 
colonies were formed, the selective colonies were picked up by trypsinised 
and the single colony was transferred to T25 cm2 flask containing a 
selective medium to enlarge the population and used for further test. 
2.2.8 Confocal microscopy, image analysis 
Cell culture  
Cells were harvested by trypsinisation.5x104 cells were plated on a sterile 
8-well chamber slide over night at 37°C for immumofluorencence 
experiment. Dose-dependent drug treatment or time-dependent treatment 
was conducted on the following day. 
Fluorescence labelling of cells 
The cells were washed twice with PBS gently to avoid the cells detached 
from the surface of the chamber slide, and then the cells were fixed by 
adding 500 µl of methanol/acetone (Volume Ratio 1:1) for 5 minutes. The 
fixed cells were washed twice with PBS, then the cells were blocked with 5% 
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BSA for 30 minutes at room temperature to block non-specific binding of 
immunoglobulin. The cells were incubated with the primary antibodies for 
1 hour at room temperature, washed three times with PBS and then labelled 
with the secondary antibodies for 1 hour in the dark, then the cells were 
washed three times in PBS. Coverslips were mounted onto slides using 
anti-fade mounting medium. Images were captured using laser-scanning 
microscope (Carl Zeiss Laser Scanning Systems LSM 510). 
2.2.9 RNA extraction 
1 x 106 cells were harvested and washed once with cold 1 x PBS, cell 
pellets were lysised in trizol in 1.5 ml eppendorf for 5 minutes at room 
temperature. The samples were vigorously shaked shortly with 250 μl of 
chloroform and then the samples were incubated for 5 minutes at room 
temperature. After centrifuge the samples at 10,000 g for 5 minutes, the 
aqueous phase was carefully pipetted off to another 1.5 ml eppendorf. The 
aqueous phase and 550 μl of isopropanol were mixed gently for 5 minutes 
at room temperature, and then mixtures were centrifuged again at maximal 
speed (14,000g) for 20 minutes. The isopropanol was discarded from 
mixtures and 1 ml of 75% EtOH in DEPC treated H2O was added for 
washing the pellet barely visible at the base of tube. The pellets were re-
centrifuged at 8,000 g for 5 minutes and air-dried. Finally, the RNA pellets 
were dissolved by adding 30-50 μl (depending on yield) of either DEPC 
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treated TE buffer or water. RNA concentration was determined 
spectrophotometrically by measuring absorbance at 260 nm (1 absorbance 
= 40 ng/ml RNA). The 260/280 ratio should be greater than 1.8. If less than 
1.5-1.6 or so, the RNA is partially degraded. Lower ratios also suggest 
DNA or thiocyanate contamination. The concentration is essentially the 
equivalent of the OD at 260 nm (in μg/μl). 
2.2.10 Reverse transcriptase polymerase chain reaction 
In this study, a promega access RT-PCR system kit was used to perform 
the experiment. This system is one step RT-PCR in a single tube in which a 
reverse transcriptase produces first a strand of cDNA from RNA, then a 
thermostable DNA polymerase produces a second strand of DNA and 
amplifies the specific DNA of interest. A ratio of 1:2 oligodT primers: 
RNA template was used in a volume of 25 μl containing 5 µl of 5 x 
AMV/Tfl reaction buffer, 1 µl of TAMV-reverse transcriptase, 1 µl of Tfl 
DNA polymerase, 2 µl of 25 mM MgSO4, 1 µl of dNTPs (10 mM of ATP, 
CTP, GTP and GTP) and nuclease free water up to 25 µl. Reverse 
transcripton was performed at 45°C for 45 minutes, following inactivation 
of AMV RT and denaturation of the RNA/cDNA hybrid by incubation at 
94°C for 2 minutes. The human housekeeping gene GAPDH was used as 
the RNA loading control, which was amplified by the same RT-PCR 
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system. The table 2.2 shows the primers, which I used in RT-PCR in my 
study. 
Amplification was performed using standard cycling parameters: 94°C 30 
seconds for denaturation, 58°C 1 minute for annealing and 68°C 1 minute 
for extension. After the final PCR cycle the final extension was at 68°C for 
5 minutes and then kept at 4°C until further analysis. The RT-PCR products 
were separated on a 1% agarose gel and the bands visualized and 
photographed under UV light. 
Table 2.2 Primers 
Target 
Primer 
Product 
Size 
Forward primer 5' - 3' Reverse primers 5' - 3' 
GAPDH 226bp GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC 
ALDH1A1 154bp TGTTAGCTGATGCCGACTTG TTCTTAGCCCGCTCAACACT 
ALDH1A3 150bp TCTCGACAAAGCCCTGAAGT TATTCGGCCAAAGCGTATTC 
ALDH2 193bp AACCAGCAGCCCGAGGTCTT AAGGTGAGCCCAGCTGGAAG 
ALDH3A1 229bp TGTTCTCCAGCAACGACAAG CTGACCTTCAGGCCTTCATC 
 
2.2.11 Purification of PCR products 
PCR products were purified using a StrataPrep® PCR Purification kit. An 
equal volume of DNA-binding solution was added to the aqueous portion 
of the PCR products. Transfer PCR product-DNA-binding-solution mixture 
to a micro-spin cup and spin at 12,000 g for 30 seconds. The PCR products 
remaining in the fiber matrix of the micro-spin were washed with 1× 
washing buffer then eluted using 50 µl of elution buffer. 
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2.3 Molecular biology protocols 
Preparation of LB plates 
LB medium was prepared by dissolving 25 g LB broth powder and 20 g 
agar into 1 L of deioned water. This was autoclaved and allowed to cool to 
50°C prior to the addition of ampicillin (50 μg/ml) or kanamycin (50 
μg/ml). The medium was mixed to ensure equal distribution of antibiotic 
and approximately 15 ml poured per 10 cm2 Petri dish. The plates were left 
to set at room temperature before being stored at 4°C. 
Transformation of competent bacterial cells 
Component bacteria DH5α was purchased from invitrogen and kept at -
80°C. An aliquot of 50μl competent bacteria DH5α was allowed to thaw on 
ice. 10 ng of DNA was added and incubated on ice for 15 minutes. The 
cells were subjected to a heat shock at for 42°C 90 seconds and returned to 
ice for 2 minutes. Added 1 ml of SOC medium to the cells and incubated at 
37°C for 1 hour in a shaking incubator. One hundred microliters of the 
reaction was spread onto a LB plate containing the appropriate antibiotic 
and incubated overnight at 37°C. 
Preparation of plasmid DNA 
Mini-preps 
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Mini-prep purification was carried out using Qifilter miniprep kit following 
the manufactures instructions. Cells were harvested by centrifugation at 
12,000 g for 5 minutes and re-suspended by pipetting in 100μl of re-
suspension buffer I (50 mM Tris-HCl, 10 mM EDTA, pH 8.0 containing 
100 μg/ml RNase A). Cells were treated with 100μl of lysis buffer II (200 
mM NaOH, 1% (w/v) SDS), mixed and incubated for 5 minutes with 
gently up and down. Lysis was terminated by the addition of 100μl of 
neutralisation buffer III (3 mM potassium acetate, pH 5.5). After 
centrifuging for 10 minutes at 12,000 g, the supernatants of cell lysates 
were transferred to mini-prep columns. The columns were centrifuged for 1 
minute at 12,000 g and washed twice with 750 μl wash buffer (1.0 mM 
NaCl, 50 mM Tris-HCl, pH 7.0, 15% (v/v) isopropanol). After washing, 
bound DNA was eluted into a clean 1.5 ml eppendorf tube with 100 μl 
DNase, RNase-free H2O. 
Maxi-preps 
The Qiagen Qiafilter kit was used to produce larger scale DNA samples. 
Purification of DNA was carried out according to the manufactures 
instructions. A 350 ml culture of transformed bacteria was pelleted by 
centrifugation for 15 minutes at 6,000 g at 4°C. The cell pellet was re-
suspended in 10 ml of pre-cold buffer P1 (50 mM Tris-HCL pH 8.0, 10mM 
EDTA, 100 μg/μl Rnase A). 10 ml buffer P2 (200 mM NaOH, 1% (w/v) 
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SDS) was added to the cells with gently up and down for incubating 10 
minutes at room temperature. Neutralized the reaction by adding 10 ml of 
buffer P3 (3.0 M potassium acetate pH 5.5) and the solution was 
immediately applied to a QIAfilter cartridge and left for 10 minutes at 
room temperature to settle. Meanwhile, a Qiagen tip 500 was equilibrated 
by the addition of buffer QBT (750 mM NaCl, 50 mM MOPS pH 7.0, 15% 
(v/v) isopropanol). After 10 minutes, the lysed cells were added onto the 
equilibrated tip and allowed to filter through. The column was washed with 
60 ml of buffer QC (1.0 M NaCl, 50 mM MOPS pH 7.0, 15% (v/v) 
isopropanol). The DNA was eluted by the addition of 15 ml of buffer QF 
(1.25 M NaCl, 50 mM Tris-HCl pH 8.5, 15% (v/v) isopropanol) to the tip. 
After adding 10.5 ml isopropanol, the DNA was precipitated by 
centrifuging at 12,000 g for 30 minutes at 4°C. The DNA pellet was 
washed with 5 ml of room temperature 70% (volume ratio) ethanol and 
then centrifuged for 15 minutes at 12,000 g at 4°C. The supernatant was 
carefully removed and the pellet allowed to air dry prior to re-suspension in 
0.5-1 ml of DNase, RNase-free H2O. 
Quantification of DNA 
DNA measurement was performed by examining the absorbance of a 1:40 
dilution of the sample at 260 nm. An A260 value of 1 unit was taken to 
 107 
 
correspond to 50 μg/ml of double stranded DNA. The sample concentration 
could be determined using the following formula. 
Sample concentration = OD 260 x dilution factor (40) x 50 μg/ml 
Digestion of DNA with restriction endonucleases 
One unit of restriction endonuclease activity was capable of completely 
digesting 1 μg of DNA depending on the manufacturer. 1 μg of DNA 
digests were prepared using the appropriate restriction enzyme (1-2 units) 
with a specified buffer providing by the manufacturer provided in a final 
volume of 20 μl. Reactions were incubated at 37°C for a minimum of 2 
hours. 
Agarose gel electrophoresis of DNA 
Digested DNA samples or PCR reactions were examined using gel 
electrophoresis. Samples were diluted in 5 × DNA loading buffer. 1.0% 
(w/v) agarose gel was prepared by mixing agarose with 1 × TAE and 2.5 
mg/ml ethidium bromide. The gels were set in a horizontal gel tank and 
once set immersed in 1 × TAE. Samples were loaded and the gels run at 
100V for 1 hour. The DNA fragments were visualized under ultraviolet 
light. The size of each fragment was assessed by comparison with DNA 
molecular markers. 
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DNA Purification from agarose gels 
The required DNA fragments were excised from the gel with a sterile 
disposable scalpel blade inside the UV transilluminator hood. Excised gel 
fragments were transferred to a sterile tube. The fragments were purified 
using the QiaQuick gel extraction according to the manufacturer’s 
instructions. Excised DNA fragments were dissolved in buffer QG 
followed by the addition of isopropanol at 37°C. The solution was loaded 
onto a purification column. After centrifugation, DNA was eluted from the 
purification column using 30 μl of sterile water. 
Ligation of DNA 
When plasmid DNA and/or PCR fragments had been digested and purified 
as described above, ligation of digested PCR or DNA fragments to the 
digested vector DNA was achieved using a Rapid DNA ligation kit. A 
molar ratio of 1:3 to 1:8 vector, PCR product/DNA fragment was used in a 
volume of 10 μl containing 1 unit of ligase and the supplied buffer. The 
reaction was incubated at room temperature for 1 hour or at 4°C overnight. 
DNA sequencing 
DNA samples were posted to the Sequencing Service (School of Life 
Sciences, University of Dundee, Scotland) for sequencing analysis. 
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2.4 Statistical Tests 
All statistics used in analysing the data were conducted using Microsoft 
Excel 2010 data analysis tools. The cut-off for statistical significance 
between samples was set to p=0.05. Any statistical tests with p<0.05 
defines ‘the results between the samples are statistically different’, p<0.001 
‘the results between the samples are statistically very different’, and p≥0.05 
defines‘there are no statistical significance between the samples’. The 
statistical test’s-test:  paired two samples for means’ was used to determine 
the statistical significance between BC cell lines that were tested under the 
exact same conditions. The statistical test “t-test”: Two-sample assuming 
unequal variance’ was used to determine the statistical significance of the 
same BC cell line that was tested under different conditions. The statistical 
test “Anova: single factor” was used to determine the statistical 
significance of the same BC cell line that was tested under different 
conditions. 
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3. Disulfiram targeted breast cancer stem 
cells via Reactive Oxygen Species-MAPK 
and NFκB pathways 
3.1 Introduction 
BC is the most common invasive cancer in women globally and the second 
most common female cancer in the UK. Although the median survival of 
BC has been significantly improved in the last three decades, the survival 
rate of the advanced BC remains very poor with only a median 2-3 years of 
survival for the patients after combinational treatment (Statistical 
Information Team, CRUK, 2010). Development of radio- and chemo-
resistance is one of the major obstacles to the success of BC therapeutics. 
Chemotherapeutic agents induce DNA damage and trigger cancer cell 
apoptosis. Meanwhile, these genetic insults also activate the anti-apoptotic 
pathways in cancer cells, which protect cancer cells from drug-induced 
apoptosis. 
NFκB is one of the major chemoresistance-related anti-apoptotic factors. 
For the past 25 years, NFκB has served as a model for inducible 
transcription factors, and plays the most important role in the development 
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of various kinds of cancer. In comparison with their normal counterparts, 
many human cancer cells including BC possess higher levels of the 
constitutive NFκB activity which can be further induced by some 
anticancer drugs e.g. PAC, dFdC and Dox. Constantly activated NFκB 
triggers a series of molecular reactions including up-regulation of anti-
apoptotic protein-encoding genes (Dutta et al., 2006) leading to cancer 
chemoresistance. In drug-resistant cancer cell lines, high levels of NFκB 
activity have been identified (Dutta et al., 2006). Ectopic overexpression of 
NFκB can block anticancer drug-induced apoptosis (Wang et al., 1999; 
Wang et al., 1998; Wang et al., 2004). Previous studies in our lab 
demonstrate that 5-FU and dFdC-resistant cancer cell lines possess higher 
NFκB activity (Wang et al., 2003). Overexpression of p50 and p65, the two 
subunits of NFκB, results in increased NFκB activity and induces 5-FU and 
dFdC resistance (Guo et al., 2009; Wang et al., 2004). Although NFκB is 
an attractive molecular target and plays a critical role in therapeutic 
intervention, inhibition of NFκB alone can only induce limited cell death 
instead of eliminating all the cancer cells. Disappointing clinical trial 
outcomes from using a NFκB inhibitor in the treatment of metastatic BC 
patients (Cresta et al., 2008; Yang et al., 2006) indicate that BC 
chemotherapy cannot be efficiently improved by only targeting NFκB 
pathway. This phenomenon indicates that BC chemoresistance is a 
multifactorial molecular event in which many biological factors and 
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signalling pathways are involved. Therefore targeting a single pathway will 
not be able to reverse chemoresistance and improve therapeutic outcomes 
in clinic.   
ROS are a group of oxygen-containing chemical species normally 
generated from mitochondrial respiratory chain reaction with reactive 
chemical properties (Gupte et al., 2009). Many chemotherapeutic agents 
can induce high levels of ROS activity, which damages DNA, protein and 
lipid membrane leading to apoptosis. In comparison with normal tissues, 
cancer cells generally possess high ROS activity (Fruehauf et al., 2007). It 
has been suggested that anticancer drugs can further induce ROS 
generation and exhaust the cellular antioxidant capacity, pushing cancer 
cells over the tolerated ROS threshold and leading to apoptosis (Lopez-
Lazaro et al., 2007). 
Mitogen-activated protein kinase (MAPK) pathways regulate a vast array 
of physiological processes, such as growth, proliferation, differentiation, 
migration and apoptosis. MAPK enzymes are regulated by a characteristic 
phosphorelay system in which a series of three protein kinases 
phosphorylate and activate one another. To date, six different groups of 
MAPKs have been characterized in mammals, extracellular signal-
regulated kinase (ERK) 1/2, ERK3/4, ERK5, ERK7/8, c-Jun N-terminal 
kinase (JNK) 1/2/3 and the p38 isoforms α/β/γ(ERK6)/δ (Schaeffer et al., 
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1999). Here, I will discuss three well-characterized subfamilies of MAPK 
(ERK, JNK and p38) pathways which will be investigated in my study.  
The ERK pathway is the most studied mammalian MAPK pathway which 
is deregulated in one third of all human cancers and linked to many other 
aspects of the tumour phenotype (Junttila et al., 2008). ERK signalling is 
activated by numerous extracellular signals including growth factors and 
mitogens, which are particular relevance to cancer. The ERK pathway is 
initiated through the activation of the small G-protein Ras, which is a 
membrane-bound protein activated through the exchange of bound GDP to 
GTP. Phosphorylation of Ras recruits cytoplasmic Raf (Raf-1, B-Raf and 
A-Raf) to the cell membrane for activation. The activated Raf will regulate 
phosphorylation of MEK (MEK1 and MEK2) followed by the activation of 
ERK (ERK1 and ERK2). Activated ERK1 and ERK2 can translocate to the 
nucleus, and then they activate several transcription factors, such as c-Fos, 
ATF-2, Elk-1, c-Jun, and c-Myc. The function of the ERK pathway has 
long been associated with cell growth, cell proliferation, and survival.  
Sustained ERK signalling promotes phosphorylation and stabilization of 
cyclin D1, c-Fos, c-Jun and c-Myc genes to push cell-cycle entry, and 
repress the expression of genes which inhibit proliferation (Yamamoto et 
al., 2006). Furthermore, high expression of ERK can lead to cell-cycle 
arrest by inducing the expression of CDK-inhibitor proteins such as p21 
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and p27 (Sewing et al., 1997; Woods et al., 1997; Mirza et al., 2004). 
ERK1 and ERK2 mediated survival signalling has been demonstrated 
mainly through activation of RSK kinase. Phosphorylation of RSK 
inactivates the pro-apoptotic protein BAD. Meanwhile, activates the 
transcription factor CREB, which promotes cell survival through 
transcriptional up-regulation of anti-apoptotic Bcl-2, Bcl-xL, and Bcl-1 
proteins (Ballif et al., 2001; Bonni et al., 1999). In addition, ERK1 and 
ERK2 activity can suppress Fas-mediated apoptosis by inhibiting the 
formation of the death-inducing signalling complex (Holmstrom et al., 
2000).  
The JNK pathway is mainly activated by cytokines or cellular stress. These 
stimuli activate JNKs through several upstream kinases (MAPKKKs) 
phosphorylated, such as DLK, ASK1, MLK-3, MKKK1-4, TAK-1, and 
TPL-2 (Davis et al., 2000; Weston et al., 2007). In order to fully activate 
JNK, activation of both MKK4 and MKK7 are needed at MAPKKs level. 
Thereby JNK is activated through phosphorylation of MKK4 and MKK7. 
JNK then activates downstream transcription factors including c-Jun, ATF-
2, Elk-1, MEF-2c, p53, and c-Myc in the nucleus. Also, JNK has other non-
transcriptional substrates such as Bcl-2 and Bcl-xL (Yamamoto et al., 
1999). The JNK family is encoded by JNK1, JNK2 and JNK3. Like all 
other MAPKs, JNKs are activated through phosphorylation of a tyrosine 
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and a threonine residue, and share 85% sequence identity and are expressed 
ubiquitously. Regulation of the JNK pathway is extremely complex; the 
activity of JNK pathway can mediate apoptosis, proliferation, or survival, 
depending on the stimuli and cellular conditions. Double knockout JNK1 
and JNK2 mice were embryonic lethal due to altered apoptosis during brain 
development (Sabapathy et al., 2001; Tournier et al., 2000). JNK3-null 
mice demonstrated differences in neuronal apoptosis as compared to wild-
type mice (Yang et al., 1997). The transcriptional factor c-Jun is a 
component of the AP-1 transcription complex, which is an important 
regulator of gene expression. Phosphorylation of c-Jun, which is directly 
activated by JNK, has been demonstrated to play a critical role in Ras-
induced tumourigenesis through transcriptional repression of the p53 gene 
(Smeal et al., 1991; Kennedy et al., 2003). The inhibition of JNK enhances 
chemotherapy-induced inhibition of tumour cell growth because of its 
ability to interfere with DNA repair in response to genotoxic drug, 
suggesting that JNK may provide a molecular target for the treatment of 
cancer. The pharmaceutical industry is bringing JNK inhibitors into clinical 
trials for cancer treatment. 
The p38 pathway is strongly activated by inflammatory cytokines and 
environmental stresses, such as TNFα, IL-1, hypoxia, ultraviolet light, and 
osmotic stress. The diverse range of signals, such as TAK1, ASK1/2, DLK, 
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MEKK4, TAO1/2/3 and MLK2/3 can activate the p38 pathway through 
several MAPKKKs. Phosphorylation of MAPKKKs then activates MEK3 
and MEK6, which directly trigger p38 protein. Once active, p38 protein can 
translocate from the cytosol to the nucleus to activate an array of 
transcription factors, including ATF-2, CHOP-1, MEF-2, p53 and Elk-1. 
The p38 protein is represented by four isoforms: p38α, p38β, p38γ, and 
p38δ. They are characterized by the presence of the conserved Thr-Gly-Tyr 
(TGY) phosphorylation motif in their activation loop (Kumar et al., 2003). 
The p38 pathway plays a role in the regulation of apoptosis, cell cycle, and 
differentiation. Stress-induced p38 activation was shown to cause G2/M 
cell cycle arrest and to regulate the cell cycle through modulation of p53 
tumour suppressor proteins (Bulavin et al., 2001). p38 is involved in both 
the activation of p53 and in p53-induced apoptosis and acts as a negative 
regulator of cell cycle progression (Kummer et al., 1997; She et al., 2001). 
Furthermore, p38 activity has been reduced in hepatocellular carcinomas in 
comparison to adjacent normal tissue, with tumour size inversely related to 
p38 activity (Iyoda et al., 2003). In contrast, a few reports showed p38 
pathway activity can promote cancer cell growth and survival. For example, 
a high level of p38 has been observed in some cancer types, such as BC 
and brain tumour. p38 activity is also involved in the invasiveness of 
several cancer cell lines and inhibition of p38 activity reduced their 
proliferation, survival, and invasion (Junttila et al., 2007; Johansson et al., 
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2000). In addition, many chemotherapeutic agents induced apoptosis by 
p38 activity. Inhibition of p38 activity can enhance apoptosis in response to 
DNA-damaging agents such as Dox and CDDP in as well as microtubule-
disrupting agents such as taxol, vincristine and vinblastine (Deacon et al., 
2003; Losa et al., 2003; Lee et al., 2006). 
The most important function of MAPKs is to control cellular responses to 
the environment and regulate gene expression, cell growth, and apoptosis, 
which is related to many human diseases. The ERK, JNK, and p38 
pathways are all molecular targets for drug development, and inhibitors of 
MAPKs will undoubtedly be one of the next group of drugs developed for 
the treatment of human disease. 
Many conventional anticancer drugs induce ROS generation and trigger 
cancer cell apoptosis via ROS-MAPK pathway. However anticancer drug-
induced ROS activation also triggers the expression and activation of a 
number of anti-apoptotic factors including NFκB that dampen the ROS-
induced cytotoxic effect (Nakano et al., 2006). Interestingly, sustained JNK 
activity is necessary for cellular homeostasis, whereas strong stress ROS-
induced apoptosis is highly reliant on the persistent activation of pro-
apoptotic MAPK pathways (JNK and p38) (Nakano et al., 2006). JNK and 
NFκB signalling often play opposing roles in cancer, activation of NFκB 
signalling can lead to the suppression of apoptosis in contrast to JNK 
 118 
 
signalling. Prolonged JNK activation was found to promote apoptosis, 
suggesting that genes are induced by TNFα in an NFκB-dependent fashion 
normally block JNK activation. In response to TNFα, the anti-apoptotic 
effect of NFκB has been shown to be mediated by the induction of genes 
that can repress JNK activity (Lee et al., 2006). ROS have emerged as 
bridging molecules mediating the crosstalk between NFκB and JNK. A 
number of data demonstrated that ROS directly activate various kinases, 
including ASK1, MEKK1, and EGFR, which in turn activate the MAPK 
cascades. NFκB down-regulates JNK activation by suppressing TNFα 
induced ROS accumulation (Kumar et al., 2003). TNFα induces JNK 
activation in wild-type cells, whereas TNFα induces ROS accumulation 
leading to prolonged JNK activation in NFκB activation-deficient cells. 
Prolonged JNK activation is inhibited by pre-treatment of cells with 
antioxidants such as N-acetyl cysteine (NAC), suggesting that the 
mechanisms of early/transient and prolonged JNK activation are 
qualitatively different (Kumar et al., 2003). ROS are toxic in cells at certain 
levels, the correct cellular response to ROS production is consequently 
critical in order to prevent further oxidative damage, and to maintain cell 
survival. However, when too much cellular damage has occurred, ROS can 
trigger both apoptotic and necrotic cell death through the JNK and p38-
MAPK pathways. The JNK pathway is one of the main signalling pathways 
that intersect with NFκB with regard to ROS and cell death. In most cases, 
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the expression of NFκB target genes typically promotes cellular survival 
(Gloire et al., 2006). Therefore ROS modulate an NFκB response. 
Meanwhile, NFκB target genes would attenuate ROS to promote survival. 
Both JNK and p38 pathways are response for pro-apoptotic which regulate 
downstream genes, as a feedback effect, some anti-apoptotic factors such 
like Bcl-2 which is NFκB downstream target genes will be triggered to 
prevent cell death. Because of the cross-talk between NFκB and ROS-
MAPK pathways, singly targeting either pathway may not be sufficient for 
inducing cancer cell apoptosis. Therefore, identification of small molecules 
which simultaneously activate the ROS-MAPK pro-apoptotic pathway and 
inhibit ROS-induced anti-apoptotic pathways may improve BC 
chemotherapy.  
DS is a commercially available anti-alcoholism drug (Johansson et al., 
1992) used in clinic for more than 60 years. Our group has previously 
demonstrated that DS inhibits NFκB activity and enhances 5-FU- and 
dFdC-induced apoptosis in drug-sensitive and resistant colon cancer cell 
lines (Guo et al., 2009; Wang et al., 2003). DS also sensitises the 
cytotoxicity of cyclophosphamide, CDDP and radiation in vitro and 
protects normal cells in kidney, gut and bone marrow in vivo whilst 
increasing the therapeutic index of a wide range of cytotoxic drugs 
(Bodenner et al., 1986; Evans et al., 1982; Hacker et al., 1982). The 
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molecular anticancer mechanisms of DS are still not very clear. Previous 
publications indicate that DS targets the cancer cells in a Cu dependent 
manner (Cen et al., 2004; Cen et al., 2002; Chen et al., 2006; Nobel et al., 
1995).  
Cu is an essential trace element for humans and only high intracellular 
concentrations of Cu have been found to generate ROS in cells which can 
damage DNA, protein and lipid membranes eventually resulting in 
apoptosis (Gupte et al., 2009). Cu-induced cell death is associated with an 
increase in ROS generation (O2
-) through reduction of Cu2+ to Cu1+ in GSH 
to GSSH (Morrison et al., 2010). This would eventually deplete the 
glutathione pool leading to accumulation of high ROS levels and cell death. 
Cu intake is tightly controlled by Ctr1 as an essential function. This is the 
main reason why Cu alone does not show cytotoxicity in the cancer cells. 
DS/Cu is a strong ROS inducer (Nobel et al., 1995) and proteasome-NFκB 
pathway inhibitor (Chen et al., 2006). A combination of DS with Cu is 
supposed to target cancer cells by simultaneously tackling both ROS and 
NFκB. 
Cancer cells contain a very small fraction (1%) of CSCs which are 
relatively quiescent and express multidrug resistant and anti-apoptotic 
proteins (Dalerba et al., 2007; Marques et al., 2010; Storci et al., 2010). 
The importance of CSCs in chemoresistance has been attracting more and 
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more attention from cancer research and clinics. Conventional anticancer 
drugs target the proliferating and differentiated tumour bulk but fail to 
eradicate the CSCs, which become the source of tumour recurrence. 
Therefore, targeting CSCs becomes one of the new strategies for reversing 
chemoresistance and drug development. ALDHs are functional markers of 
normal and breast cancer stem cells (BCSCs) (Ginestier et al., 2007; 
Marcato et al., 2011). It was recently reported that targeting the ALDH1A1 
gene could kill the ovarian CSCs (Landen et al., 2010). DS is a specific 
inhibitor of ALDHs (Lam et al., 1997). Therefore, it may also be an 
inhibitor of BCSCs. 
The aim of the study in this chapter is to determine the anticancer activity 
of DS supplemented with physiological concentration of Cu. I also 
examined the chemosensitizing effect of DS/Cu on PAC induced 
cytotoxicity in a panel of BC cell lines. 
3.2 Methods  
General methodologies have been described in the chapter II. The 
following are the specific methods used in this study. 
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3.2.1 MTT and CI-isobologram  
Overnight-cultured T47D, MCF7 and MDA-MB-231 cells were exposed to 
various concentrations of PAC, DS+Cu1µM or in combination of PAC and 
DS+Cu1µM at a constant PAC: DS ratio of 62.5:1 for 72 hours. The cells 
were then subjected to MTT analysis as described above. The 
combinational cytotoxic effect between PAC and DS/Cu1µM was 
determined using CI-isobologram analysis (CalcuSyn software, Biosoft, 
Cambridge, UK). The combination index (CI) was determined by mutually 
exclusive equations. 
3.2.2 Reactive Oxygen Species activity detection  
The intracellular ROS levels were determined using 2', 7’-
dichlorodihydrofluorescein diacetate (H2DCFDA) probe (Invitrogen, 
Paisley, UK). T47D, MCF7 and MDA-MB-231 BC cells (1×106) were 
cultured in 24-well plates with 1 ml of serum- and phenol red-free DMEM 
medium (Sigma) containing 20 µM of H2DCFDA. Fluorescence was 
measured in 96-well plates at excitation 490 nm and emission 520 nm 
using a Fluoroskan Ascent fluorometer (Thermo Scientific, 
Northumberland, UK). 
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3.2.3 Clonogenic assay 
T47D, MCF7 and MDA-MB-231 BC cells (5×104/well in 6-well plates) 
were exposed to a designated concentration of DS/Cu1µM, PAC or PAC + 
DS/Cu1µM for 24 hours. The cells were collected and further cultured for 7 
(MDA-MB-231 and MCF7) to 14 (T47D) days in 6-well plates containing 
drug-free medium at a cell density of 2.5×103/well. Clonogenic cells were 
determined as those able to form a colony consisting of at least 50 cells. 
3.2.4 Detection of aldehyde dehydrogenases positive 
population  
The ALDH positive population in drug-treated T47D, MCF7 and MDA-
MB-231cell lines was detected by ALDEFLUOR kit (StemCell Tech., 
Durham, NC, USA) following the supplier’s instruction. The cells (2.5×105) 
were analyzed after being stained in ALDH substrate containing assay 
buffer for 30 min at 37°C. The negative control was treated with 
diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor. 
3.2.5 In vitro mammosphere culture  
The T47D, MCF7 and MDA-MB-231 BC cells were cultured in ultra-low 
adherence 6-well plates (Corning, MA, USA) containing 2 ml of stem cell 
culture medium [SCM, serum-free DMEM-F12 supplemented with B27 
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(Invitrogen, Paisley, UK), 20 ng/ml epidermal growth factor (Sigma), 10 
ng/ml basic fibroblasts growth factor (R & D System, Abingdon, UK), and 
10 µg/ml insulin (Sigma)] at a density of 10,000 cells/ml. After 7-10 days 
culture, the mammospheres were photographed and subjected to further 
treatments. 
3.2.6 Flow cytometric analysis of CD24 and CD44 expression  
The adherent or mammosphere cells were trypsinised and passed through a 
25G needle. The cells (2.5 x 105) were incubated with CD24 and CD44 
antibodies (BD Pharmingen, Oxford, UK) for 20 minutes at 4°C. Unbound 
antibodies were washed off with 2% FCS HBSS (Sigma) and the cells 
(10,000 events) were examined no longer than 1 hour after staining on a 
BD Facscalibur. 
3.3 RESULTS  
3.3.1 The cytotoxicity of disulfiram in breast cancer cells was 
copper dependent 
In CuCl2 (1 µM) supplemented medium, DS was highly cytotoxic to BC 
cell lines (IC50_72h: 110 nM to 476 nM, Fig. 3.1 and Table 3.1). DS was 
also toxic to cancer cell lines in the complete medium without CuCl2 
supplement with higher IC50 (456 nM to 1,100 nM, Fig. 3.1 and Table 3.1). 
 125 
 
A biphasic effect was observed in 2 out of 3 BC cell lines. The cancer cells 
appeared to be protected at a higher concentration of DS. DS alone in 
serum-free medium (to rule out the influence of trace amount of Cu 
contained in FCS) or Cu alone was not toxic to BC cell lines even at a very 
high concentration (20 µM). The drug-induced morphological changes are 
shown in Fig. 3.1. The flow cytometric DNA content analysis demonstrated 
that cells induced to apoptosis (sub-G1 population) is significant increased 
after 72 hours of DS/Cu treatment, but similar results could not be found in 
other groups (Fig. 3.2). The cleaved poly-(ADP-ribose) polymerase (PARP) 
protein, an indicator of caspase activation, was detected in DS/Cu treated 
cells. DS/Cu significantly inhibited BCL2 and induced BAX expression 
respectively therefore increased the BAX/BCL2 ratio in DS/Cu treated 
cells (Fig. 3.3). 
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Table 3.1 Cytotoxicity of different treatments to breast cancer cell lines 
 
Abbreviations: CI=combination index; Cu=copper; DS=disulfiram; PAC=paclitaxel. The figure 
represents IC50 value from three experiments [mean (SD)]. **Compared with PAC alone, significant 
difference (p<0.01, n=3). The cells were treated for 72 hours. DS/Cu: DS in medium supplemented 
with 1μM CuCl2; DS-serum: DS in serum-free medium; DS+serum: DS in serum-containing 
medium. CI: combination index. 
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Fig. 3.1 Disulfiram was cytotoxic to breast cancer cells in a copper-dependent manner. MTT 
cytotoxicity assay. The BC cells were exposed to different treatments for 72 hours. The morphology 
(× 100 magnification) of BC cell lines after 72 hours drug exposure (DS: 1µM of DS in serum free 
medium, Cu: CuCl2 1µM, DS/Cu: DS 1µM + Cu 1µM). 
 128 
 
 
Fig. 3.2 Flow Cytometry Analysis. The DNA contents of BC cells after 72 hours drug exposure 
(DS: 1 µM of DS in serum-free medium, Cu: CuCl2 1µM, DS/Cu: DS1µM + Cu1µM). The DNA contents 
in the treated cells (10,000 events) were determined. The sub-G1 population represents the apoptotic 
cells (** p<0.01, n=3). 
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Fig. 3.3 Expression of apoptosis-related proteins. The cleavage of PARP protein and the 
expression levels of BCL2 and BAX after 72 hours drug exposure were determined by western blot. 
Tub: α-tubulin used as a loading control. 
3.3.2 Disulfiram/copper synergistically enhanced the 
cytotoxicity of paclitaxel in breast cancer cell lines  
In combination with DS/Cu, the cytotoxicity of PAC was significantly 
enhanced in PAC sensitive (4-16 fold) and resistant (> 1,000 fold) cell lines 
(Fig. 3.1 and Table 3.1). There was a very strong synergistic effect between 
DS/Cu and PAC over a wide range of concentrations. In contrast to the 
slight induction of apoptosis at a low concentration of PAC alone (1 nM), 
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the proportion of apoptotic cells was massively increased by DS/Cu (DS 
100-150 nM/Cu 1 µM) and PAC in combination (Fig. 3.4). 
 
 
Fig. 3.4 MTT cytotoxicity assay and Flow Cytometry Analysis. Analysis of the combined effect 
of PAC and DS/Cu1µM. PAC: DS/Cu1µM = 1:62.5. The PAC-induced apoptosis was enhanced by 
DS/Cu. The DNA contents in the cell lines treated for 72 hours with PAC (1 nM) or PAC plus 
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DS/Cu (DS: MCF7, 100 nM; MDA-MB-231, and T47D, 150 nM; Cu: CuCl2 1 µM) were 
determined by flow cytometry. (** p<0.01, n=3). 
3.3.3 Reactive Oxygen Species activation was responsible for 
Disulfiram/copper-induced cytotoxicity  
The DS-induced cytotoxicity was highly Cu-dependent. Cu is an active 
redox metal element, which can trigger ROS generation and induce 
apoptosis in cancer cells (Morrison et al., 2010). ROS may be the mediator 
for DS/Cu-induced apoptosis. Therefore, I examined the effect of DS/Cu 
on the generation of ROS in BC cell lines. My study shows that DS 
significantly induced ROS activity in BC cell lines (p<0.01). N-acetyl-L-
cysteine (NAC) is a ROS inhibitor, which can block ROS, induced 
apoptosis (Halasi et al., 2013). The DS/Cu induced ROS activity in the BC 
cell lines was reversed by the addition of a ROS inhibitor, NAC (p<0.01; 
Fig. 3.5). To determine the effect of ROS on DS/Cu-induced cell death, the 
cytotoxicity assay was performed with or without ROS inhibitor. Fig. 3.5 
shows that in line with the change of ROS activity, the DS/Cu-induced 
cytotoxicity was significantly reversed by the addition of NAC in the 
culture (p<0.01). 
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Fig. 3.5 ROS was responsible for disulfiram/copper-induced cytotoxicity. The BC cell lines were 
loaded with fluorescent dye H2DCFDA and exposed to DS5 µM/Cu5 µM or DS/Cu plus NAC (10 mM) 
for 3 hours. The fluorescent strength was detected by fluorometer at Ex 490 nm and Em 520 nm. The 
effect of ROS and MAPK pathway inhibitors on DS/Cu-induced cytotoxicity. The cancer cells were 
exposed to DS250nM/Cu1µM, DS/Cu plus NAC (10 mM), JNK inhibitor SP600125 (10 µM) or p38 
inhibitor SB203580 (10 µM) for 72 hours and subjected to MTT assay. 
3.3.4 Disulfiram/copper triggered persistent activation of JNK 
and p38 pathways  
Fig. 3.6 showed the effect of PAC, DS/Cu and PAC/DS/Cu on the 
activation of the JNK pathway. Total JNK protein expression was not 
affected by the above treatments. However, the expression of 
phosphorylated JNK, c-Jun and total c-Jun was persistently (up to 24 hours) 
 133 
 
induced by DS/Cu and PAC/DS/Cu. In contrast, the expression of these 
proteins was not, or only very mildly, up-regulated by PAC. High levels of 
phosphorylated p38 were also detected up to 24 hours following DS/Cu and 
PAC/DS/Cu exposure (Fig. 3.6). To determine the causal relationship 
between ROS and JNK, p38 pathways, BC cell lines were exposed to 
DS/Cu for 24 hours with or without the addition of NAC. NAC 
significantly inhibited or totally blocked DS/Cu-induced c-Jun and p38 
phosphorylation (Fig. 3.7).  
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Fig. 3.6 The effect of disulfiram/copper on MAPK pathway. The overnight cultured BC cells 
were exposed to PAC1µM, DS1µM/Cu1µM or PAC1µM/DS1µM/Cu1µM for indicated time lengths. (A) The 
expression levels and phosphorylation status of proteins in JNK pathways were detected by western 
blot in different treatment time points (1, 8, 24 hours). (B) Phosphorylation of p38 were detected by 
western blot after 24 hours treatment. 
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Fig. 3.7 The effect of disulfiram/copper/NAC on MAPK pathway.  The activation of JNK and 
p38 pathways was reversed by NAC. The phosphorylation of c-Jun and p38 in BC cell lines was 
determined by western blot after exposure to DS/Cu or DS/Cu plus NAC (10 mM) for 24 hours. 
3.3.5 Disulfiram/copper inhibited NFκB activity in breast 
cancer cell lines  
NFκB is an ROS-induced transcription factor with strong anti-apoptotic 
activity which in turn dampens the pro-apoptotic effect of ROS (Nakano et 
al., 2006). Blockage of NFκB activation enhances ROS-induced 
cytotoxicity. Both PAC and DS/Cu inhibited NFκB DNA binding activity 
in BC cell lines. The strongest inhibition was observed in the cells treated 
with PAC/DS/Cu in combination (Fig. 3.8). The inhibition of NFκB 
transcriptional activity was also detected in PAC, DS/Cu and PAC/DS/Cu 
treated cells by reporter gene assay (Fig. 3.8). 
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Fig. 3.8 NFκB activity has been inhibited by disulfiram/copper. (A) NFκB DNA binding activity 
was analysed by EMSA assay. Nu: western blot of nucleolin was used as a protein loading control. 
(B) The BC cell lines were treated with PAC1µM, DS1µM/Cu1µM or PAC/DS/Cu for 24 hours. NFκB 
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transcriptional activity examined by luciferase reporter gene assay after exposure to PAC1µM, 
DS1µM/Cu1µM or PAC/DS/Cu for 24 hours. 
3.3.6 Disulfiram/copper inhibited the clonogenicity in breast 
cancer cell lines  
In this study, I also used clonogenic assays to determine the ability of 
DS/Cu to induce ‘reproductive death’ (Franken et al., 2006) in BC cells. 
After 16 hours exposure to PAC (40 nM: 4 to 18-fold higher than IC50 
concentration), DS (200-250 nM: sub-IC50 concentration)/Cu1µM or PAC 
and DS/Cu in combination. The treated cells were collected and cultured in 
drug free medium for 7-14 days. The colony number was reduced by 
exposure to PAC, DS or Cu alone. The colony number in PAC, DS and Cu 
treated groups was decreased which was caused by slow growth of the 
surviving cells leading to the cell number in some colonies not reaching the 
counting threshold (50 cells). In contrast, the clonogenicity of BC cell lines 
was significantly inhibited by DS/Cu and totally eradicated by exposure to 
PAC plus DS/Cu (Fig. 3.9). 
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Fig. 3.9 The effect of disulfiram/copper on the clonogenicity. Clonogenic assay. The cells 
exposed  to Cu 1µM, PAC 40 nM, DS (250 nM for MDA-MB-231 and T47D, 200 nM for MCF7) 
DS/Cu or PAC/DS/Cu for 24 hours were cultured in drug-free medium in 6-well plates at a cell 
density of 2.5 × 103/well for 7-10 days. The colonies were stained with crystal violet, counted and 
photographed as described in Materials and Methods. 
3.3.7 Disulfiram/copper targeted breast cancer stem cells  
Furthermore, we examined the effect of different treatments on CSCs 
population in MDA-MB-231 and T47D cell lines. The mammosphere 
formation in both cell lines was completely blocked by exposure to 
DS1µM/Cu1µM or DS/Cu plus PAC40nM for 48 hours but not affected by PAC, 
DS or Cu alone (Fig. 3.10). To determine the targeting effect of DS/Cu on 
CSCs, the BCSCs markers in drug-treated mammosphere cells were also 
analysed. Fig. 3.11 demonstrates that the ALDH positive population in 
 139 
 
mammospheres was significantly inhibited by DS/Cu but not affected or 
even enriched by DS or Cu treatment. In order to determine the effect of 
DS/Cu on CSCs, the expression status of CD24Low/CD44High, another 
marker of BCSCs, was also examined. After 16 hours exposure to different 
drugs, the CD24Low/CD44High population in the mammosphere cells was 
determined by flow cytometry. In comparison with the attached cells the 
mammosphere population contained a significantly higher percentage of 
CD24Low/CD44High BCSCs (Fig. 3.11). The percentage of 
CD24Low/CD44High cells in mammosphere was reduced following 16 hours 
exposure to DS/Cu and PAC/DS/Cu but not influenced by PAC, DS or Cu 
(Fig. 3.11). 
 
Fig. 3.10 The effect of disulfiram/copper on cancer stem cells in breast cancer cell lines. DS/Cu 
and PAC/DS/Cu inhibited mammosphere formation. The BC cells were treated with PAC40nM, 
DS250nM, Cu1µM, DS/Cu or PAC/DS/Cu for 48 hours and then sub-cultured in drug-free SCM in 
ultra-low attachment 6-well plates (5,000 cells/well) for 7 days and photographed at × 40 
magnification. 
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Fig. 3.11 The effect of DS/Cu on CSCs markers in BC cell lines. DS/Cu inhibited ALDH 
expression in mammospheres. The ALDH+VE population was flow cytometrically determined in 
mammospheres exposed to drugs (Cu1µM, DS1µM or DS1µM/Cu1µM) for 16 hours. D. DS/Cu abolished 
CD24Low/CD44High population in mammospheres. The expression of CD24 and CD44 was examined 
after 16 hours exposure to Cu1µM, DS1µM, PAC100nM or DS/Cu/PAC. The inserted numbers in the 
frame represent percentage of ALDH+VE or CD24Low/CD44High cells (mean ± SD from 3 experiments, 
**p<0.01). 
3.4 Discussion 
DS is a Food and Drug Administration-approved anti-alcoholism drug used 
in clinic for over 60 years with extensive availability of pre-clinical and 
clinical safety data (Eneanya et al., 1981). The study in this chapter 
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demonstrates that DS is highly cytotoxic to BC cell lines in a Cu-dependent 
manner. DS can chelate Cu to form a DS/Cu complex. Cu is a crucial trace 
element that plays a critical role in the redox chemistry, growth and 
development of every living organism (Turnlund et al, 1998). It is also an 
indispensable catalytic and structural cofactor that drives a wide array of 
important biochemical processes. In the body Cu exists in both oxidation 
states, oxidized Cu (II) and reduced Cu (I). The major biological molecules 
functions of Cu is to react directly with molecular oxygen to produce free 
radicals. There is a long history of trying to use Cu for cancer therapeutics 
(Gupte et al., 2009; Hieger et al, 1926). The successful animal experiment 
was published almost 9 decades ago. Since then, no further report has been 
published. Based on our data, single Cu treatment didn’t show any 
cytotoxicity to the T47D and MCF7 cell lines in the MTT assay. The 
intracellular transport of Cu is still one of the major hurdles for its clinical 
efficacy due to the complicated environment in the cancer cells. Ctr1 is a 
Cu transporter, responsible for the transport of Cu into cells (Kim et al., 
2008). The cellular intake of Cu is tightly controlled by Ctr1. In addition, 
cancer cells have been reported to show elevated Cu level resulting in 
higher ROS levels, whereas high Cu is the instinctive characteristic of 
cancer cells (Kim et al., 2008). Due to the intrinsic antiapoptotic 
mechanisms, no apoptosis is induced in cancer cells. 
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A derivative of DS, N,N-diethyldithiocarbamate (deDTC), binds to Cu 
forming a Cu(deDTC)2 complex which improves the intracellular 
trafficking of Cu and this is probably responsible for DS induced apoptosis 
(Cen et al., 2004). Furthermore, DS can also penetrate into cancer cells to 
chelate free intracellular Cu to form Cu(deDTC)2. In comparison with 
normal tissues, many cancers including BC possess higher levels of Cu (2-
3 fold) (Margalioth et al., 1983; Rizk et al., 1984), which may enable DS to 
target cancer cells selectively (Bodenner et al., 1986; Chen et al., 2006; 
Evans et al., 1982; Hacker et al., 1982; Iljin et al., 2009). Similar results of 
high level Cu have been found in the cancer cell lines as well. In line with a 
previous report (Wickstrom et al., 2007), a biphasic cytotoxic effect of DS 
was observed in BC cell lines tested in complete medium without Cu 
supplement. BC cells were killed at low concentration but revived at higher 
DS concentrations (~ 10 µM). The mechanism of the biphasic effect is still 
not very clear. A degraded product of DS may compete trace amounts of 
Cu, block formation of Cu(deDTC)2 and inhibit transport of Cu into cells 
(Cen et al., 2004). 
We have previously reported that DS enhances the cytotoxicity of 5-FU 
and dFdC in colon and BC cell lines (Guo et al., 2009; Wang et al., 2003). 
In this study, we demonstrated the synergistic cytotoxic effect of DS/Cu 
and PAC on BC cell lines.  
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Previous studies indicate that in combination with Cu, DS induces ROS 
activity in melanoma cell lines (Cen et al., 2002; Morrison et al., 2010). 
The recent study from Dou’s group demonstrates that gold-dithiocarbamato 
complexes strongly induce ROS and inhibit proteasome activity in BC cells 
(Zhang et al., 2010b). In consistence with these results, our study showed 
that DS/Cu induced ROS activity which was responsible for DS/Cu 
induced cytotoxicity in BC cell lines. ROS is not the only target for the 
cytotoxicity of BC cells. The ROS-induced apoptosis is commonly 
mediated by the persistent activation of JNK and p38 MAPK pathways 
(Junttila et al., 2008). In our study, I have detected different time points for 
the treatment of DS/Cu in BC cell lines, the results showed that both JNK 
and p38 pathways were persistently (over 24 hours) activated 
(phosphorylation of c-Jun and p38) by DS/Cu and blocked by NAC. JNK 
and p38 inhibitors reduced cytotoxicity of DS/Cu, although to a lesser 
degree than ROS inhibition. Therefore ROS-activated JNK and p38 
pathways were, at least partially, responsible for ROS-induced apoptosis. 
The persistent activation of JNK and p38 induces apoptosis via 
mitochondrial apoptotic pathways (Junttila et al., 2008). It is very possible 
that mitochondrial damage can be detected in BC cells of DS/Cu treatment. 
The DS/Cu induced apoptosis was confirmed by DNA content and PARP 
protein cleavage. The expression of BAX and BCL2 proteins was induced 
and suppressed by DS/Cu respectively leading to increased BAX/BCL2 
 144 
 
ratio. The elevated BAX/BCL2 ratio indicated that the intrinsic apoptotic 
pathway may be involved in DS/Cu induced apoptosis. 
Due to the high proliferative rate and energy requirement, cancer cells are 
under higher ROS stress than their normal counterparts. High levels of 
ROS can damage DNA, mitochondrial inner membrane and membrane 
phospholipids leading to apoptosis (Gupte et al., 2009). However ROS also 
activate a wide range of anti-apoptotic factors. The effect of ROS on cancer 
cells depends on the balance between ROS-induced pro- and anti-apoptotic 
factors. Further inducing ROS can result in cells undergoing apoptosis. 
JNK and p38 are the major pathways of MAPK responsible for ROS 
induced apoptosis. From our results, DS significantly induced ROS activity 
in BC cell lines. The DS/Cu induced ROS activity in the BC cell lines was 
reversed by the addition of NAC, a ROS inhibitor. The expression of 
phosphorylated JNK, c-Jun and total c-Jun was induced by DS/Cu. 
Meanwhile, high levels of phosphorylated p38 were also detected. ROS 
have emerged as bridging molecules mediating the crosstalk between 
NFκB and JNK pathway. Therefore, high ROS is triggered by its inducer 
DS/Cu thereby actives JNK and p38 pathway to regulate NFκB. NFκB is 
one of the most important ROS-induced anti-apoptotic factors (Gloire et al., 
2006). The activation of NFκB in turn inhibits ROS and JNK, p38 
activation and ultimately inhibits ROS-induced apoptosis. Consistent with 
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previous publications (Guo et al., 2009; Wang et al., 2003), our data 
indicated that DS/Cu inhibited both binding activity and transcriptional 
activity of NFκB, and ultimately induced the cells undergo apoptosis. To 
date, these results indicate that DS/Cu may induce apoptosis of BC cells by 
simultaneously inducing ROS generation and inhibiting ROS-NFκB 
pathway. 
It has been widely accepted that CSCs are responsible for tumour 
recurrence and may display significant resistance to different cytotoxic 
drugs (Liu et al., 2010). The characteristics that define CSCs include self-
renewal, clonogenic and tumorigenic potential, and transient quiescence, 
which are believed to contribute to CSCs resistance to conventional 
therapies. In order to test the effect of DS/Cu on the regeneration of 
minimal-residual-cancer-cells, I used clonogenic assay, a gold measure to 
detect the cell ‘reproductive death’ after cytotoxic agent treatments 
(Franken et al., 2006). In contrast to the moderate inhibiting effect of PAC, 
DS and Cu on clonogenicity of BC cells, the colony formation was 
significantly reduced or completely eradicated by DS/Cu and PAC/DS/Cu 
respectively. These results indicated that a small population of BC cells 
may be responsible for regeneration of cancer mass after PAC treatment. 
However, DS/Cu or PAC in combination with DS/Cu can kill these 
stubborn cancer cells. DS/Cu reverses cancer cell chemoresistance induced 
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by a wide range of different mechanisms (Guo et al., 2009; Wang et al., 
2004; Wang et al., 2001; Wang et al., 2003). From the results of the effect 
of DS/Cu on clonogenicity of BC cell lines, we further examined the effect 
of DS/Cu on BCSCs.   
The stem cell culture system was developed by Dontu (Dontu et al., 2003). 
The cells were cultured in serum-free condition at a non-adherent system. 
The stem cells can survive and proliferate in this system and form grape-
like clusters, which are named as ‘mammospheres’. The mammospheres 
consist of enriched stem cell population, which is capable of differentiating 
along multiples lineages (Dontu et al., 2003). The mammosphere culture 
system has now been used to identify and enrich the putative stem cells in 
BC cell lines. Here, we cultured mammosphere of MDA-MB-231 and 
T47D to examine the effect of different treatments on CSCs population. 
The mammosphere forming ability in both cell lines was completely 
blocked by exposure to DS/Cu for 48 hours. Furthermore, we determined 
the targeting effect of DS/Cu on CSCs and the BCSCs markers in drug-
treated mammosphere cells. It has been widely accepted that high ALDH 
activity can be detected in CSCs (Ginestier et al., 2007). This is not only a 
marker but also responsible for chemo- and radio resistance in BC cell lines 
MDA-MB-231 and MDA-MB-468 (Croker et al., 2012). ALDH1A1 has 
been identified as a functional marker of several different types of CSCs 
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including BCSCs (Alison et al., 2010; Ginestier et al., 2007). Therefore 
ALDHs may be redundantly expressed in different cancer types, and 
targeting one isoform may not be sufficiently for CSCs targeting. DS is a 
strong inhibitor for both cytosol and mitochondrial ALDHs (Eneanya et al., 
1981; Lam et al., 1997). My study is the first report of using DS to target 
BCSCs. The ALDH+VE population in BCSCs was significantly inhibited by 
DS/Cu. The ability of BC cell lines to form mammospheres was completely 
inhibited by exposure to DS/Cu for 24 hours. The effect of DS/Cu on CSCs 
was also confirmed by the reduction of the CD24Low/CD44High population. 
The detailed molecular mechanisms underlying the effect of DS/Cu on 
BCSCs are unclear. ALDHs detoxify intracellular aldehydes which can 
form adducts with glutathione, nucleic acids and amino acids leading to 
cell death (Marchitti et al., 2008). The high expression of ALDHs in CSCs 
may be protective. Mammalian cornea cells contain abundant ALDH 
playing a critical role in scavenging ROS and reducing UV-induced 
oxidative stress (Estey et al., 2007). ALDH deficiency in the central 
nervous system is associated with progressive neurodegeneration (Marchitti 
et al., 2007). Inhibition of NFκB pathway and induction of ROS results in 
reduction of stem-like properties in CSCs derived from pancreatic cancer 
and leukemia (Greten et al., 2004; Jin et al., 2010; Rausch et al., 2010). 
DS/Cu may target BCSCs by simultaneously inhibiting NFκB and 
activating ROS activity. 
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In conclusion, DS/Cu inhibited BCSCs and enhanced cytotoxicity of PAC 
in BC cell lines. This may be caused by simultaneous induction of ROS 
and inhibition of NFκB. 
4. Disulfiram reverses chemoresistance in 
an acquired paclitaxel resistant triple 
negative breast cancer cell line 
4.1 Introduction 
Triple negative breast cancer (TNBC), an aggressive variant of BC 
accounting for approximately 15-20% of all BC cases (Carey et al., 2006), 
is characterized by tumours that do not express the ER, PR and HER2 
(Bauer et al., 2007). Globally, approximately 170,000 cases of TNBC 
phenotype are detected in the estimated 1 million BC incidences identified 
annually (Anders et al., 2009). Approximately 80% of TNBC cases are 
classified as basal-like and another minority subtype of TNBC, termed 
claudin-low, which are uniquely characterized by low to absent expression 
of differentiated luminal cell surface markers but enrichment of cancer 
stem cell-like features (Prat et al., 2010). In general, TNBC patients are at 
high risk of early relapse with a sharp decline in survival outcomes during 
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the first 3 to 5 years after diagnosis (Cheang et al., 2008; Liedtke et al., 
2008; Dent et al., 2007). The best median survival period of advanced 
TNBC is 12 months, much shorter than the duration of survival seen in 
other subtypes of advanced BC. TNBC has a poorer prognosis than other 
types of invasive BC, the claudin-low subtype of TNBC has an even poorer 
prognosis with less of a response to chemotherapy than other basal-like BC. 
In clinic, general characteristic of TNBC are including present as interval 
cancer, high risk of early recurrence, rapid progression from the onset of 
metastasis to death, and highly chemosensitive. The molecular features of 
TNBC have been described that elevated mitotic activity, amplified Ki67 
index, marked cellular pleomorphism, high nuclear cytoplasmic ratio, scant 
stromal content, central necrosis or central a cellular zones, multiple 
apoptotic cells, pushing margins of invasion and stromal lymphocytic 
inﬁltration (Livasy et al., 2006; Rakha et al., 2006; Fulford et al., 2006; 
Fadare et al., 2007). The optimal therapeutic method for TNBC patients is 
systemic cytotoxic chemotherapy, which is the mainstay treatment of 
TNBC, because endocrine therapy or trastuzumab (HER2-targeted agents) 
produce no clinical benefits for the patients (Liedtke et al., 2008; Carey et 
al., 2007; Rouzier et al., 2005). However, patients with TNBC have poorer 
outcomes compared with other BC subtypes. Chemoresistance needs to be 
overcome in the next few years if any significant clinical strides are to be 
made. In the early stage of TNBC, neoadjuvant and adjuvant therapy is the 
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main treatment for patients with TNBC at risk of relapse (Goldhirsch et al., 
2009). However, cytotoxic chemotherapy is recommended for patients with 
TNBC who develop metastases. Current treatment agents for both stages of 
TNBC include anthracyclines, taxanes, and platinum agents. 
Anthracyclines and taxanes are used as prior neoadjuvant or adjuvant 
regimen depending on the patient characteristics. TNBC with specific 
DNA-repair defects is sensitive to platinum agents, thus CDDP-based 
chemotherapy is more efficacious against TNBC patients (Isakoff et al., 
2010). More recently, PARP inhibitors, epidermal growth factor receptor 
(EGFR) inhibitors, and anti-angiogenic agents have been proposed as a 
therapeutic mechanism in TNBC. Moreover, it has been reported that 
genistein is well recognised as a protective factor against BC and its 
mechanism of action has proved to suppress the growth of TNBC cell line 
as well as inhibiting NFB activation via Notch-1 signalling pathway (Pan 
et al., 2012). Similarly, a study has reported that -mangostin has the effect 
on cell cycle alteration and inducing apoptosis in TNBC cell line (Shibata 
et al. 2011). All these data support that more and more potential 
chemotherapy agents have been discovered and applied in the treatment of 
patients with TNBC, whereas there are no preferred chemotherapy 
regimens are being selected with similar considerations as with other BCs. 
 151 
 
Therefore, with on-going studies of platinum-based combination therapy, it 
is important to find a more effective chemotherapy agent to target TNBC.  
As discussed above, due to lack of a molecular target to be tackled, there 
are very few chemotherapeutic agents available for TNBC chemotherapy. 
CDDP is commonly used in combination with PAC for the treatment of 
patients with TNBC. PAC is one of candidate’s therapeutic agents in 
chemotherapy of early stage and metastatic TNBC. PAC targets cancer 
cells mainly by binding to and stabilising microtubules (Schiff et al., 1979), 
arresting cancer cells in G2/M mitotic checkpoint, and subsequently 
inducing apoptosis via intrinsic apoptotic pathway (Ferlini et al., 2009). As 
with other anticancer drugs, TNBC cells can develop acquired resistance 
after repeated exposure to PAC. The acquired chemoresistance remains a 
major hurdle for the PAC-based chemotherapy. The most recognised 
resistant mechanisms include overexpression of Pgp encoded by the 
ABCB1 gene and alterations in microtubule system (Trock et al., 1997). 
The acquired PAC resistance can also be introduced by mutations in 
tubulin, which modulate the binding affinity of PAC to microtubules. The 
following molecular mechanisms are also related to PAC resistance e.g. 
HER2 overexpression (Knuefermann et al., 2003) altered apoptotic and 
molecular signalling pathways (Takahashi et al., 2005; Chabalier et al., 
2006; Huang et al., 1997). Chemotherapy would benefit from identifying 
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new compounds to target alternative chemoresistant pathways and/or 
sensitise cancer cells to classical anticancer drugs.   
CDDP is a small molecule platinum compound that was first found to 
inhibit the growth of Escherichia coli and later used to treat testicular and 
bladder cancer (Rosenberg et al., 1973). CDDP is employed for the 
treatment of a wide range of solid malignancies, including testicular, 
ovarian, head and neck, colorectal, bladder, lung and BCs. CDDP showed a 
high level and broad spectrum of anticancer activity via multiple 
mechanisms. The most prominent mode of action involves the generation 
of DNA lesions followed by the activation of the DNA damage response 
and the induction of mitochondrial apoptosis, and this effect is related to 
inhibition of DNA synthesis and repair that might result in cell cycle arrest 
at the G1, S, or G2-M phase, therefore apoptosis will be induced (Desoize 
et al., 2002). Interestingly, it has been reported that CDDP also induces 
ROS to trigger cell death in vitro and in vivo. The formation of ROS 
depends on the concentration of CDDP and the duration of exposure 
(Brozovic et al., 2010). Further study on the cytotoxicity of CDDP shows 
that two pathways may contribute to CDDP-induced apoptosis in vitro. One 
involves the tumour-suppressor protein p53, and the other one is mediated 
by the p53-related protein p73 (Jordan et al., 2000). Due to the sensitivity 
of CDDP is p53 related in cancer, CDDP-inducible p53 gene therapy might 
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enhance the effectiveness of commonly used chemotherapeutic agents, 
leading to a promising treatment for cancers (Wang et al., 2006). 
The first exciting clinical trial of CDDP in BC patients without previous 
chemotherapy was reported by Kolaric and Roth (1983) with a dose of 30 
mg m-2 I.V. daily for 4 days every 3 weeks (Kolaric et al., 1983). After this, 
an accumulating number of studies suggest CDDP can be used as the first 
line anticancer drug in BC, especially in TNBC. However, the single drug 
therapy may induce chemoresistance. In order to increase the patient’s 
survival periods, CDDP is currently used in combination with other 
anticancer drugs such as dFdC or PAC in chemotherapy, and also in Phase 
I to III clinical trials. Acquired drug resistance occurs when tumour cells do 
not respond to treatment with anticancer drugs including CDDP. Several 
CDDP resistance mechanisms are as follows, (a) decreased intracellular 
drug accumulation and/or increased drug efflux; (b) drug inactivation by 
increased levels of cellular thiols; (c) evasion of apoptosis by increased 
nucleotide excision-repair activity and decreased mismatch-repair activity; 
(d) alterations in drug target (Sedletska et al., 2005; Brabec et al., 2005; 
Kartalou et al., 2001).  Due to the unwanted resistance of CDDP, patients 
receiving CDDP experience severe side effects that limit the dose, which 
can be administered. The side effects of CDDP include nausea and 
vomiting, myelosuppresion and immunosuppression. More specific side 
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effects include damage to kidneys (nephrotoxicity), peripheral nerves 
(neurotoxicity) and the inner ear (ototoxicity) (Shah et al., 2009; Gunes et 
al., 2009; Florea et al., 2006). CDDP has proven to be one of the more 
efficient anticancer chemotherapeutic agents in the fight against several 
solid cancers. Unfortunately, cancer cells either intrinsically resistant or 
relatively rapidly become resistant to CDDP, leading to relapse and 
therapeutic failure. Therefore, more research is necessary in order to 
improve anticancer treatments and to decrease toxic effects. 
The MDA-MB-231 cell line originated from an epithelial adenocarcinoma 
of the mammary gland, which was isolated from a pleural effusion of a 54 
year old Caucasian female in 1971 (Zhang et al., 1991). This cell line is 
one of the commonly used types for screening of new anti-neoplastic drugs 
by National Cancer Institute. MDA-MB-231 cells possess an 'epithelial 
like' appearance as they are adherent, invasive and poorly differentiated. 
Furthermore, they also behave aggressively, are metastatic in nature and 
have been found to express neither estrogen, progesterone nor HER2 
receptor, apart from the presence of basal expression of epidermal growth 
factor receptor (EGFR). Hence, MDA-MB-231 is TNBC cell lines. In 
addition, these cells also acquire p53 mutation and strong Ki67 expression, 
which is an important marker for cell proliferation (Neve et al. 2006; Keam 
et al. 2011). 
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It has been suggested that human BC contains a small population of CSCs, 
which can be detected by the expression of stem cell markers (ALDHs, 
CD24Low/CD44High) and activation of embryonic related pathways (Sox2, 
Oct4, Nanog) (Marques et al., 2010). BCSCs are slow cycling and 
quiescent population expressing high levels of Pgp (Dean et al., 2009). The 
cancer cells with CSC phenotypes are highly resistant to a variety of 
conventional anticancer drugs and responsible for cancer recurrence. 
Targeting CSCs may improve the outcomes of cancer chemotherapy 
(Clevers et al., 2011). 
DS, a commercially available anti-alcoholism drug, shows anticancer 
activity in vitro and in vivo. It also potentiates cyclophosphamide, CDDP 
and radiation in vitro and protects normal cells in kidney, gut and bone 
marrow in vivo whilst increasing the therapeutic index of cytotoxic drugs. 
The randomized clinical trial indicates that in combination with 
chemotherapy, ditiocarb, the derivative of DS, significantly improves 5-
year overall survival of high risk BC patients. The anticancer activity of DS 
is Cu dependent. Cu plays a crucial role in redox reactions and triggers 
generation of ROS in human cells. DS/Cu is a strong ROS inducer and 
proteasome-NFB pathway inhibitor. DS specifically inhibits the activity 
of ALDH, a functional CSCs marker and ROS scavenger. A combination 
of DS with Cu may target cancer cells by simultaneous modulation of both 
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ROS and NFB. DS and its metabolites can also covalently modify 
cysteine residues within nucleotide binding domain of Pgp and 
permanently inhibit Pgp activity. This will potentially reverse multidrug 
resistance. 
4.2 Methods  
General methods have been described in chapter II, the following are the 
methodologies specifically used in this study. 
4.2.1 Cell lines and reagents 
The PAC resistant cell line (MDA-MB-231PAC10) was generated from 
MDA-MB-231 (purchased from ATCC) by being continuously cultured in 
medium containing PAC (Sigma, Dorset, UK) respectively in a stepwise 
concentration-increasing procedure. CDDP, DS and copper (II) chloride 
(CuCl2) were purchased from Sigma. 
4.2.2 Grow curves and doubling time analysis 
The cells (5×103/well) were cultured in 24-well plates in triplicate. The 
cells were collected by trypsinization and cell numbers in each of three 
wells were counted every 24 hours for 120 hours. The cell doubling time 
was calculated using the program from the Doubling Time Online 
Calculator http://www.doubling-time.com/compute.php. 
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4.2.3 Cell culture and cytotoxicity analysis 
All cell lines were cultured in DMEM (Lonza, Wokingham, UK) 
supplemented with 10% FCS, 50 units/ml penicillin, and 50 g/ml 
streptomycin. The MDA-MB-231PAC10 cells were maintained in the 
medium containing 10 nM of PAC. For in vitro cytotoxicity assay, the 
overnight cultured cells (5,000/well) in 96-well flat-bottomed microtiter 
plates were exposed to drugs for 72 hours (PAC) or 120 hours (CDDP) and 
subjected to a standard MTT assay. 
4.2.4 Immunofluorescent flow cytometry and confocal 
microscopy 
The expression of Nanog, Oct4 and Sox2 was determined by 
immunofluoresence flow cytometry and confocal microscopy. For 
immunocytochemistry confocal microscopy analysis, the cells were grown 
on a culturing chamber slide (Sigma, Dorset, UK) overnight and fixed by 
acetone/methanol and permeabilized by 0.1% triton-X100. After being 
blocked with 3% BSA for 1 hour the cells were stained with primary 
antibodies (1:50 dilution 5 g/ml) and FITC-conjugated secondary 
antibody for 1 hour at RT. The coverslips were mounted on glass slides 
with VectaShield mounting media containing the nucleic acid stain, 4,6-
diamidino-2-phenylindole (DAPI; Vector Laboratories Inc., Burlingame, 
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CA), and examined by laser scanning confocal microscopy using a Zeiss 
Axiovert 200 microscope and ZEN 2009 software (Carl Zeiss Canada Ltd., 
Mississauga, CA). For immunofluorescent flow cytometric analysis, the 
cells were cultured in T25 flasks until 80% confluence and collected by 
trypsinization. The cells were stained in suspension using the same 
concentration of antibodies and procedure as immunocytochemistry 
analysis. The positively stained population was detected using a FACS 
Calibur flow cytometer with 488 nm blue laser and standard FITC 530/30 
nm band pass filter. 
4.3 RESULTS 
4.3.1 MDA-MB-231PAC10 cells are resistant to chemotherapy 
drugs 
The cytotoxic effect of PAC on both sensitive and resistant cell lines was 
compared by MTT assay (Table. 4.1 and Fig. 4.1A). The MDA-MB-231 
cells are sensitive to the cytotoxicity of PAC with an IC50_72h of 8.7nM. In 
contrast, the MDA-MB-231PAC10 cell line is highly resistant to PAC with an 
IC50_72h over 1000 nM. The cytotoxic effect of CDDP on MDA-MB-
231PAC10 cell line was also evaluated. It has been demonstrated that MDA-
MB-231PAC10 cells are also significantly cross-resistant to CDDP (Table. 
4.1 and Fig. 4.1B). 
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Table 4.1 Cytotoxicity of PAC, CDDP and DS to MDA-MB-231 and 
MDA-MB-231PAC10 breast cancer cell lines 
 
The table represents IC50 value from three experiments [mean (SD)]. **p<0.01’ *p<0.05 (n=3). The 
cells were treated for 72 hours. DS/Cu: DS in medium supplemented with 1M CuCl2. CP: cisplatin 
(CDDP); PAC: paclitaxel; DS: disulfiram. 
 
Fig. 4.1 MDA-MB-231PAC10 cell line is resistant to PAC and cross-resistant to CDDP. The 
MDA-MB-231PAC10 and MDA-MB-231 cell lines were exposed to PAC (A) and CDDP (B) for 72 
and 120 hours respectively. 
In line with the MTT data PAC (20 nM) abolished the clonogenicity of the 
parental cell line but no effect on MDA-MB-231PAC10 cells (Fig. 4.2A and 
B). Due to the slower proliferation rate, the colonies developed from the 
resistant cell line are smaller than that from the parental cell line.  
 160 
 
 
Fig. 4.2 Clonogenic assay of MDA-MB-231PAC10 and MDA-MB-231. (A) and (B) The cells were 
exposed to PAC (20 nM) for 72 hours and then subcultured in drug-free medium at a cell density of 
2,500 cells/well in 6-well plates for 10 days. The colony number of clonogenic assay. The colonies 
with ≥ 50 cells were counted. The figures indicate mean (SD). N=3, **p<0.01. 
MDR1 overexpression is the most common mechanism involved in 
multidrug resistance which includes PAC resistance. High expression of 
Pgp was detected in the PAC resistant cell line by Western blot (Fig. 4.3A). 
PAC induces apoptosis mainly via intrinsic apoptotic pathway. Therefore 
the protein expression status of BAX and BCL2 (two major components 
involved in intrinsic apoptotic pathway) was examined by Western blot. 
Fig. 4.3B shows that the MDA-MB-231PAC10 cell line expresses 
significantly higher background levels of BCL2 protein than those in the 
parental cells. The BCL2/BAX ratio in the resistant cell line is markedly 
higher than that in the parental cell line.  
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Fig. 4.3 Protein expression detected by Western blotting. Protein expression of Pgp (A), BAX 
and BCL2 (B). MDA: MDA-MB-231; PAC10: MDA-MB-231PAC10 
4.3.2 Resistance of MDA-MB-231PAC10 cell line to paclitaxel-
induced apoptosis 
After 72 hours exposed to 20 nM PAC, the phase contrast microscopic 
images demonstrate apoptotic morphologies (cell blebbing and nuclear 
condensation and fragmentation) in MDA-MB-231 but not in the MDA-
MB-231PAC10 resistant cells (Fig. 4.4).  
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Fig. 4.4 MDA-MB-231PAC10 cell line is resistant to PAC-induced apoptosis by morphologies 
observation. The morphology (× 200 magnification) of parental and resistant cells after 72 hours 
exposure to PAC (20 nM). 
Flow cytometric DNA content analysis manifested that PAC induced a 
significantly higher (p<0.01) apoptotic sub-G1 population (30.4%) in the 
parental cell line than those in the untreated cells (0.4%) (Fig. 4.5A). PAC 
(20 nM, 72h) also introduced G2/M-phase blockade leading to an increased 
G2/M population (untreated: 17.9%, treated: 36.4%; p<0.01) and a 
decreased G0/G1 population (dropped from 64.9% to 15.6%, p<0.01) (Fig. 
4.5B) in the parental cell line. In contrast, there is no significant effect of 
PAC on the apoptotic status in the resistant cells. The cell cycle status in 
MDA-MB-231PAC10 cell line is also not affected by PAC exposure (Fig. 
4.5C). 
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Fig. 4.5 MDA-MB-231PAC10 cell line is resistant to PAC-induced apoptosis detected by flow 
cytometric DNA analysis. (A) Histogram of flow cytometric DNA content analysis. The effect of 
PAC (20 nM, 72 hours) on cell cycle parameters in MDA-MB-231 (B) and MDA-MB-231PAC10 (C) 
cell lines. The figures represent mean (SD) from three experiments. 
As mentioned above, BAX and BCL2 are two golden components involved 
in intrinsic apoptotic pathway, thus PAC inducible apoptosis was examined 
by Western blot. Fig. 4.6 shows that PAC exposure induces BAX 
expression leading to high BAX/BCL2 ratio in the parental cells but no 
effect on the resistant cells. 
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Fig. 4.6 BAX and BCL2 protein expression. Western blotting analysis of BAX and BCL2 protein 
expression in MDA-MB-231 and MDA-MB-231PAC10 cell lines after exposure to PAC (20nM) for 
72 hours. 
4.3.3 MDA-MB-231PAC10 has longer doubling time 
In the cell culture, the drug resistant MDA-MB-231PAC10 cells grow 
markedly slower than MDA-MB-231 cells. Therefore we compared the 
doubling time and cell cycle parameters in these two cell lines. Fig. 4.7 
shows the growth curves of both cell lines. The doubling time of MDA-
MB-231PAC10 cells (64.9h) is significantly longer than that of the sensitive 
cells (31.7h) (p<0.01).  
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Fig. 4.7 Growth curves of MDA-MB-231 and MDA-MB-231PAC10. MDA-MB-231PAC10 cell line 
has longer doubling time. MDA: MDA-MB-231, PAC10: MDA-MB-231PAC10. The figures represent 
the mean of three experiments. **p<0.01. 
Further cell cycle study on both cell lines using flow cytometry analysis 
(Fig. 4.8) shows that in comparison with the parental cell line, the MDA-
MB-231PAC10 cells have significantly higher G0/G1 and lower S-phase 
population. 
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Fig. 4.8 Cell cycle status of MDA-MB-231 and MDA-MB-231PAC10 cell lines respectively. The 
figures represent mean (SD) of three experiments. **p<0.01. 
The expression levels of cell cycle determinant proteins were examined by 
Western blot. Fig. 4.9 shows the Western blotting image and relative band 
density analysed by ImageJ program. Relative density index = (Target 
protein/Tubulin) x 100. The expression of p21 is tightly controlled by p53 
(Lazzarini et al., 2008), and p21 protein mediates the p53-dependent cell 
cycle G1 phase arrest in response to chemotherapy agents. Therefore, the 
expression of p21 and p53 was examined (Woods et al., 1997). The results 
showed p21 is markedly overexpressed in the resistant cell line, but p53 is 
moderately up-regulated, so are cyclin D1 and cyclin E. 
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Fig. 4.9 Expression of cell cycle protein. Western blotting analysis of cell cycle related proteins in 
MDA-MB-231 and MDA-MB-231PAC10. The bar chart on the right represents relative density index 
of the bands. 
4.3.4 MDA-MB-231PAC10 cells demonstrate cancer stem cells 
characteristics  
It has been widely accepted that CSCs are responsible for chemo- and 
radio-resistance. The resistant cell line is slow cycling with high expression 
of p21 protein and expresses high levels of Pgp which are the common 
features in CSCs. Therefore we examined CSC markers in the resistant and 
parental cell lines. High ALDH activity is a functional marker of CSCs 
derived from different cancer types including BC (Ginestier et al., 2007). 
Fig. 4.10 shows that in comparison with the parental cells the MDA-MB-
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231PAC10 cell line possesses higher ALDH
+ population which also express 
higher levels of embryonic stem cell markers (Oct4, Sox2 and Nanog). 
 
Fig. 4.10 Cancer stem cell markers were expressed in MDA-MB-231PAC10 cell line detected by 
Flow cytometry. Flow cytometric analysis of ALDH activity and Oct4, Sox2 and Nanog protein 
expression levels.  
In order to further confirm the CSC marker existing in MDA-MB-231PAC10 
cell line, immunofluorescence confocal microscopy has been used in my 
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study. Fig. 4.11 shows high expression of Oct4 and Sox2 in the PAC 
resistant cell line.  
 
Fig. 4.11 Cancer stem cell markers were expressed in MDA-MB-231PAC10 cell line detected 
by confocal microscopy.  High expression of Oct4 and Sox2 was detected in MDA-MB-231PAC10 
cells by immunofluorescence confocal microscopy. 
The overexpression of Oct4 and Sox2 protein was also detected by Western 
blotting assay (Fig. 4.12). The expression of NFB and HIF2 protein was 
also examined by Western blotting analysis because emerging evidence 
 170 
 
indicates that hypoxia and NFB are responsible for maintaining stemness 
in CSCs (Wang et al., 2004). In comparison with the parental cell line, 
higher levels of HIF2 and NFB p65 protein were detected in the nuclear 
protein of MDA-MB-231PAC10 cells. The expression levels of cytoplasmic 
NFB p65 in the resistant and parental cell lines are comparable (Fig. 4.12). 
 
Fig. 4.12 Protein expression of cancer stem cell markers. High expression of HIF2α, NFκBp65, 
Sox2 and Oct4 protein was detected in nucleus of MDA-MB-231PAC10 cell line. Nucl, nucleus; Nuc, 
nucleolin; Tub, α-tubulin. 
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4.3.5 Disulfiram is highly cytotoxic in MDA-MB-231PAC10 cells 
and reverses paclitaxel resistance 
Our previous studies demonstrate that DS is a strong CSCs inhibitor and 
highly cytotoxic to a wide range of cancer cell lines. In spite of resistance 
to PAC and CDDP, the sensitivity of MDA-MB-231PAC10 cell line to DS is 
comparable to that of parental cells (Fig. 4.13). The clonogenecity of both 
parental and resistant cell lines is completely abolished after very short 
exposure (4 hours) to DS /Cu (Fig. 4.13).  
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Fig. 4.13 Disulfiram is highly cytotoxic in MDA-MB-231PAC10 cell line as well as in MDA-MB-
231. (A) MTT cytotoxicity assay. The MDA-MB-231 and MDA-MB-231PAC10 cell lines were 
exposed to different concentrations of DS in combination with 1μM of CuCl2 for 4 hours and then 
released in drug-free medium for 72 hours. (B) and (C) Clonogenic assay. The cells were exposed to 
DS 1as plus Cu 1lu for 4 hours and then subcultured in drug-free medium at a cell density of 2,500 
cells/well in 6-well plates for 10 days. The colony number of clonogenic assay. The colonies with ≥ 
50 cells were counted. The figures indicate mean (SD). N=3. 
4.3.6 Disulfiram/copper induces apoptosis in MDA-MB-
231PAC10 cell line 
After 24h exposed to DS/Cu, the phase contrast microscopic images show 
massive apoptotic cells were detected in MDA-MB-231PAC10 (Fig. 4.14A). 
Flow cytometric DNA content analysis indicated that DS/Cu induced a 
significantly higher (p<0.01) apoptotic sub-G1 population (50%) in 
resistant cell line than those in the untreated cells (5%) (Fig. 4.14B and C).  
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Fig. 4.14 Disulfiram induces apoptosis in MDA-MB-231PAC10 cells. (A) The morphology (×100 
magnification) of MDA-MB-231PAC10 cells after drug exposure. (B) and (C) The influence of DS/Cu 
on cell cycle parameters in MDA-MB-231PAC10 cells. The figures in C represent mean (SD) from 
three independent experiments. DS 1μM /Cu 1μM. 
DS/Cu inhibits and induces the expression of Bcl2 and BAX in MDA-MB-
231PAC10 cells respectively leading to significantly increased BAX/BCL2 
ratio in the resistant cell line (Fig. 4.15). Although DS is a specific inhibitor 
of MDR1 activity, the protein expression of Pgp in MDA-MB-231PAC10 cell 
line was not affected by DS/Cu exposure (Fig. 4.15).  
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Fig. 4.15 The effect of Disulfiram on apoptosis related protein expression in MDA-MB-
231PAC10 cells. Western blotting analysis of DS-induced alteration in BAX, BCL2 and Pgp 
expression in MDA-MB-231PAC10 cells. The cells were exposed to DS (1μM) and CuCl2 (1μM) for 4 
hours and then released in drug-free medium for 24 hours. 
The effect of DS/Cu on cell cycle regulating proteins was analysed by 
Western blot. Fig. 4.16 shows that DS/Cu induces the expression of p21 
and p53 protein but has no effect on CDK2, Cyclin D1 and E expression. 
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Fig. 4.16 The effect of Disulfiram on cell cycle related protein expression in MDA-MB-231PAC10 
cells. Western blotting examination of the effect of DS/Cu on cell cycle related protein expression. 
The cells were exposed to DS (1μM) and CuCl2 (1μM) for 4 hours and then released in drug-free 
medium for 24 hours. 
4.3.7 Disulfiram inhibits the expression of cancer stem cells 
markers and reverses paclitaxel resistance in MDA-MB-
231PAC10 cells 
Nowadays, CSCs are believed to be one of the key factors involved in 
chemoresistance (Balic et al., 2006). The MDA-MB-231PAC10 cell line is 
composed of high population of CSCs. Furthermore, we examined if 
DS/Cu inhibits the CSCs in the resistant cell line. The ALDH activity in the 
resistant cell line is inhibited after exposure to DS/Cu for 4 hours. DS/Cu 
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also inhibits the expression of Sox2 and Nanog in the resistant cells (Fig. 
4.17).  
 
Fig. 4.17 Disulfiram/copper inhibits cancer stem cells markers in MDA-MB-231PAC10 cells. 
DS/Cu inhibits ALDH activity and the expression of Sox2 and Nanog protein in MDA-MB-231PAC10 
cell line. The cells were exposed to DS (1μM) and CuCl2 (1μM) for 4 hours. 
Furthermore, I also examined whether DS/Cu can enhance the cytotoxicity 
of PAC and reverse PAC resistance in MDA-MB-231PAC10 cell line. In 
combination with DS/Cu, the cytoxicity of PAC in MDA-MB-231PAC10 
cells is markedly higher than exposure to PAC or DS/Cu alone (Fig. 4.18). 
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CI-isobologram indicates that the cytotoxicity of DS/Cu + PAC is 
synergistic in a wide range of concentrations (IC20-IC95). 
 
Fig. 4.18 Disulfiram/copper synergistically enhances cytotoxicity of PAC in MDA-MB-231PAC10 
cells. The cytotoxicity of DS/Cu and PAC in MDA-MB-231PAC10 cells is synergistic. The figures 
represent the mean from three independent experiments. Fa-CI plot of Isobologram analysis. The CI 
value below 1 indicates synergistic effect between DS/Cu and PAC. The cells were exposed to DS 
(1μM) and CuCl2 (1μM) for 4 hours and then released in drug-free medium for 24 hours. 
4.4 Discussion 
In comparison with other BC subtypes, TNBC have poorer 
chemotherapeutic outcomes with only 12 months of median survival time 
in advanced TNBC. Although in recent years taxane- and platin-based 
primary chemotherapy demonstrates high efficacy in TNBC treatment 
(Frasci et al., 2009), drug resistance remains the major barrier for the 
clinical success of this regimen. Initial treatment of TNBC often leaves 
residual disease, after that, regrowth TNBC becomes resistant to all 
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available chemotherapy. This is mainly because the relapsed TNBC has a 
capacity of pan-resistance, which is similar to the characteristics of drug 
resistant bacteria (Falagas et al., 2008). Pan-resistance is the most 
disturbing and intractable form of resistance for cancer patients due to the 
chemoresistance of cancer cells to the whole range of anticancer drugs as 
well as ionizing radiation. It is very possible that the cancer cells have lost 
all targetable defects after the initial treatments to protect themselves 
avoiding cell death or transfer to distant place to regrowth tumour. Three 
explanations, e.g. mimicry, defence and compensation, of pan-resistance 
have been proposed by Piet, (Piet et al., 2012). Cancer cells can mimic 
normal cells with some proliferation strategies. Thus cancer cells pretend to 
be normal cells by imitating rapid growth of host tissues with high turnover 
rates, making the tumour equally sensitive/resistant to drugs as normal 
tissues. I would rather prefer the defence and compensation are the case of 
the pan-resistance rather than the mimicry due to lack of strong evidence to 
support. Cancer cell defence is the ability to keep all drugs away from their 
targets. Pgp up-regulation could be part of this defence system by 
preventing the drug from reaching its target. The mechanism of 
compensation in the cancer cells is involved in many aspects. 
Compensation represents adaptations that affect multiple targets, such as 
increasing the activation of anti-apoptotic pathway, slowing down the cell 
cycle to avoid drug targeting, and increasing DNA repair. Moreover, CSCs 
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have been recognised as having an important role in pan-resistance as well 
as for the cancer relapse. Overall, based on the finding in my study, I will 
in turn to discuss the characteristic of acquired PAC resistant TNBC cell 
line (MDA-MB-231PAC10) and how DS target TNBC and reverse the PAC 
resistant in this cell line. 
In comparison with the parental line, the MDA-MB-231PAC10 cell line is 
highly resistant to PAC-induced cytotoxicity (>115-fold), inhibition of 
clonogenicity (~400-fold) and apoptosis (~75-fold). The MDA-MB-
231PAC10 cell line is also significantly cross-resistant to CDDP (~2.5-fold, 
p=0.01). In line with previous reports, Pgp is dramatically overexpressed in 
the resistant cell line. Although high expression of Pgp plays a role in PAC 
resistance, MDR1 has no influence on cancer cell sensitivity to CDDP. 
These results indicate that as a key factor in cell defence mechanism, Pgp 
may only play a very small part in pan-resistance characteristics in MDA-
MB-231PAC10 cells. The intrinsic apoptotic pathway plays a main role in 
both PAC and CDDP induced apoptosis. As a feedback to the 
chemotherapy drugs induced apoptosis, high background expression of 
BCL2 protein was detected in MDA-MB-231PAC10 cells leading to a higher 
BCL2/BAX ratio which may desensitize the resistant cell line to PAC and 
CDDP induced apoptosis. 
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Furthermore, the resistant cell line proliferates slower with significantly 
longer doubling time. Flow cytometry analysis demonstrates that a 
significantly higher population of the resistant cells are blocked in G0/G1 
phase with fewer cells entering S-(p<0.01) and G2/M-phase. PAC exposure 
induces G2/M-phase arrest in the parental cell line but has no effect on the 
resistant cell line. It has been known for long time that classical anticancer 
agents primarily target cycling cancer cells. The quiescent cancer cell 
population located in G0/G1-phase is resistant to most chemotherapeutic 
agents and ionizing irradiation. The quiescence has been considered as the 
main reason for the pan-resistance at the beginning, but it is not an 
explanation for it because however slow the tumour grows, it will continue 
to proliferate (Stewart et al., 2007; Sijbers et al., 1996; Guo et al., 2008). 
PAC is predominately an M-phase-specific drug which stabilizes 
microtubules causing an M-phase arrest followed by apoptosis (Schiff et al., 
1979). Therefore PAC will lose its anticancer activity if the cancer cells are 
prevented from entering G2/M phase by G0/G1 phase arrest. p21Waf1 is a 
CDK inhibitor inactivating the activity of cyclin A, cyclin E and CDK2 
which are essential for G1/S transition. p21Waf1 overexpression induces 
anticancer drug resistance (Bunz et al., 1990; Lazzarini et al., 2008). 
Western blot shows that p21Waf1 protein is massively up-regulated in the 
resistant cell line. Because MDA-MB-231 is p53 mutant, the up-regulation 
of p21Waf1 in the resistant cell line is p53 independent. The High p21Waf1 
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expression may be responsible for the G0/G1 block in the resistant cell line. 
It has been demonstrated that bryostatin-1 induced PAC resistance via up-
regulation of p21Waf1 (Koutcher et al., 2000). Flavopiridol and bryostatin-1 
are CDK inhibitors, which slow down cell cycle. After pre-exposure to 
flavopiridol or bryostatin-1, BC cells become highly resistant to PAC due 
to flavopiridol and bryostatin-1 induced G0/G1 arrest. The cell cycle 
disturbance may be, at least partly, responsible for PAC resistance in 
MDA-MB-231PAC10 cell line. Previous studies indicate that overexpression 
of p21 and cell cycle perturbations can induce CDDP resistance (Koster et 
al., 2010; Wilkins et al., 1997). The overexpression of p21 and cell cycle 
perturbation in MDA-MB-231PAC10 cell line may be at least partly 
responsible for the cross-resistance between PAC and CDDP. These results 
also support that cell cycle slowing down may contribute to the pan-
resistance through its compensation mechanism in cancer cells. 
Another concept of pan-resistance has been proposed is CSCs. Cancer cell 
population contains a small proportion of CSCs. It has been widely 
accepted that CSCs are responsible for tumour recurrence and display 
significant resistance to cytotoxic drugs with different acting and resistant 
mechanisms. It has recently been reported that CSCs are involved in 
acquired taxane resistance (Domingo et al., 2012; McAuliffe et al., 2013). 
In contrast with the fast growing cancer mass, CSCs are quiescent and slow 
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cycling cells expressing stem cell markers. High expression of Pgp is also a 
common feature of CSCs. Recent reports indicate that p21Waf1 is 
indispensable for maintaining the quiescent status, stemness and preventing 
excess DNA-damage accumulation in CSCs. Our findings in MDA-MB-
231PAC10 cell line (for instance, high p21 expression, cell cycle slowing 
down, and high expression of Pgp) indicate that this cell line may contain 
high population of CSCs which may play a key role in the PAC resistance 
and CDDP cross-resistance. Based upon this hypothesis we examined 
several other CSC phenotypes. High levels of ALDH, a functional CSC 
marker, were detected in the resistant cells by ALDEFLOUR analysis. 
Recent publications (Landen et al., 2010; Schafer et al., 2012) indicate that 
high ALDH activity confers chemoresistance upon cancer cells, which can 
be reversed by targeting ALDH. High expression of the embryonic stem 
cell-associated genes Sox2, Oct4 and Nanog was also detected in the 
resistant cell line. Hypoxia induced HIFs overexpression and NFκB 
pathway activation is responsible for chemoresistance (Wang et al., 2004) 
and also the determinant factors for maintaining stemness of CSCs. Even 
cultured in normoxic condition, the overexpression and nuclear 
translocation of HIF2α and NFκBp65 were detected in the resistant cell line. 
Further studies are being performed in our lab to elucidate the relationship 
between these factors and CSC-related chemoresistance. 
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DS is a very efficacious CSC-targeting agent and demonstrates strong 
chemoresistance-reversing activity. Previous clinical studies manifest that 
DS and its derivative effectively improve survival of breast and other 
cancer patients. In this study I examined the direct cytotoxic and PAC-
resistance-reversing effect of DS on MDA-MB-231PAC10 cell line. Our 
results show that although MDA-MB-231PAC10 cells are resistant to both 
PAC and CDDP, the cytotoxicity of DS is very comparable in both 
resistant and sensitive cell lines. DS completely eradicates the 
clonogenicity in both parental and resistant cell lines. The ALDH activity 
and the expression of Sox2 and Nanog in the resistant cell line are 
markedly inhibited by DS exposure. Therefore DS may sensitize MDA-
MB-231PAC10 cell line to PAC and CDDP by targeting CSCs. The 
simultaneous inhibition and induction of BCL2 and BAX indicates that DS 
may induce apoptosis in the resistant cells via an intrinsic pathway. 
Although DS inhibits MDR1 activity, it has no effect on the expression of 
Pgp. There is no effect of DS on cell cycle status in the resistant cell line. 
Similar to many other DNA targeting agents, DS exposure further induces 
p21 expression in the resistant cells. 
In conclusion, in this part of my study, I characterized a newly developed 
PAC-resistant BC cell line, MDA-MB-231PAC10 and investigated the 
potential PAC resistant mechanisms. Our data show that the resistant cell 
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line is slow growing and contains a high population of cells with CSC 
characteristics. I also demonstrated that DS efficiently reverses the PAC 
and CDDP resistance in MDA-MB-231PAC10 cell line. Further study on DS 
may lead to the discovery of a new efficient chemotherapy agent not only 
for BC patients but also for all cancer patients. 
5. Tackling hypoxia-induced NFκB 
activation to target breast cancer stem 
cells 
5.1 Introduction  
Although mortality has been declining and the median survival rate of BC 
has been significantly improved in the majority of developed countries due 
to systemic therapy in early BC treatment, the therapeutic outcomes of 
A/MBC remain poor with a median 5-year survival rate from diagnosis of 
only about 23% (Guarneri et al., 2004). Chemotherapy is the main arm of 
treatment for the A/MBC after surgery and radiotherapy. Unfortunately, 
response duration remains disappointingly short and long-term survival rate 
remains low. The main limitation for the success of A/MBC treatment is 
chemoresistance. The relapsed A/MBC is commonly pan-resistant to a 
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wide range of anticancer drugs, which cannot be explained by individual 
genetic and biochemical resistant pathways. Therefore tackling the pan-
resistance will substantially improve the therapeutic outcomes of A/MBC 
patients. 
CSCs have been considered to have similar characteristics with normal 
stem cells from tumour-prone tissue. Apparent differences also exist 
between CSCs and normal stem cells. Normal stem cells are maintained 
under tight homeostatic regulation and are passively protected in the stem 
cell niche in adult tissue, whereas CSCs may actively contribute to 
tumourigenesis through the CSC niche. BC is a highly heterogeneous 
disease containing a very small fraction (1%) of BCSCs population with 
stem cell characters (Tirino et al., 2013). In 2003, the BCSCs were first 
discovered when a CD24low/CD44high subpopulation of tumour cells from 
human patient samples were shown to have tumour-initiating capacity in 
immunodeficient mice (Al-Hajj et al., 2003). Then the development of 
biomarkers to identify BCSCs as well as the validation of in vitro and 
mouse models has facilitated the isolation and characterization of these 
cells from murine and human tumours. BCSCs can be identified by 
detection of stem cell markers (ALDHs, CD24low/CD44high) and activation 
of embryonic related pathways (Sox2, Oct4, Nanog), which are commonly 
shared with other kinds of cancer (Marques et al., 2010). CD44, single-pass 
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type I transmembrane protein, has been identified as a cellular adhesion 
molecule for hyaluronic acid, a major component of the extracellular 
matrix. There are numbers of isoforms that are generated through 
alternative splicing of CD44 precursor mRNA. The standard isoform of 
CD44 is expressed predominantly in hematopoietic cells and normal 
epithelial cell subsets (Aruffo et al., 1990; Nagano et al., 2004; Ponta et al., 
2003). Although the exact function of CD44 expression in CSCs remains 
unclear, CD44 is widely accepted to be associated with EMT and the 
features of CSCs, e.g. interaction with the corresponding niche (Jin et al., 
2006), the potential for cell migration and homing (Sackstein et al., 2008), 
the capacity for defense against ROS, and resistance to apoptosis (Shi et al., 
2012; Toole et al., 2008). It has been reported that CD44 expression 
influences the stem-like properties of CSC populations isolated from the 
human breast through RNA interference-mediated depletion of CD44 
suggesting that CD44 is a potential target for CSC-directed therapy (Pham 
et al., 2011). Furthermore, expression of stemness genes is also used to 
characterize CSCs. Nanog is a homeodomain-containing transcription 
factor and, along with the POU domain-containing Oct4 and high mobility 
group domain-containing SRY Sox2, is part of the key set of transcription 
factors that have emerged as the master regulatory mechanisms of stem cell 
pluripotency and differentiation. They are essential for the maintenance of 
pluripotent embryonic stem cells (Chambers et al., 2004; Mitsui et al., 
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2003; Kashyap et al., 2009; Pan et al., 2007). Expression of these genes 
could be a function of malignant transformation and is not unique to BCSC 
population. Accumulating data show that high expression of these genes 
could be detected in BC, lung, ovarian cancers and glioblastoma (Tirino et 
al., 2011; Eramo et al., 2010). 
Human Nanog protein consists of 305 amino acids. Overexpression of 
Nanog is thought to be an indicator of a poor prognosis for BC patients. In 
comparison of the non-stemness cancer cells, high expression level of 
Nanog has been shown in CSCs in BC (Nagata et al., 2012). Several 
studies demonstrated that cancer cells with high levels of the CSC surface 
marker would possess higher levels of Nanog as well (Xu et al., 2012; He 
et al., 2012; Leung et al., 2010). It has been considered that Nanog is not 
only a CSC marker, but also promotes CSC-like characteristics in BC. For 
instance, overexpression of Nanog increased drug-resistance capacity in 
BC cell lines and the Nanog protein can bind to the promoter region of 
cyclin D1 and regulate cell cycle and proliferation (Jeter et al., 2011; Choi 
et al., 2012).  
Oct4 is a member of the POU family of transcription factors and plays a 
pivotal role in the maintenance of self-renewal and pluripotency in 
embryonic stem cells. Oct4 is expressed in many malignant tumours and 
the expression profile has been related to tumour grade and disease 
 188 
 
progression (Huang et al., 2012; Zhang et al., 2010c). It has been reported 
that Oct4 expression is present in both normal adult stem cell and CSCs 
(Tai et al., 2005). An important study has demonstrated that high 
expression of Oct4 in normal breast cells led to the generation of cells with 
tumour-initiating and colonization abilities. These cells developed high-
grade, poorly differentiated BC in nude mice (Beltran et al., 2011). 
Furthermore, high Oct4 expression has been shown to enhance the features 
of CSCs in a mouse model of BC (Kim et al., 2011).  
Sox2 is a member of a superfamily of proteins that all possess a high 
mobility group (HMG) box DNA-binding domain and it is pivotal for early 
development and maintenance of undifferentiated embryonic stem cells. A 
recent study showed that two cell subsets have been identified based on 
differential Sox2 transcription activity in MCF7 and ZR75 BC cell lines, 
and subset possessing Sox2 transcription could significantly form more 
colonies in methylcellulose and more mammospheres in vitro whereas 
knockdown Sox2 in the subset abolished these abilities (Wu et al., 2012). 
Therefore, it can be concluded that Sox2 transcription activity was 
responsible for the tumourigenicity and CSCs phenotypes in BC (Wu et al., 
2012). Moreover, down-regulating Sox2 drastically reduced their 
transformed properties in vitro and BC cells with depletion of Sox2 
couldn’t form mammospheres and differentiation any more. All these 
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studies indicated that Sox2 expression promoted and maintained the 
stemness of CSCs.  
CSCs are responsible for chemoresistance and tumour relapse. CSCs are 
relatively quiescent, express multidrug resistant and anti-apoptotic proteins 
(Storci et al., 2010; Simsek et al., 2010). Investigation of CSC character 
will contribute to understanding the role of CSC in therapeutic failure. 
Further study on CSC may develop a novel specific targeting drug for CSC 
to prolong the survival rate for cancer patient. It is widely understood that 
the CSC is more than a functional unit. Emerging evidence suggests that 
CSC resides in a hypoxic/necrotic tumorous area named as CSC niche, 
which controls self-renewal and differentiation of CSCs. Moreover, CSCs 
can be generated in the niche for maintenance purposes through induction 
of CSC features. The niche is also recognized involved in metastasis by 
induction of the EMT, leading to dissemination and invasion of tumour 
cells. The secondary tumours also seem to initiate in the premetastatic 
niche. Therefore, the microenvironment plays a crucial role in primary 
tumour growth as well as metastasis formation (Bao et al., 2012). Low 
oxygen in the niche of the cancer cells termed hypoxia, which is one of the 
most pervasive microenvironmental stresses and has been recognized as the 
most common features of solid tumours. Clinically, hypoxia and its 
signalling pathway have been shown to be associated with radio- and 
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chemo-resistance, contributing to increased risk of tumour recurrence and 
metastasis, leading to reduced overall survival rate and increased mortality 
(Jubb et al., 2010). A wide range of studies has also demonstrated that 
hypoxia plays a pivotal role in the maintenance of the stemness of CSCs 
(Thomlinson et al., 1955; Brown et al., 1998). The hypoxia-induced and 
retained CSC characteristics can be reversed into differentiated phenotype 
in normoxic condition and vise versa. In vitro, the CSC and non-CSC 
phenotypes are interconvertible in spheroid and monolayer culture 
respectively (Zeng et al., 2011). Therefore the stemness of CSCs is highly 
environment-dependent and the environmental oxygen concentration plays 
determinant roles in the maintenance of the stemness in CSCs (Cummins et 
al., 2005). Although most publications emphasize the importance of the 
HIFs in induction and maintenance of CSC phenotypes, the detail 
molecular mechanistic relationship between hypoxia and CSCs is still not 
fully elucidated. Approximate 20 different transcription factors are induced 
directly or indirectly by hypoxia including NFB (Arlt et al., 2003). NFB 
is a transcription factor, which plays an important role in cell survival, 
proliferation, invasion, migration, angiogenesis, tumour metastasis and 
chemoresistance (Wang et al., 2007; Walmsley et al., 2005). Moreover, 
emerging evidence suggests that NFκB also plays an important role in 
EMT and CSCs, contributing to tumour aggressiveness (Sarkar et al., 2008; 
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Widera et al., 2008). Hypoxia could activate NFB signalling pathway in a 
variety of cells including cancer cells. In most normal cells, NFB is 
sequestered in the cytoplasm as an inactive complex through the direct 
binding to its natural inhibitor, the inhibitor of NFB (IB). Upon various 
stimuli, IB will be phosphorylated by IB kinase complex (IKK,,), 
ubiqutinated and promptly degraded which releases NFB from NFB-IB 
complex. The liberated NFB dimers are then translocated into the nucleus, 
binding to the promoter region of the relevant downstream genes and 
triggering a series of molecular reactions (Scortegagna et al., 2008).  
It is believed that high activation of NFκB inhibited apoptosis to enable a 
hypoxic cell to survive through the period of hypoxic insult. The hypoxic 
action of NFκB signalling pathway also involves promoting hypoxic 
inflammatory response through the regulation of gene expression of 
proinflammatory cytokines as well as adhesion molecules, enzymes, and 
pro-inflammatory enzymes (Taylor et al., 2008; Taylor et al., 2009). 
Furthermore, it is reasonable to speculate that hypoxia induced NFκB 
activation may be contributing to the maintenance of CSCs during the 
development and progression of tumours especially because both HIFs and 
NFκB signalling pathways are known to maintenance of stem cell 
phenotype and function in tumour niche. Hypoxic activation of NFB 
pathway may be HIF1-dependent. The functional loss of HIF1 could 
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decrease NFκB activation and p65 expression whereas increased 
expression of HIF1 results in the activation of NFκB through hyper 
phosphorylation of IκB and phosphorylation of p65 at Ser276 in 
keratinocytes (Scortegagna et al., 2008). The molecular mechanism of how 
the HIF pathway regulates the NFκB pathway has not been fully 
understood, but HIF pathway activates NFκB pathway mainly through the 
regulation of IKK signalling-mediated regulation of canonical NFκB 
signalling (Cummins et al., 2006) In addition to HIF-mediated activation of 
NFB, it has recently been demonstrated that hypoxia can directly induce 
NFB which in turn regulates HIF pathway. The promoter region of HIF1 
contains B site. The mutation of this B site will lead to the loss of 
hypoxia-induced HIF1 activation (Van et al., 2008). Moreover, blocking 
individual NFκB members by their specific siRNAs can decrease HIF1 
activity. The activation of NFB induced by TNF and p50/p65 
transfection lead to increased levels of HIF1 mRNA and protein. 
Therefore NFB can regulate HIF1 signalling pathway to maintain the 
basal levels of HIF1 under normoxic condition and further induce it under 
hypoxia (Van et al., 2008; Bracken et al., 2005). An earlier report 
demonstrated that NFB also induces HIF2 activation via influence of the 
interaction between IKK and CBP/p300 (Tian et al., 2012; Schreck et al., 
1992).   It has been reported that the interaction of HIF and NFκB pathways 
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contributes to BC metastasis through the induction of EMT together with 
migration through p65-lysine acetylation and HDAC dependent epigenetic 
mechanism to up-regulate NFκB and HIF (Bendinelli et al., 2009). In 
summary, the interaction between HIF and NFκB signalling pathways 
plays a pivotal role in tumour aggressiveness. 
Recent studies indicate that NFB plays a pivotal role in hypoxia-induced 
CSC phenotypes and is responsible for the chemoresistance in CSCs. 
Although the CSC concept is still debatable (Yip et al., 2011), it is widely 
accepted that the cancer cells expressing CSC markers are resistant to 
chemo- and radiotherapy. Therefore, development of anti-CSC drugs to 
target CSC determinant pathways will improve chemotherapeutic outcomes. 
DS is a commercially available anti-alcoholism drug (Chen et al., 2006) 
and shows anticancer activity in vitro and in vivo (Wang et al., 2003; Guo 
et al., 2010). It also potentiates cyclophosphamide, CDDP and radiation in 
vitro and protects normal cells in kidney, gut and bone marrow in vivo 
whilst increasing the therapeutic index of cytotoxic drugs (Liu et al., 2012; 
Dufour et al., 1993). The anticancer activity of DS is Cu dependent. Cu 
plays a crucial role in redox reactions and triggers the generation of ROS in 
human cells. DS/Cu is a strong ROS inducer and proteasome-NFκB 
pathway inhibitor. Combination of DS with Cu may target cancer cells by 
simultaneous modulation of both ROS and NFκB. DS and its metabolites 
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can also covalently modify cysteine residues within the nucleotide binding 
domain of Pgp and permanently inhibit Pgp activity (Hinohara et al., 2012). 
This will potentially reverse multidrug resistance. Although the anticancer 
activity of DS has been reported for a long time, there are very few 
successful cases reported in clinic. This discrepancy is mainly introduced 
by the very short half-life of DS in the bloodstream. The currently 
developed technologies in nano-encapsulation may be able to translate this 
drug into cancer indication. 
In this study, I examined the effect of hypoxia on maintenance of stemness 
of CSCs and elucidated the bridging role of NFB in linking hypoxia and 
CSCs. Furthermore, the anticancer efficacy of a newly developed liposome 
encapsulated DS have also examined in BC cell lines and BC xenografted 
nude mice.  
5.2 Methods 
5.2.1 In vitro mammosphere and suspension culture and 
cytotoxicity assay  
The BC cells were cultured in ultra-low adherence 6-well plates (Corning, 
MA, USA) containing 2 ml of stem cell culture medium [SCM, serum-free 
DMEM-F12 supplemented with B27 (Invitrogen, Paisley, UK), 20 ng/ml 
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epidermal growth factor (Sigma), 10 ng/ml basic fibroblasts growth factor 
(R & D System, Abingdon, UK), 10 µg/ml insulin (Sigma)] at a density of 
10,000 cells/ml. For the suspension culture, the cells were cultured in full 
medium (DMEM supplemented with 10% FCS, 2 mM L-glutamine, 50 
units/ml penicillin, 50 μg/ml streptomycin). After 6 days culture, the 
mammospheres and suspending cell balls were photographed and subjected 
to further treatments. For in vitro cytotoxicity assay, the cells cultured in 
suspension or mammospheres were trypsinised and seeded in 96-well 
plates at a density of 5,000 cells/well and exposed to drugs for 72 hours 
before MTT assay. 
5.2.2 Measurement of hypoxia in cell culture 
The hypoxic status was determined using the HypoxyprobeTM-1 Plus Kit 
supplied by Hypoxyprobe Inc (Burlington, MA, USA) following the 
supplier’s instruction. For immunocytochemistry assay, the cells were 
cultured in 8-well chamber slides at normoxic (20% oxygen) or hypoxic [1% 
oxygen in Hypoxic Chamber (StemCell, Durham, NC, USA)] conditions 
for 24 hours and labelled with Hypoxyprobe for 2 hours. The hypoxic cells 
were detected by confocal microscope after staining with FITC-conjugated 
anti-hypoxyprobe Mab. The mammospheres and cells in suspending 
condition were cultured for 6 days. The mammospheres and suspended 
cultured cells were labelled with Hypoxyprobe for 24 hours and 
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cytospinned at 800 g for 3 minutes to spread the spheres onto Polylysine-
coated slides (VWR, Lutterworth, UK). For flow cytometric analysis, the 
cells were cultured in 25 cm flasks at the above conditions. After 
immunocytochemistry staining the cells were subjected to flow cytometric 
analysis. The hypoxic population was detected using a FACSCalibur flow 
cytometer with 488 nm blue laser and standard FITC 530/30 nm bandpass 
filter. To determine the effect of hypoxia on drug sensitivity, the cells were 
cultured in 1% oxygen condition at a cell density of 1 x 103 cells/well in 
96-well plate for 4 days and exposed to anticancer drugs for another 72 
hours before MTT assay. The parallel MTT assay was performed in 
normoxic condition. 
5.2.3 Immunofluorescent flow cytometric analysis of 
embryonic stem cell markers 
The expression of Nanog, Oct4 and Sox2 was determined by 
immunofluoresent flow cytometry. The sphere and hypoxia-cultured cells 
were collected by trypsinization. The cells fixed by acetone/methanol and 
permeabilized by 0.1% triton-X100. After being blocked with 3% BSA for 
1 hour the cells were stained with primary (1:50 dilution) and FITC-
conjugated secondary antibodies respectively for 1 hour at RT. The 
positively stained population was detected using a FACSCalibur flow 
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cytometer with 488 nm blue laser and standard FITC 530/30 nm bandpass 
filter. 
5.2.4 Total RNA isolation and RT-PCR 
Total RNA was isolated using TRIzol reagent (Invitrogen, Paisley, UK) 
according to the manufacturer’s protocols. The mRNA expression levels of 
ALDH 1A1 (NM_000689), 1A3 (NM_000693), 2 (NM_000690) and 3A1 
(NM_000691) genes were determined using the Access RT-PCR System 
(Promega, Southampton, UK) following the instruction of the supplier. The 
human housekeeping gene GAPDH (XR018317) was used as the RNA 
loading control. The sequences of the primers and the sizes of the amplified 
fragments are table 2.2. The RT-PCR amplification conditions were as 
follows. One cycle at 48°C for 45 minutes; 1 cycle at 94°C for 2 minutes; 
35 cycles at 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 1 minute; 
1 cycle at 72°C for 5 minutes. The RT-PCR products were separated on a 1% 
agarose gel and the bands visualized and photographed under UV light. 
5.2.5 Human breast cancer xenograft experiments 
Five-week-old female BALB/c Nu/Nu athymic nude mice (Biotechology & 
Cell Biology Shanghai, China) were housed under pathogen-free conditions 
according to Fourth Military Medical University (FMMU), China animal 
care guidelines and the animal experiments were reviewed and approved by 
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the Ethical Committee of FMMU. MDA-MB-231 cells (1 x 106) were 
subcutaneously injected at one flank of the mice. When the tumour volume 
(V) reached ~200mm3, the tumour bearing mice were randomly subdivided 
into three groups (8 mice/group) and treated 2 times/week with Lipo-DS 
(75 mg/kg) empty liposome (0.2 ml) and no treatment. The tumour volume 
was calculated by the following formula: V= (L×W2) ×0.5, where L is the 
length and W is the width of the tumour. The xenograft size was observed 
twice per week for 4 weeks. After 4 weeks or when the xenograft reached 
1500mm3, the animals were sacrificed. The tumours were removed, 
photographed and subjected to further analysis. 
5.2.6 Immunohistochemistry 
The tumour and normal tissues were paraffin embedded. After 
deparaffinization and rehydration, the slide was blocked its endogenous 
peroxidase by 3% hydrogen peroxide, incubated with primary antibody 
Ki67 antibody (1:200, Cell signaling), ALDH1 (1:100, ABCam), NFκBp65 
(1:200, Cell Signaling) then with biotinylated secondary antibody, 
antimouse immunoglobulin G (H + L), followed by incubation in ABC 
reagent (Avidin and Biotinylated horseradish peroxidase Complex, DAKO 
Labs, Cambridgeshire, United Kingdom). Finally, the slide was mounted 
with 3, 3’-diaminobenzidine and visualized under a microscope. 
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5.2.7 H&E staining 
Paraffin-embedded sample slides were deparaffinized and hydrated, and 
then stained with hematoxylin for 1 minute. After rinsing, the slides were 
then stained with eosin for 1 minute, followed by more rinsing, and 
coverslips were mounted onto slides with Permount. 
5.2.8 Terminal deoxyribonucleotidyl transferase–mediated 
dUTP nick end labelling assay 
Tumour tissues were paraffin embedded and stained according to the 
instructions of the manufacturer. Briefly, after deparaffinization and 
hydration, the tissue was incubated with Working Strength TdT Enzyme, 
Working Strength Stop/Wash Buffer, conjugated with antidigoxigenenin, 
and then stained with peroxidase substrate and incubated in ABC reagent 
(Avidin and Biotinylated horseradish peroxidase Complex, DAKO Labs, 
Cambridgeshire, UK). Finally, the slide was mounted with 3, 3’-
diaminobenzidine and visualized under a microscope. 
5.3 Results 
5.3.1 Hypoxia is responsible for maintaining stemness and 
drug resistance in cancer stem cells and suspension cells  
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The in vitro MSC culture conditions are adopted from normal stem cell 
culture system, but serum-free system is very costly and does not very well 
mimic the physiological condition. In this study, I firstly examined if 
serum-free is an essential condition to maintain the stemness of MSC in 
vitro. Two BC cell lines were cultured in parallel in both classical serum-
free spheroid stem cell culture system (MSC) and normal serum-rich 
medium (SUS). After 5 days culture, BC cells formed typical 
mammospheres in both conditions. The spheres formed in the serum-rich 
medium are markedly tighter than their counterparts cultured in serum-free 
stem cell medium (Fig. 5.1A). Furthermore, both MSC and SUS cells have 
significantly higher proportion of cells expressing stem cell markers 
(ALDH+ and CD24low/CD44high) then the attached cells and CSC related 
embryonic proteins (Sox2, Nanog and Oct4). In comparison with the MSC, 
most of the stem cell-related markers are expressed at higher levels in the 
SUS cells (Fig. 5.1B). Fig. 5.1C and D demonstrate that in comparison with 
the adherent cells, a high population of hypoxic cells were detected in both 
MSC and SUS cells using HypoxyProbe. 
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Fig. 5.1 Hypoxia induces expression of stem cell markers in breast cancer cell lines. (A) The 
morphology of spheres cultured in serum-free (MSC) and serum-containing (SUS) medium (40X 
magnification). (B) Flow cytometric analysis of ALDH activity and expression of CD24, CD44, 
Oct4, Sox2 and Nanog proteins in monolayer- and suspension-cultured cells. (C) Flow cytometric 
analysis of hypoxic cells stained with Hypoxyprobe. (D) Confocal microscopy images of the 
hypoxic cells detected by Hypoxyprobe in serum-free (MSC) and serum-containing (SUS) medium 
cultured BC cells (X400 magnification). ATT: monolayer culture; MSC: serum-free stem cell 
culture; SUS: serum-containing medium culture in suspension. The figures in the frame represent 
Mean (SD). 
It has been reported that the hypoxic condition in the stem cell niche is 
essential for maintaining the stemness. I hypothesized that the sphere shape 
growth may prevent penetration of oxygen into the centre of the 
mammospheres and a relatively hypoxic condition will be generated in the 
centre of the spheres. Therefore I cultured both cell lines in 1% oxygen 
condition for 5 days to determine the relationship between hypoxia and 
CSC characters. The results show that similar to the sphere cells, the 
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hypoxic condition-cultured monolayer cells express high levels of stem cell 
markers and embryonic pathway-related proteins (Fig. 5.1E, F and G).  
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Fig. 5.1 Hypoxia induces expression of stem cell markers in BC cell lines. (E) Hypoxyprobe 
stained hypoxic population in hypoxia-cultured BC cells was detected by flow cytometry and 
immunocytochemistry (F) respectively. (G) Flow cytometric Comparison of ALDH activity and 
expression levels of CD24, CD44, Oct4, Sox2 and Nanog proteins in normoxia- and hypoxia-
cultured cells. ATT: monolayer culture; MSC: serum-free stem cell culture; SUS: serum-containing 
medium culture in suspension. The figures in the frame represent the Mean (SD). 
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CSCs are commonly de novo resistant to a wide range of anticancer drugs 
and become the source of cancer recurrence. I further examined the 
sensitivity of the cells cultured in both systems. Table 5.1 shows that BC 
cells cultured in both systems are highly resistant to three first line anti-BC 
drugs. The above results suggest that the culture medium has no effect on 
cancer cell sensitivity to anticancer drugs. Similar to the CSC and SUS 
cells, the cells cultured in hypoxic condition are significantly resistant to 
chemotherapeutic agents (Table 5.1). All of these data indicate that hypoxia 
may play a key role in determining the stemness and chemosentivity in BC 
cells. 
Table 5.1 Cytotoxicity of conventional anticancer drugs in breast cancer 
cell lines 
 
The figure represents IC50 value from three MTT experiments [mean (SD)]. The cells were exposed 
to drugs for 72 hours. ATT: attached cells; MSC: mammosphere cells; SUS: suspension culture in 
normal medium; Hypo: hypoxic culture (O2 < 1%). dFdC: gemcitabine, DOX: doxorubicin, PAC: 
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paclitaxel.  Mock: Empty vector transfected cells; C2, P1, C1, C3: NFκB p65 transfected clones. ** 
p<0.01 (n=3) compared with Mock cells. 
5.3.2 NFκB activation plays pivotal role in maintaining cancer 
stem cell stemness and chemoresistance  
In this study, high nuclear expression of HIF2 was detected in the cells 
cultured in hypoxia, CSC and SUS conditions. In line with this alteration, 
p65 nuclear translocation has been observed in all of these three culture 
conditions (Fig. 5.2A). Phosphorylation of NFB p65 subunit and AKT 
was also detected in these cells (Fig. 5.2B). EMSA demonstrated that the 
NFB DNA binding activity was induced in the cells cultured in these 
three conditions. These results indicate that both hypoxia and NFB 
pathways were activated in all of these three conditions.  
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Fig. 5.2 NFB is responsible for maintaining cancer stem cell characters in suspension-
cultured and hypoxic cells. (A) High levels of NFB p65 and HIF2 protein were detected in the 
nuclear protein extracted from suspension-cultured and hypoxic cells. Nuc: nucleolin used as a 
loading standard. (B) Phosphorylated AKT, NFB p65_Ser276 and degradation of IB were 
detected in suspension-cultured and hypoxic cells by western blot. -Tub: -tubulin used as a 
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loading control. (C) High NFB DNA binding activity was detected by EMSA. Mut and WT: 
mutant and wide type probe competition. High NFB p65 protein  
To examine the determinant role of NFB in maintenance of stem cell 
characters and chemosensitivity, I transfected both MCF7 and T47D cell 
lines with the cDNA of NFB p65 subunit. High p65 protein levels and 
transcriptional activity of NFB were detected in the transformed clones 
(Fig. 5.2 D and E). Flow cytometry data show that all the transformed 
clones possess considerable higher population of cells with CSC markers 
(Fig. 5.2F). Furthermore I examined the chemosensitivity in the transfected 
cell lines (Table 5.1). In comparison with the mock transfected cell lines, 
the p65 transfected cell lines are highly resistant to three first line anti-BC 
chemotherapeutic agents (DOX, PAC and dFdC). These data indicate that 
NFB may play a key role in the network of hypoxia-induced CSC 
characters and cancer chemoresistance. 
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Fig. 5.2 NFB is responsible for maintaining cancer stem cell characters in suspension-
cultured and hypoxic cells. (D) and transcriptional activity (E) were detected in p65 transfected 
clones (C1, C3, P1 and C2) by western blot and luciferase reporter gene assay respectively. Mock: 
empty vector transfected cells. (F) High ALDH+ and CD24low/CD44high population was detected in 
NFB p65 transfected clones. The figures in the frame represent Mean (SD) 
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5.3.3 Lipo-disulfiram targets cancer stem cells in vitro  
In line with my previous results, I further examined the toxicity and 
specificity of Lipo-DS in BC cell lines in combination with 10 M of 
CuCl2. Lipo-DS is high cytotoxicity to the CSCs derived from MCF7 and 
T47D (Fig. 5.3A). Lipo-DS/Cu induced and inhibited the expression of 
BAX and BCL2 respectively (Fig. 5.3B). The clonogenicity in both MCF7 
and T47D cell lines was completely blocked after 1 hour Lipo-DS/Cu 
treatment. The sphere-forming ability in two BC cell lines was also 
completely inhibited after 4 hours Lipo-DS/Cu treatment. This effect was 
not observed in Lipo-DS or Cu treated cells (Fig. 5.3C). Lipo-DS/Cu also 
abolished the ALDH+ and CD24low/CD44high CSC population in the 
mammospheres. In contrast, the CSC population in the mammospheres was 
not affected by Lipo-DS, Cu and anti-BC drugs (Fig. 5.3D and E).  
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Fig. 5.3 (A-E) Cytotoxic effect of Lipo-disulfiram/copper on breast cancer stem cells. (A) 
Comparable cytotoxicity of Lipo-DS/Cu in monolayer-cultured cells and BCSCs was detected by 
MTT assay. The cells were exposed to Lipo-DS/Cu for 72 hours. (B) Lipo-DS/Cu induced BAX and 
cleaved PARP and reduced Bcl2 expression were detected by western blot. The cells were treated in 
Lipo-DS (1 M)/CuCl2 (10 M) for 4 hours and in drug-free free stem cell culture medium for 24 
hours. (C) Lipo-DS/Cu abolished sphere-forming ability in BC cell lines. The cells were cultured in 
Lipo-DS (1 M)), CuCl2 (10 M) or Lipo-DS/CuCl2 for 4 hours and in drug-free free stem cell 
culture medium for 7 days. (D) The effect of different treatments on CD24low/CD44high population. 
(E) The effect of different treatments on ALDH activity in BCSCs. For experiments D and E, 7-day-
cultured sphere cells were trypsinized and exposed to different agents for 4 hours and released for 24 
hours.  
Four major ALDH isoenzymes have been detected for response to ALDH 
activity in CSCs. ALDH1A1 mRNA and protein were not detected in the 
attached and spheroid cultured cells in both cell lines. In contrast, it was 
highly expressed in another BC cell line, MDA-MB-231, which we used as 
the positive control. ALDH2, a mitochondria located isoenzyme, was 
expressed at low levels and not inducible in CSCs. However, the mRNA 
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and protein of ALDH1A3 and 3A1 were expressed at very low levels in the 
attached cells and markedly induced by CSC culture (Fig. 5.3F). This result 
indicates that ALDH1A3 and 3A1 may contribute to the high ALDH 
activity in the CSCs derived from MCF7 and T47D cell lines. 
 
Fig. 5.3F Effect of Lipo-disulfiram/copper on ALDH isoenzymes. (F) Expression of ALDH 
mRNAs in attached and spheroid cells. The whole proteins were extracted from the BCSCs exposed 
to different agents for 4 hours and released in drug-free medium for 24 hours. 
5.3.4 Lipo-Disulfiram simultaneously triggers Reactive 
Oxygen Species-MAPK activation and inhibits NFκB pathway 
in cancer stem cells  
As demonstrated, previous in chapters, DS/Cu activates ROS-MAPK and 
inhibits NFB pathways simultaneously in cancer cells. The effect of Lipo-
DS/Cu on these pathways in CSCs was examined. Fig.5.4A and B show 
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that Lipo-DS/Cu treated CSCs generated high ROS activity which was 
reversed by the ROS inhibitor, NAC. In line with this result, Lipo-DS/Cu 
induced cytotoxicity was also reversed by NAC (Fig. 5.4C). In comparison 
with normal cell lines, Lipo-DS/Cu (1 M/10 M) selectively induced 
higher ROS activity and more cell killing in cancer cells (Fig. 5.4D and E).  
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Fig. 5.4 Lipo-DS/Cu induces ROS-MAPK and inhibits NFB pathways and specifically targets 
breast cancer cells. (A) Top: Flow cytometric detection of Lipo-DS/Cu-induced ROS activity in BC 
cells. Dot-line: control, Solid-line: Lipo-DS/Cu. Bottom: Lipo-DS/Cu-induced ROS activity was 
reversed by NAC. (B) The Lipo-DS/Cu-induced cytotoxicity was reversed by NAC. (C) Lipo-DS/Cu 
specifically induced ROS activity in BC cell lines. (D) Lipo-DS/Cu demonstrated higher cytotoxic 
effect on BC than in normal cell lines (MCF10A: Human Mammary Epithelial Cell Line; HeCV: 
Human Endothelial Cell Line). (E) Clonogenic assay shows that Lipo-DS/Cu abolished colony-
forming ability in BC cell lines but had no effect on normal cell lines. The cells were exposed to 
drugs for 1 hour and released in drug free medium for 72 hours (MTT) and 10 days (clonogenic 
assay).  
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Lipo-DS/Cu significantly induced the expression of major MAPK pathway 
elements (p-JNK, p-c-JUN, c-JUN and p-p38), whereas the ERK 
expression was not altered (Fig. 5.4F). Furthermore, Lipo-DS/Cu inhibited 
IB degradation, p65 nuclear translocation has been found in both MCF7 
and T47D CSCs (Fig. 5.4G). The phosphorylation of NFB p65 and AKT 
in the CSCs was also inhibited by Lipo-DS/Cu (Fig. 5.4H). 
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Fig. 5.4 Lipo-disulfiram/copper induces ROS-MAPK and inhibits NFB pathways and 
specifically targets breast cancer cells. (F) The effect of different treatments on JNK, p38 and 
ERK pathways. (G) Lipo-DS/Cu blocked NFB p65 nuclear translocation. (H) Lipo-DS/Cu induced 
IB expression and inhibited phosphorylation of AKT and NFB p65. The sphere cells were 
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tripsinized and exposed to different treatments (Lipo-DS 1 M, Cu 10 M, Lipo-DS/Cu) for 4 hours 
and released in drug-free medium for 24 hours. 
5.3.5 Lipo-disulfiram inhibits breast cancer xenografts in vivo  
The anticancer efficacy of Lipo-DS has been examined in vivo. The dose of 
Lipo-DS (75 mg/kg) was equivalent to 9 times the human oral dose of 
500mg/day. The drug was administered 3 times/week for 3 weeks. The 
Lipo-DS i.v with/without Cu supplement and Cu alone were compared to 
determine the necessity of Cu supplement in the anticancer efficacy of 
Lipo-DS in vivo. The oral administration of DS supplemented with Cu was 
used to compare the anticancer efficacy of different administrative routes. 
Fig. 5.5A and B show that both Lipo-DS/Cu and Lipo-DS significantly 
inhibited tumour growth. Oral administration of DS/Cu also inhibited 
tumour growth although not reaching statistical significance. Cu alone had 
no effect on tumour growth. Consistent with the in vitro data, Lipo-DS 
induced BAX and inhibited BCL-2 expression, which is in line with the 
TUNEL result (Fig. 5.5C and D). Furthermore, I examined the effect of 
Lipo-DS on the vital organs. Fig. 5.5E shows that supplemented with Cu, 
both oral and intravenous administration of Lipo-DS introduced liver 
damage. Some necrotic cells were identified in the liver of mice treated 
with Lipo-DS i.v/Cu or DS p.o/Cu. 
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Fig. 5.5 Lipo-disulfiram inhibited growth of breast cancer xenografts. MDA-MB-231 cells 
(1×106) were subcutaneously injected at one rear flank of the mice. When the tumour volume 
reached ~200mm3, the tumour bearing mice were randomly subdivided into 5 groups (8 mice/group) 
e.g. control; DS 75 mg/kg p.o + copper gluconate (CuGlu) 8 mg/kg p.o; CuGlu 8 mg/kg p.o; Lipo-
DS 75 mg/kg i.v; Lipo-DS 75 mg/kg i.v + CuGlu 8 mg/kg p.o. The drugs were administered 3 
times/week for successive 3 weeks. (A) Growth curves of tumour size. Arrows represent drug 
administration. (B) The effect of different treatments on tumour weight after 28 days observation. (C) 
The effect of different treatment on Ki67 and TUNEL expression (400 magnification). (D) The 
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effect of different treatments on BAX and BCL2 expression. (E) Histo-pathological images of vital 
organs (H&E staining, 400 magnification). 
5.4 Discussion    
Stem cells possess two unique characteristics: pluripotency and self-
renewal, which maintain the organ’s structure and function. Recent 
findings suggest that a small population of cells in tumours behave in a 
similar manner to normal stem cells (Dick et al., 2008). Such cells are 
CSCs and are considered to be critically important for tumour proliferation, 
invasion, and metastasis. The concept of CSCs is derived from normal stem 
cells suggesting that a very small population of cells in cancer bulk 
possesses stem cell markers. These cells are relatively quiescent, resistant 
to most anticancer drugs and develop into the original cancer when 
inoculated into immunodeficient mice. The CSC culture system is adapted 
from the normal stem cell culture system. In contrast to the normal stem 
cells, the monolayer-cultured non-CSCs and sphere-cultured CSCs are 
interconvertible. The essential growth factor-supplemented serum-free 
spheroid culture has been widely used as a gold method in vitro to prevent 
differentiation, purge the differentiated progenies, and enrich stem cell 
population (Myant et al., 2013). However, the serum-free stem cell 
culturing system is very expensive and does not very well imitate the 
physiological in vivo conditions. Therefore, I set up BC cell lines in 
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suspended culture system using both serum-free stem cell medium and 
serum-rich medium in parallel to determine the necessity of the stem cell 
medium in maintaining the stemness of CSC in vitro. After 5 days culture, 
the BC cells in both systems formed spheres and clusters (Fig. 5.1A) which 
represent both cell proliferation and aggregation because if it is not single 
cell inoculation, the aggregation of the suspended cells is inevitable, no 
matter how low the density of the seeded cells (Myant et al., 2013). The 
expression of stem cell and embryonic markers was significantly induced 
in the cells cultured in both systems, even higher in suspension cells (Fig. 
5.1B). These results indicated that the stemness is not determined by 
culture medium, and serum-free stem cell culture system is not essential for 
CSC culture. Therefore, there must be some common factors introducing 
and maintaining stemness in the cells cultured in both systems. It is widely 
accepted that hypoxia is a determinant of stemness in stem cell niche (Zeng 
et al., 2011). I hypothesized that due to the penetrating distance of oxygen, 
hypoxia may be cumulated in the centre of the sphere which becomes the 
stem cell niche. Compared with the monolayer-cultured cells, high 
population of hypoxic cells was detected in the sphere-cultured cells (Fig. 
5.1C and D). The spheres developed in serum-containing culture are 
significantly bigger and tighter than those grown in serum-free culture and 
contain more hypoxic cells (Fig. 5.1A). In line with the sphere-cultured 
cells, high population of CSCs was also detected in hypoxia-cultured (<1% 
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O2) BC cells. The BC cells cultured in these three conditions are highly 
resistant to dFdC, Dox and PAC by MTT assay. Chemoresistance is a 
common feature of CSCs as well as hypoxic cells. These results indicate 
that the stem cell characters in the sphere-cultured cells may be introduced 
by hypoxia in the centre of the spheres and the stem cell medium is not 
necessary for the in vitro CSC culture. 
Although it is widely observed that hypoxia can induce stem cell characters 
in normal and CSCs, the detail molecular mechanisms and pathways are 
still largely unknown. It is reasonable to believe that hypoxia-activated HIF 
pathways are essential for cellular response to hypoxia. However, many 
other transcription factors, e.g. NFB, are also crucial for hypoxia-induced 
phenotypes. Activation of NFB pathway has been reported in 
inflammation-induced hypoxia which enables the survival of the 
inflammatory cells. Recent studies indicate that NFB also plays a pivotal 
role in CSCs, tumour progress and chemoresistance (Zhang et al., 2011; 
Johansson et al., 1992). In my study, nuclear translocation of HIF2 and 
NFB p65 protein was detected in spheroid and hypoxia cultured cells. 
These cells also demonstrated IB degradation and p65 phosphorylation. 
The activation of AKT, the transcription factor upstream of NFB, was 
also observed. High NFB DNA binding activity was induced in the cells 
cultured in all three conditions. In this study, NFB pathway is activated in 
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BC cells cultured in all of the three culturing systems (CSC, suspension and 
hypoxia). In order to examine the importance of NFB in determination of 
CSC traits, I have transfected BC cells with NFB p65. The transfected 
clones expressed high levels of BCSC markers (CD24low/CD44high, ALDH+; 
Fig. 5.2F) and were highly resistant to dFdC, Dox and PAC. These data 
demonstrate that NFB transfection definitely conferred CSC traits onto 
BC cells. The resistant levels of most of the NFB transfected clones to 
Dox were lower than those in the spheroid and hypoxic cells. Therefore, 
some other factors may also be involved in the resistance of Dox in the 
sphere- and hypoxia-cultured cells. 
DS is an NFB inhibitor and it targets CSCs and reverses chemoresistance 
in BC cell lines. The application of DS in cancer therapeutics is limited by 
its very short half-life in the bloodstream (Junttila et al., 2008). To 
overcome this hindrance, we recently developed a Lipo-DS to extend the 
half-life of DS in the bloodstream (Nakano et al., 2006). In line with our 
previous reports, the cytotoxicity of Lipo-DS is Cu dependent. The 
cytotoxicity of Lipo-DS/Cu is comparable in both BCSCs and attached 
cells. After very short exposure (4 hours) to Lipo-DS/Cu, the expression of 
BCSC markers (ALDH+, CD24low/CD44high) in the sphere cells was 
inhibited and the sphere-forming ability in the BC cell lines was completely 
abolished (Fig. 5.3C). In contrast, the BCSC markers were not affect by 
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conventional anticancer drug, Lipo-DS or Cu alone (Fig. 5.3D and E). 
Although Lipo-DS/Cu inhibited ALDH activity, it had no effect on ALDH 
isoenzymes (1A1, 1A3, 2 and 3A1) at mRNA and protein levels (Fig. 5.3F). 
It has been reported that ALDEFLOUR detects enzyme activity of 
ALDH1A1. In this study, I could not detect ALDH1A1 mRNA and protein 
expression in both cell lines but it is highly expressed in MDA-MB-231 
cell line. Therefore, the expression of ALDH1A1 may be cell line 
dependent.  ALDH2, a mitochondrial isoenzyme, was detected at very low 
basal levels but not induced by spheroid and hypoxic culture. High 
expression of ALDH1A3 and 3A1 mRNA and proteins was detected in 
sphere-cultured cells. Therefore ALDH1A3 and 3A1 may be responsible 
for the high ALDH activity in BCSCs in these two cell lines. A study 
reported that ALDH1A3 is responsible for the high ALDH activity in BC 
(Marcato et al., 2011). 
Selectivity is one of the key issues for anticancer drug development. The 
cytotoxicity of Lipo-DS/Cu is ROS dependent. ROS damage DNA, RNA 
and induce apoptosis. Cancer cells possess but are also able to tolerate 
significantly higher levels of ROS due to the balance of anti-apoptotic 
mechanisms e.g. NFB in cancer cells (Margalioth et al., 1983). Lipo-
DS/Cu selectively induced ROS activity in BC in comparison with normal 
cell lines and showed significantly higher cytotoxicity in BC than normal 
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cells. Similar phenomenon was also obtained by clonogenic assay (Fig. 
5.4E). ROS induced-apoptosis is highly MAKP pathway-dependent. Lipo-
DS/Cu persistently activated JNK, C-Jun and p38 MAPK pathways but had 
no effect on ERK pathway, which is responsible for cell growth, 
proliferation and survival (Junttila et al., 2008). Apart from activation of 
pro-apoptotic pathways, ROS also trigger the expression of anti-apoptotic 
proteins, which neutralize the pro-apoptotic effects of ROS. NFκB is one of 
the most important ROS-induced transcription factors (Gloire et al., 2006). 
NFκB inhibits JNK and p38 activation by suppressing ROS accumulation 
in cancer cells. Cancer cell fate is highly dependent on the crosstalk 
between JNK/p38 and NFκB pathways. The NFκB activity in BC cell lines 
was significantly inhibited by Lipo-DS/Cu (Fig. 5.4A and B). Simultaneous 
activation of ROS-JNK/p38 and inhibition of NFκB pathways may 
contribute to Lipo-DS/Cu induced cytotoxicity in the BC cell lines. 
Although Cu is essential for the in vitro cytotoxicity of DS, the anticancer 
efficacy of DS in combination with Cu has never been investigated in vivo. 
In this study, I first tested the anticancer efficacy of free DS and an 
intravenously applicable Lipo-DS in combination with Cu in BC xenograft. 
In combination with CuGlu, intravenous administration of Lipo-DS 
demonstrated the strongest anticancer efficacy. Furthermore, I also 
examined whether the intrinsic Cu in BC xenograft can enable the 
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anticancer effect of Lipo-DS. Lipo-DS injection alone also showed strong 
anticancer activity also it was significantly lower than that of Lipo-DS/Cu 
combination. Oral version of DS/Cu also showed mild in vivo anticancer 
activity. The Lipo-DS, Lipo-DS/Cu and DS/Cu induced apoptosis was 
evidenced by TUNEL and western blotting results (Fig. 5.5C and D). In 
consistence with our in vitro data ki67 immunohistochemistry staining 
indicated that the anticancer effect of DS and Lipo-DS is proliferation-
independent. To determine the in vivo non-specific toxicity of DS, the 
pathological changes of vital organs (liver, lung and kidney) in different 
groups were examined (Fig. 5.5E). Cu induced congestion in major organs. 
There is no toxicity was observed in the vital organs except the liver in 
Lipo-DS/Cu treated mice in which some necrotic cells were observed. Our 
unpublished data indicate that in combination with Cu, the in vivo 
anticancer effect of nano-encapsulated DS could be achieved at 
significantly lower dose with no toxicity in the liver. Therefore the dose of 
Lipo-DS in the Lipo-DS/CuGlu still needs to be adjusted. 
In conclusion, hypoxia induced NFκB activation is responsible for 
stemness and chemoresistance in BCSCs. Lipo-DS targets NFκB pathway 
and CSCs. As a clinically available drug, further study may translate DS 
into cancer therapeutics. 
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6. Development of an acquired 
gemcitabine resistant triple negative 
breast cancer cell line  
6.1 Introduction 
dFdC is a nucleoside analogue used for systemic treatment of patients with 
BC. As the first line drug, dFdC has a high initial activity against tumours, 
but is induced to acquire resistance later. In clinic, as a single agent, dFdC 
yields response rates ranging from 14%-37% as first-line therapy for 
advanced BC and 23%-42% as salvage therapy (Possinger et al., 1999). 
Used in combination with other chemotherapy agents such as PAC and 
CDDP, dFdC can have even higher response rates. Moreover, the side-
effect of dFdC in patients with BC has been favourable compared to other 
commonly used cytotoxic agents, and the patients present less fatigue, with 
a notable absence of alopecia and gastrointestinal symptoms. The action of 
dFdC involves DNA chain termination and mechanisms that result in self-
potentiation. The detail of dFdC metabolism and chemoresistance 
mechanisms have been reviewed in chapter I. Here, I will focus my review 
on two key factors e.g. deoxycytidine kinase (dCK) and ribonucleotide 
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reductase subunit 1 (RRM1) playing a pivotal role in the dFdC 
chemoresistance. dCK is an enzyme, which originates from a family of 
nucleoside kinases which phosphorylate the 5’-hydroxyl group on 
(deoxy)ribonucleosides and play a vital role in the salvage pathway. dCK is 
a rate limiting enzyme for phosphorylation of deoxynucleotides for DNA 
synthesis. It also activates a number of anticancer and antiviral nucleoside 
analogues (Ewald et al., 2008), particularly dFdC in this study. It has been 
reported that dCK is involved in cellular response to DNA damage and its 
activity will be enhanced following treatment with ionising radiation. Thus, 
this exhibits the potential of dCK activity in radiosensitising effect of dFdC 
(Pauwels et al. 2006). In addition, dCK can inactivate cyclin-dependent 
kinase 1 (CDK1) which leads to G2/M checkpoint initiation upon DNA 
damage. This observation is clearly seen in human cervical carcinoma cell 
line HeLa and human embryonic kidney cell line HEK293T (Yang et al. 
2012). Therefore, deficiency in dCK activity has been considered to be one 
of the main mechanisms responsible for the development of resistance to 
dFdC. RR is an iron-dependent enzyme and a main element in the DNA 
replication that catalyses the conversion of ribonucleotide diphosphate to 
deoxyribonucleotide diphosphate (Kolberg et al. 2004). Active RR is a 
heterotetrameric enzyme composed of two homodimers of nonidentical 
subunits, RRM1 and RRM2. RRM1 contains the substrate binding and 
catalytic site as well as the allosteric effector sites while RRM2 contains a 
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diiron site and a tyrosyl radical that is essential for catalysis (Davidson et 
al., 2004). dFdC inhibits RR activity and blocks the conversion of 
ribonucleotide diphosphate into deoxyribonucleotide diphosphate which 
will exhaust the DNA building materials and lead cancer cells into 
apoptosis. High expression of RRM1 has been observed in dFdC resistant 
cancer cell lines. The expression levels of RRM1 are also reversely related 
to the prognosis of non-small-cell lung cancer patients who were subjected 
to a combinational therapeutics of dFdC and CDDP (Rosell et al., 2004; 
Davidson et al., 2004). To date, both dCK and RR have been extensively 
investigated as potential predictive markers of tumour sensitivity to dFdC 
(Ueno et al., 2007). 
Acquired chemoresistant cancer cell lines are important for investigation of 
the mechanisms of cancer chemoresistance. In this part of my study, I 
developed and preliminarily characterised a dFdC resistant BC cell line, 
MDA-MB-231GEM100. 
6.2 Methods  
General methods have been described in chapter II. The following are the 
methodologies specifically used in this study. 
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6.2.1 Cell culture  
The dFdC (MDA-MB-231GEM100) resistant cell lines were generated from 
MDA-MB-231 (purchased from ATCC) by being continuously cultured in 
medium containing dFdC (Sigma, Dorset, UK) in a stepwise concentration-
increasing procedure. Firstly, the MDA-MB-231 cells were cultured in 
medium with dFdC (20 nM) for 4 weeks, then the concentration of dFdC in 
the culture medium was increased to 50 nM, after 8 weeks cell culture, the 
MDA-MB-231 cells were cultured in medium containing dFdC (100 nM) 
for another 8 weeks. The MDA-MB-231GEM100 cells were maintained in the 
medium containing 100 nM of dFdC. All cell lines were cultured in 
DMEM (Lonza, Wokingham, UK) supplemented with 10% FCS, 50 μg/ml 
penicillin, and 50 μg/ml streptomycin.  
6.3 RESULTS 
6.3.1 MDA-MB-231GEM100 cells are resistant to gemcitabine 
The cytotoxic effect of dFdC on both sensitive and resistant cell lines was 
compared by MTT assay (Table 6.1 and Fig. 6.1). The IC50_72h of MDA-
MB-231 cell line to dFdC is 32.8 nM. In contrast, the MDA-MB-231GEM100 
cell line is highly resistant to dFdC with an IC50_72h of 91.9 nM.  
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Table 6.1 Cytotoxicity of dFdC to MDA-MB-231 and MDA-MB-
231GEM100 breast cancer cell lines 
 
The figure represents IC50 value from three experiments [mean (SD)]. **p<0.01’ *p<0.05 (n=3). The 
cells were treated for 72 hours. 
 
Fig. 6.1 MDA-MB-231GEM100 cell line is resistant to dFdC. The MDA-MB-231GEM100 and MDA-
MB-231 cell lines were exposed to dFdC for 72 hours before MTT assay. MDAGEM: MDA-MB-
231GEM100, MDA: MDA-MB-231. 
Furthermore the regenerating abilities of resistant and wild type cell lines 
were examined using clonogenic assay. In line with the MTT data, 30 nM 
dFdC eliminated the clonogenicity of the parental cell line but no obvious 
effect on MDA-MB-231GEM100 cells (Fig. 6.2). Due to the slower 
proliferation rate, the colonies developed from the resistant cell line are 
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smaller than that from the parental cell line. The number of colonies also 
indicated that in long term DA-MB-231GEM100 is also survived from dFdC 
exposure. 
 
Fig. 6.2 Clonogenic assay of MDA-MB-231GEM100 and MDA-MB-231. The cells were exposed to 
dFdC (30 nM) for 72 hours and then subcultured in drug-free medium at a cell density of 2,500 
cells/well in 6-well plates for 10 days. The colonies (≥ 50 cells) grown in each well were counted. 
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The figures indicate mean (SD). N=3. **p<0.01. MDA: MDA-MB-231, MDAGEM: MDA-MB-
231GEM100 
6.3.2 Resistance of MDA-MB-231GEM100 cell line to 
gemcitabine-induced apoptosis 
After 72h exposure to 30nM dFdC, the phase contrast microscopic images 
show that sensitive cells undergo apoptosis. In contrast, there was no 
obvious apoptotic morphological change observed in the resistant cells (Fig. 
6.3). 
 
Fig. 6.3 MDA-MB-231GEM100 cell line is resistant to gemcitabine-induced apoptosis. The 
morphology (× 100 magnification) of MDA and MDAGEM cells treated with dFdC (30 nM) for 72 
hours. MDA: MDA-MB-231; MDAGEM: MDA-MB-231GEM100 
Furthermore the DNA contents in both cell lines were examined by flow 
cytometry. The cells were treated with dFdC 50 nM for 72 hours and 
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results showed a significantly higher apoptotic sub-G1 population in the 
parental cell line than resistant cell line (Fig. 6.4A). The treatment 
increased S-phase population in the parental cell line. In contrast, there is 
no significant effect of dFdC on the apoptotic status in the resistant cells. 
The S-phase cells in MDA-MB-231GEM100 cell line have a limited effect by 
dFdC exposure (Fig. 6.4B and C). 
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Fig. 6.4 MDA-MB-231GEM100 cell line is resistant to gemcitabine-induced apoptosis detected by 
flow cytometric DNA analysis. (A) Flow cytometric analysis of resistant to dFdC-induced 
apoptosis in MDA-MB-231GEM100 cell line. (B) and (C) The effect of dFdC (50 nM, 72 hours) on cell 
cycle parameters (Apoptosis and S-phase cells) in MDA-MB-231 and MDA-MB-231GEM100 cell lines. 
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The figures represent the mean (SD) from three experiments. MDAGEM: MDA-MB-231GEM100, MDA: 
MDA-MB-231. 
6.3.3 MDA-MB-231GEM100 cell line has a longer doubling time 
Quiescence is a common feature of drug resistant cancer cell lines. In my 
study, I observed that the drug resistant MDA-MB-231GEM100 cells grow 
significantly slower than MDA-MB-231 cells. Therefore I compared the 
doubling time between these two cell lines. Fig. 6.5 shows the growth 
curves of both cell lines. The doubling time of MDA-MB-231GEM100 cells 
(81.7h) is significantly longer than that of the sensitive cells (30.8h) 
(p<0.01).  
 
Fig. 6.5 Growth curves of MDA-MB-231 and MDA-MB-231GEM100 cells. The cells (5×103/well) 
were cultured in 24-well plates in triplicate. The cells were collected by trypsinization and cell 
numbers in each of three wells were counted every 24 hours for 120 hours. MDA-MB-231GEM100 cell 
line proliferates slower. MDA: MDA-MB-231, MDAGEM: MDA-MB-231GEM100 cells. The figures 
represent mean of three experiments. **p<0.01. 
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6.3.4 Expression of gemcitabine resistance-related proteins in 
MDA-MB-231 and MDA-MB-231GEM100 
It is widely known that deregulation of some key factors, e.g. dCK and 
RRM1, is involved in dFdC chemoresistance. The expression of dCK and 
RRM1 were detected in both MDA-MB-231 and MDA-MB-231GEM100 cell 
lines by Western blot (Fig. 6.6). The expression of dCK was considerably 
low while RRM1 exhibited higher in resistant MDA-MB-231GEM100 cell 
line when compared to sensitive MDA-MB-231 cell line. No expression of 
Pgp in both MDA-MB-231 and MDA-MB-231GEM100 cell lines (Fig. 6.6). 
Resistant MDA-MB-231PAC10 BC cell line, which expresses high levels of 
Pgp was used as a positive control.  
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Fig. 6.6 dFdC related protein expression. Western blotting analysis of Pgp, dCK and RRM1 
expression. MDA: MDA-MB-231; MDAGEM: MDA-MB-231GEM100; MDAPAC: MDA-MB-231PAC10. 
6.4 Discussion 
TNBC have poor chemotherapeutic outcomes compared with other BC 
subtypes. Although the therapeutic outcomes of TNBC have been 
improved significantly in the recent years, chemoresistance remains the 
major obstacle for clinical success. dFdC has a wide range of anti-tumour 
activity against malignancies. dFdC resistance remains vital for the cause 
of relapsed tumours. The resistant cell line is important for investigation of 
the mechanisms of dFdC resistance. Therefore I have developed a dFdC 
resistant TNBC cell line from parental MDA-MB-231 cell line by 
continuously culturing in medium containing dFdC in a stepwise 
concentration-increasing procedure. To validate the characteristics of the 
newly developed dFdC resistant cell line could be contribute to the 
understanding of chemoresistance in future work. 
The in vitro cytotoxicity assay revealed that MDA-MB-231GEM100 cell line 
is more highly resistant to dFdC-induced cytotoxicity than sensitive MDA-
MB-231 cell line. The IC50 of resistant cell line (91.9 nM) is obviously 
higher than that of sensitive cell line (32.8 nM). In line with the MTT data, 
clonogenicity of sensitive cell line has almost been abolished by exposure 
to 30 nM dFdC. In contrast there was no significant cytotoxic effect of 
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dFdC at the same concentration on resistant cell line. Cell morphology 
change is also observed; the sensitive cells seemed to shrink and more 
nuclear degradation. In contrast, dFdC did not induce any apoptotic 
morphological change in the resistant cell line. All these data indicate that 
MDA-MB-231GEM100 cell line is successfully induced to be resistant to 
dFdC. The smaller size of colony of resistant cell line is caused by the 
slower proliferation of resistant cells.  
The major obstacle to efficacy of chemotherapy is the development of 
acquired resistance, which is emerges through unresponsiveness to drugs 
after an initial success of treatment mainly due to their positioning 
alteration in the cell cycle. dFdC is an antimetabolite and an S-phase 
dependent type of drug. Flow cytometric DNA content analysis showed 
that high population of apoptosis cells in sensitive cell line exposed to 
dFdC (50 nM, 72h) in contrast with a sharp decrease of apoptosis cells in 
the resistant cell line. Moreover a high proportion of cells gathered in the 
S-phase in sensitive cell line treated with dFdC whereas a little bit drop of 
S-phase cells in resistant cell line. It could be explained that there is a lack 
of dFdC sensitivity towards resistant cells leading to less apoptotic activity. 
In addition, the growth curve also showed that the resistant cell line has a 
longer doubling time with nearly three-folds. These data reflect that why 
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the cell cycle status does not have significant change after dFdC treatment, 
suggests dFdC is responsible for S-phase arrest.  
Understanding alterations in expression of genes, which characterise the 
response of cancer cells to dFdC treatment in the process of acquired 
resistance, would allow us to improve therapeutic strategies for BC. 
Therefore, some proteins, which may be involved in dFdC resistance, have 
been examined. In comparison with sensitive cell line, a considerable 
down-regulation of dCK and up-regulation of RRM1 have been found in 
the resistant cell line. dCK enzyme plays an important role in conversion of 
dFdC into its active form and RRM1 is one of the main targets for dFdC 
(Jordheim et al., 2006; Bergman et al., 2005). Several reports suggested 
that there is a link between low expression of dCK and overall survival. 
One study demonstrated a low OS in patients who had pancreatic 
adenocarcinoma received dFdC treatment for either metastatic or resected 
disease had low dCK expression. Similarly, an investigative study on 
pancreatic cancer with dFdC therapy presents a poor prognosis to patient 
when dCK expression level is low (Sebastiani et al. 2006). RRM1 was 
known as a primary potential regulatory gene in the pathogenesis of a 
variety of cancers. RRM1 overexpression is also subjected to a 
disadvantage in OS. This is evidently verified in RRM1 mRNA expression 
in advanced NSCLC treated with dFdC and CDDP (Rosell et al. 2004). In 
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addition, high RRM1 expression also could lead to shorter progression-free 
survival compared to low RRM1 expression in nasopharyngeal carcinoma 
(NPC) patients treated with dFdC-based chemotherapy (Zhao et al. 2012). 
MDR is known for its unresponsiveness to a variety of chemotherapeutic 
agents against cancer (Tan et al. 2000). Accumulating publications 
indicated that the main mechanism in cancer cells is increased drug efflux 
by overexpressing MDR related ABC transporters (Victor et al, 1997). One 
of these commonly discussed among researchers is Pgp. Pgp is used to test 
in our study but no expression can be found in MDA-MB-231GEM100 cell 
line. However, Pgp is highly overexpressed in resistant MDA-MB-231PAC10 
cell line due to the presence of a substrate in PAC (Tiwari et al. 2009). 
Based on my data, dFdC resistance is not related to Pgp. It has been 
reported that the cellular influx of dFdC involves membrane equilibrative 
(ENT) or concentrative (CNT) nucleoside transporters, such as hENT1, 
hENT2, hCNT1 and hCNT3 (Shah et al., 2007). Due to the time limitation, 
I did not examine the alteration of these proteins in the resistant cell line in 
my study. 
To summarize, I have characterized a newly developed dFdC-resistant BC 
cell line, MDA-MB-231GEM100, and this cell line is a useful model to 
investigate the mechanism of dFdC resistance in the BC. Further study on 
this model will give us hints leading to overcome dFdC related 
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chemoresistance. My data show that the MDA-MB-231GEM100 is more 
resistant to dFdC and growing slow, low dCK and high RRM1 have been 
detected in MDA-MB-231GEM100. In future, continuing with the current data, 
I highly recommend my college should examine the cytotoxicity effect of 
DS on MDA-MB-231GEM100. The link between dFdC resistance and BC 
stem cell could be also investigated as well as the intercellular signalling 
pathways such as NFκB, ROS-MAPK and stem cell related pathways. 
7. General Discussion 
Cancer is a serious public health problem worldwide and it is also a major 
cause of mortality with 28% of all deaths in the UK in 2010. BC is the most 
common female cancer with the second leading cause of cancer death after 
lung cancer since 1998 among women in the UK. In the past 30 years, 
despite the major advances that have been made in understanding the 
biological and clinical nature of BC, it is still the most prevalent type of 
cancer among women in the developed world and its incidence has shown a 
continuous rise in recent decades (Statistical Information Team, CRUK, 
2010). Nowadays, BC has become a significant public health problem due 
to high mortality all over the world. Early stage BC patients with the 
appropriate treatments have long-term overall survival. Although 
improvements with better understanding of the use of adjuvant therapies 
 248 
 
for early stage BC, the treatment of A/MBC remains a major challenge. 
Chemotherapy is one of the principal treatments for the A/MBC due to its 
chemosensitive such that symptom control and prolongation of survival can 
be achieved. However, response duration remains disappointingly short and 
long-term survival remains uncommon (Rouzier et al., 2005). While 
chemotherapy is often capable of inducing cell death in tumours and 
reducing the tumour bulk, many cancer patients experience tumour 
recurrence and ultimately death because of treatment failure. The major 
reason for therapeutic failure of patients with A/MBC has been thought to 
be the drug resistance, which is the main limitation of chemotherapy 
effectiveness. Several mechanisms have been proposed to implicate in 
chemoresistance including overexpression of MDR, disfuntion of apoptosis 
signalling pathways, CSCs, and hypoxic microenvironment in tumour bulk 
(Moscow et al., 1988; Longley et al., 2005; Bharadwaj et al., 2004; 
Heinemann et al., 1992; Kiyomiya et al., 2001). Currently, the demand for 
a novel anticancer drug is vast and urgent for the cancer patients. The 
medical need for better cancer therapies is undiminished while drug 
development is slow and costly, mainly due to the large risk of toxicity of 
novel molecules. Development of a new drug takes on average 15 years 
and US$1.5bn with only 5-25% of new oncology drugs in clinical 
development actually reaching the market (Walker et al., 2009). This 
dilemma has led to a booming interest in repurposing of known drugs into 
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new use in the USA, Europe and emerging economies. Nowadays over 
30,000 drugs have been on market. Taking their derivatives into account, 
this is a tremendous resource for drug repositioning. Importantly, the safety 
and pharmacokinetic profiles of these drugs are well established. 
Repurposing of such drugs would greatly reduce the time and cost for 
development of a new drug, which is not only beneficial for the public but 
also profitable for the pharmaceutical companies. As an anti-alcoholism 
drug used in clinic for over 60 years, the metabolism and clinical 
pharmacology of DS are well understood. Previous studies indicate its 
anticancer potential in several different cancer types (Guo et al., 2009; 
Wang et al., 2004). Therefore I intend to translate it into cancer 
therapeutics in my study. My data have demonstrated that DS does not have 
toxicity to normal cells, but exhibits excellent activity against BC in vitro. 
Importantly, I have also demonstrated that this drug specifically and 
effectively destroys drug resistant CSCs and reverses chemoresistance. 
Furthermore, DS potentiates the cytotoxicity of two first-line conventional 
anti-BC, PAC and dFdC in vitro (Yip et al., 2011; Liu et al., 2012). 
Although DS shows strong anticancer activity in laboratory its application 
in cancer clinic is highly limited by its bio-instability. The half-life of DS in 
the blood stream is only ~4 minutes (Cobby et al., 1977). Clinical 
translation of DS as an anti-cancer drug is limited by its rapid degradation 
and extensive metabolic conversion. While the DS metabolites are active 
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against alcoholism, the anti-cancer activity requires unmodified DS. 
Therefore, in order to translate DS into cancer therapeutics, we need an 
efficacious delivery system to protect DS in bloodstream and transport it 
into cancer tissues. Our collaborators in Shenyang Pharmaceutical 
University, China encapsulated DS into liposome and extend the half-life 
of DS in the bloodstream to about 2 hours. The liposomal DS (Lipo-DS) 
improved the anticancer efficacy of DS in a mouse model. 
Cu is an essential trace element that plays a critical role in oxidation-
reduction (redox) reactions and in scavenging free radicals (Turnlund et al., 
1998). As early as 400 B.C., Hippocrates prescribed Cu compounds to treat 
diseases (Turnlund et al., 2006), and the successful animal experiment in 
cancer treatment was published almost 9 decades ago (Hieger et al., 1926), 
whereas scientists are still uncovering new information regarding the 
functions of Cu in the human body (Prohaska et al., 2012). In the body, Cu 
shifts between the cuprous (Cu1+) and cupric (Cu2+) forms, and the majority 
is Cu2+ form. Based on my results, single Cu treatment does not show any 
cytotoxicity to the BC cell lines. The intracellular transport of Cu is still 
one of the major hurdles for its clinical efficacy due to the complicated 
environment in the cancer cells. Ctr1 is a Cu transporter, responsible for the 
transport of Cu into cells. In order to maintain redox homeostasis, 
intracellular Cu levels are strictly controlled by Ctr1 (Kim et al., 2008).  
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The anticancer activity of DS is Cu2+ dependent. DS strongly chelates Cu 
to form a DS/Cu complex. Cancer tissues possess significantly higher 
levels of Cu than their normal counterparts. This statement will give DS the 
selectivity to target cancer cells. The potential explanation of Cu-induced 
cellular toxicity is that Cu ions participate in the formation of ROS. Cu 
induces the generation of hydroxyl radicals (OH-) from H2O2. The hydroxyl 
radical is the most powerful oxidizing radical as it is theoretically capable 
of reacting with every biological molecule and thus initiates oxidative 
damage. As a strong bivalent metal ion chelator, DS and its derivative, 
N,N-diethyldithiocarbamate (deDTC), can form a complex [Cu(deDTC)2] 
with Cu. This DS/Cu complex can transport Cu into cancer cells in a Ctr1-
independent manner thus overcoming the transporter-controlled regulation 
of intracellular Cu homeostasis (Cen et al., 2004). My results indicate that 
the cytotoxicity of DS/Cu in BC is ROS-related. DS/Cu induced ROS 
activity and cytotoxicity was reversed by NAC, an inhibitor of ROS. 
DS/Cu persistently activated JNK and p38 MAPK pathways that promote 
ROS-induced apoptosis in both cancers (Junttila et al., 2008). In my study, 
I have examined different time points for the treatment of DS/Cu in BC (1, 
8, 24 hours) cell lines, the results showed that both JNK and p38 pathways 
were persistently activated (phosphorylation of c-Jun and p38) by DS/Cu 
and blocked by NAC. In contrast, DS/Cu did not activate the ERK pathway, 
which plays an essential role in cell growth, proliferation and survival 
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downstream of ROS. ROS-activated JNK and p38 pathways were partially 
responsible for ROS-induced apoptosis because the inhibitors of JNK and 
p38 reduced cytotoxicity of DS/Cu but to a lesser degree than ROS 
inhibition. It widely known that the activation of JNK and p38 induces 
apoptosis via mitochondrial apoptotic pathways (Junttila et al., 2008). Pro-
apoptotic BAX was induced and anti-apoptotic BCL2 was inhibited by 
DS/Cu leading to an increased BAX/BCL2 ratio and thus a pro-apoptotic 
phenotype in response to ROS. These results indicate that DS/Cu may 
trigger intrinsic apoptosis via persistent activation of JNK and p38 
pathways that is ROS-dependent. NFκB is one of the most important ROS-
induced anti-apoptotic factors (Gloire et al., 2006). The activation of NFκB 
in turn inhibits ROS and JNK, p38 activation and ultimately inhibits ROS-
induced apoptosis. Cancer cell fate is highly dependent on the crosstalk 
between JNK/p38 and NFκB pathways. My data showed that both the 
binding activity and transcriptional activity of NFκB were significantly 
inhibited by DS/Cu in BC cell lines, and ultimately induce the cells to 
undergo apoptosis. To date, one of the possible cytotoxicity mechanisms of 
DS/Cu is simultaneous inducing ROS generation to activate ROS-MAPK 
pathway and inhibiting NFκB pathway. 
The most important and novel finding in my study has been thought that 
DS can reverse the chemoresistance by targeting CSC. CSCs are 
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considered to be a very small population of cancer cells that can have 
unlimited growth, self-renewal, as well as differentiation into other, more 
specialized cancer cell types (Ichim et al., 2006). CSCs have been 
implicated in the initiation and development of malignancy. Many cases 
demonstrated that CSCs are able to survive and regenerate the tumour even 
after a large percentage of malignant tissue has been destroyed by 
chemotherapy, and this has been considered as one of the major causes of 
chemoresistance, which ultimately leads to the cancer relapse. My results 
showed that DS in combination with Cu could target CSC to reverse the 
chemoresistance and prevent the tumour recurrence. The first evidence is 
from MDA-MB-231PAC10, a cell line resistant to PAC. Cancer cells 
displaying reduced sensitivity to drugs through continued exposure can also 
become cross-resistant to other unrelated classes of chemotherapeutic drugs. 
The pan-resistance is the major obstacle to successful chemotherapy. 
Inadequate drug exposure and insufficient dosage are the main reasons to 
induce the multidrug resistance during chemotherapy. MDA-MB-231PAC10 
resistant cell lines were generated from MDA-MB-231 by being 
continuously cultured in medium containing PAC (10 nM) in a stepwise 
concentration-increasing procedure. A few different chemotherapy drugs 
share a common transport mechanism, which is controlled by ABC 
transporter family. As a member of ABC transporter family, high 
expression of the MDR1 gene in multidrug resistant cancer cells leads to a 
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large production of MDR1 protein, which is commonly known as Pgp.  It 
pumps out anti-cancer drug from the cytosol to the extracellular medium by 
using the energy of ATP hydrolysis (Moscow et al., 1988; Gottesman et al., 
1993). High expression of Pgp is also a common feature of CSCs. My 
results showed that MDA-MB-231PAC10 cell line shows high expression of 
Pgp protein and the cell cycle of MDA-MB-231PAC10 is slower than the 
sensitive cell line. These results suggest that this cell line may contain high 
population of CSCs, which may play a key role in PAC resistance. MTT 
results showed that DS/Cu is highly cytotoxicity to both sensitive and 
resistant cell lines. The CSC markers in this resistant cell line were also 
inhibited by DS/Cu. DS/Cu could reverse the PAC-induced 
chemoresistance by targeting CSC. Furthermore, I have examined the 
effect of DS/Cu on several CSC phenotypes in different cell lines in my 
study. Accumulating evidence indicates that ALDH may not only be a 
surrogate marker but also a functional target for anti-CSC chemotherapy. 
High levels of ALDH were detected in the resistant cells, the similar high 
activity of ALDH has been found in BC stem cells. It is believed that all 
three stemness factors (Nanog, Oct4 and Sox2) play a crucial role in the 
survival of a population of CSCs with drug resistance phenotype (Linn et 
al., 2010). In my study, the embryonic stem cell-associated genes Sox2, 
Oct4 and Nanog also showed up-regulation in resistant cell line as well as 
BC stem cells. Meanwhile, high activities of CD44+/CD24- and CD133+ 
 255 
 
have been detected in BC stem cells. Inhibition of ALDH activity by 
DS/Cu was confirmed by ALDEFLOUR analysis in BC stem cells, as well 
as resistant cell line. Further study on the ALDH showed that DS/Cu had 
no effect on ALDH isoenzymes (1A1, 1A3, 2 and 3A1) at mRNA and 
protein levels. Although it has been reported that ALDEFLOUR detects 
enzyme activity of ALDH1A1, no ALDH1A1 mRNA and protein 
expression can be detected in BC stem cells whereas they are highly 
expressed in MDA-MB-231 cell line. Therefore, the expression of 
ALDH1A1 may be cell line dependent.  ALDH2 was detected at very low 
basal levels in BC stem cells. High expression of ALDH1A3 and 3A1 
mRNA and proteins was detected in BC stem cells. ALDH1A3 and 3A1 
may be responsible for the high ALDH activity. A study reported that 
ALDH1A3 is responsible for the high ALDH activity in BC (Marcato et al., 
2011). In addition, DS/Cu has markedly suppressed the stem cell markers 
CD44+/CD24- and CD133+ in BC stem cells. The expression of Nanog, 
Sox2 and Otc4 in BC stem cells and resistant cell line has been 
significantly inhibited by DS/Cu exposure. Overall, CSC markers are not 
only highly relevant for studies on the biology of CSC, but could also serve 
as useful markers to monitor the efficacy of differentiation therapy and may 
have a potential role to be targeted for the cancer therapy. However, the 
cellular cytotoxicity effect of DS/Cu on CSC is still not fully understood. 
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My study elucidates the possible mechanistic roles of DS/Cu in targeting 
BCSCs and reversion of chemoresistance. 
It has been proposed that specific therapies against CSCs may lead to the 
development of curative strategies. New therapies should eradicate the 
minority population of CSCs, instead of the rapidly dividing but terminally 
differentiated cells, which constitute the bulk of the tumour. It is 
predictable that the specific targeting CSCs population should result in 
better control of the disease. The small molecules may be usefully applied 
for anti-CSC therapies. These approaches include the targeting of CSC via 
developmental stem cell pathways and targeting CSC via CSC 
microenvironment. In my study, DS plus Cu has been used as a bullet to 
target CSC. The NFB pathway and hypoxia have been considered to play 
the key role in the CSC-related chemoresistance process (Scortegagna et al., 
2008). Firstly, in order to confirm if the CSC features can be also induced 
by hypoxia, I have cultured monolayer BC cells under hypoxic condition 
(O2<1%). In line with the spheres-cultured cells, high population of CSC 
have been detected in the hypoxic cells. The CSC markers have shown 
significant increase in both hypoxic monolayer cells and spheres-cultured 
cells, including ALDH, CD44+/CD24-, and the expression of stem cell and 
embryonic markers (Nanog, Sox2 and Oct4) was significantly induced in 
the cells cultured in both systems. Moreover, hypoxia is a determinant of 
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stemness in stem cell niche. Due to the penetrating distance of oxygen, 
hypoxia may be cumulated in the centre of the sphere. Confocal 
microscopy images showed that compared with the monolayer-cultured 
hypoxic cells, high population of hypoxic cells was detected in the sphere-
cultured cells. The most important finding is that both hypoxic monolayer 
cells and sphere-cultured cells are highly resistant to PAC, dFdC and Dox. 
Chemoresistance is a common feature of CSCs. These results indicate that 
the stem cell characters in the sphere-cultured cells may be introduced by 
hypoxia. The detail molecular mechanisms and pathways linking hypoxia 
and CSCs are still largely unknown. It is generally believed that hypoxia-
activated HIF pathways are important for cellular response to hypoxia 
(Raval et al., 2005). Moreover, as the most important transcription factors, 
NFB is also crucial for hypoxia-induced phenotypes. As I have mentioned, 
NFB also plays a pivotal role in CSCs, tumour progress and 
chemoresistance (Zhang et al., 2011; Johansson et al., 1992). In my study, 
nuclear translocation of HIF2 and NFB p65 protein was detected in both 
hypoxic monolayer cells and spheres cells. The activation of AKT was 
detected and IB degradation and p65 phosphorylation have been found 
in these cells. Moreover, the NFB DNA binding activity was also induced 
in hypoxic monolayer cells and spheres cells. Therefore NFB pathway is 
activated in CSC and hypoxic cells. This suggests that NFB show its 
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importance of NFB in determination of CSC traits. In order to confirm 
this, I transfected BC cells with NFB p65. The transfected clones 
expressed high levels of stem cell markers and were highly resistant to 
dFdC, Dox and PAC. Therefore NFB definitely conferred CSC traits onto 
BC cells. DS is an NFB inhibitor targeting CSCs and reversing 
chemoresistance. The cytotoxicity of DS/Cu is comparable in both BC stem 
cells and attached cells. DS/Cu has inhibited all the CSC markers, but these 
markers were not affected by conventional anticancer drug. As the similar 
manner in BC cell lines, the cytotoxicity of DS/Cu is ROS dependent in BC 
stem cells. DS/Cu selectively induced ROS activity and showed 
significantly higher cytotoxicity in BC stem cells than in normal cell lines. 
In line with the previous data, ROS induced-apoptosis by DS/Cu is highly 
MAKP pathway-dependent with JNK, C-Jun and p38 increase but no effect 
on ERK. NFκB is one of the most important ROS-induced anti-apoptotic 
factors. Moreover NFκB inhibits JNK and p38 activation and suppresses 
ROS accumulation in cancer cells (Gloire et al., 2006; Nakano et al., 2006). 
Simultaneous activation of ROS-JNK/p38 and inhibition of NFκB pathway 
may contribute to DS/Cu induced cytotoxicity in the BC stem cells. 
In summary, DS/Cu is not only highly cytotoxic to BC, but can also reverse 
chemoresistance by targeting CSC. DS shows very strong anticancer 
activity in vitro but free DS is always easily degraded in the bloodstream 
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before they reach the tumour in the body. Our partners encapsulated the 
free DS into Lipo-DS and further study on the effect of Lipo-DS in BC 
xenografts in vivo. The animal study results showed that Lipo-DS/CuGlu 
injection has the strongest anticancer efficacy. Lipo-DS inhibited the 
ALDH+ CSC population in the xenografts. In order to examine the 
selectivity of DS in vivo, the results of the histo-pathological changes of 
vital organs (liver, lung and kidney) show no toxicity in the vital organs 
except in some necrotic cells in the liver of Lipo-DS/Cu treated mice. To 
date, as a well-understood, safe drug that has been used in anti-alcoholism 
clinic for over 60 years, DS does not have toxicity to normal cells but 
demonstrates excellent activity against a wide range of cancers, including 
the most aggressive form of colon, breast, and brain cancer in vivo and in 
vitro. Importantly, this drug specifically and effectively destroys drug 
resistant CSCs and reverses chemoresistance. 
In future, in order to reduce the dose of DS in vivo, nano-encapsulated DS 
could be used for the next stage of research. Novel combination therapies 
targeting different parts of the tumour microenvironment are critical in 
order to completely eradicate drug-resistant cancer cells and CSCs. 
Nanomedicine significantly extends the range of existing anticancer drugs 
and treatment strategies and can be useful in targeting CSCs. 
Nanotechnology-based drug delivery system (NDDS) is a rapidly evolving 
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and expanding interdisciplinary field involved in an amalgamation of 
chemistry, engineering, biology and medicine. Nanoparticles (NPs) have 
unique advantages in delivering anticancer drugs to tumour sites and 
changing the pharmacokinetics and biodistribution of drugs, both of which 
result in higher antitumour efficiency while reducing side effects. Currently 
available NPs in cancer therapeutics include dendrimers, liposomes, lipid 
NPs, polymeric NPs, micelles, gold NPs and protein NPs etc. These NPs 
can encapsulate and deliver intact drug to cancer tissues. We hypothesized 
that encapsulation of DS into long circulating nano-materials will improve 
the anticancer efficacy of DS and finally translate it into clinical trials. In 
the proposed study, we will further reformulate the DS using different 
types of nanomaterials, and perform a series of in vitro and in vivo 
experiments to explore several features of these novel nanoparticles 
including their biodistribution, long-term fate, toxicity and antitumour 
efficacy. Also, the detailed mechanism of DS release from these 
nanoparticles and how these DSF-loaded nanoparticles execute their 
antitumour activity will be studied. More importantly, the effect of these 
nano-encapsulated DS on different cancer models will be examined to 
evaluate the targeted therapeutic effects. The ultimate goal is to select the 
best formulation of DS (highest antitumour efficacy without toxicities) for 
further translational study. Through the effort of a team of researchers 
comprising nanotechnology engineers, chemists, biologists and oncologists 
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from different countries, it will be possible to develop DSF-nanoparticles 
that are both effective and safe, and can thus move a step closer towards 
human trials.  
Furthermore, in line with the exciting data of DS in BC cell lines, I have 
demonstrated that DS/Cu enhances the cytotoxicity of dFdC in 
glioblastoma multiforme (GBM) cell lines. Both dFdC and DS can traverse 
the BBB and get into GBM tissue. The synergistic effect between DS/Cu 
and dFdC may help to overcome de novo dFdC resistance in GBM cells 
and be beneficial for dFdC-based chemotherapy in GBM patients. My 
study also indicates that DS/Cu alone or in combination with dFdC may be 
a successful therapeutic for chemoresistant GBM by successfully targeting 
chemoresistant CSC via ROS generation and attenuation of ALDH 
mediated protection from oxidative damage (See the attached paper in 
Appendix). I highly recommend further study to investigate the opportunity 
of using DS in GBM. This may lead to development of novel effective anti-
GBM agents with significant clinical importance in GBM treatment due to 
DS have small molecular weight to pass the BBB and specific targeting 
GCSCs in GBM. 
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